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Abstract 
5’-methylcytosine (5mC) plays a crucial role in the epigenetic regulation of gene 
expression and, until recently, was the only known epigenetic mark to result from the 
chemical modification of bases in mammalian deoxyribonucleic acid (DNA). The 
discovery of 5’-hydroxymethylcytosine (5hmC) at physiologically significant levels 
in a wide range of tissues, particularly those of the central nervous system, suggests 
that this novel epigenetic modification may have a similarly important function to 
5mC in transcriptional regulation. The highest levels of 5hmC have been consistently 
found in fully differentiated cell types, whilst stem cells seem to be characterised by 
very low or insignificant levels of 5hmC. It therefore appears that loss of 
pluripotency is associated with a substantial increase in global 5hmC levels and this 
modification may play a crucial role in this switch in cell fate. The central aim of this 
project was to investigate the potential role of 5hmC by profiling both 5mC and 
5hmC in parallel during the differentiation of embryonic stem cells (ESCs) down a 
neural lineage, allowing for a deeper understanding of the potential function of 
5hmC in the genome. Analysis of genome-wide 5mC and 5hmC patterns in ESCs, 
neural stem cells (NSCs) and astrocytes supported the hypothesis that dynamic 
changes in the distribution of both modifications contribute to neural specification. 
Striking differences in 5hmC levels between in vitro- and in vivo-derived samples 
were observed, suggesting that cell culture models may not successfully recapitulate 
5hmC profiles observed during normal development. Finally, a novel method was 
successfully developed and validated for genome-wide 5hmC profiling (oxBS-
450K), allowing sensitive and reproducible detection of 5hmC at single-base 
resolution.  
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Chapter 1 Introduction 
1.1 The epigenetic code 
Normal developmental processes are dependent on stable, long-term modifications to 
the transcriptional potential of a cell that do not affect the underlying nucleotide 
sequence. These epigenetic modifications function alongside the genetic code to 
shape cell phenotype during differentiation through the control of chromatin 
dynamics and gene expression patterns. Mechanisms of epigenetic activity typically 
refer to histone modifications, non-coding ribonucleic acid (RNA) signalling and the 
methylation of cytosine bases within DNA, which together regulate the 
transcriptional profile of a cell (Figure 1-1). Epigenetic modifications may be 
mitotically inherited across multiple cell divisions and thus contribute to stable 
cellular identity, whilst DNA methylation has also been shown to exhibit 
transgenerational heritability (Chong and Whitelaw, 2004; Holliday, 1987; 
Margueron and Reinberg, 2010).  
Epigenetic states are considered dynamic sets of modifications that may undergo 
changes during cellular reprogramming events or in response to environmental cues 
(Feil and Fraga, 2012; Meissner, 2010). Site-specific, temporal changes are observed 
in the 5’-methylcytosine (5mC) content of gene promoters, whilst two waves of 
global DNA demethylation take place during early embryogenesis, first in the 
paternal pronucleus at the one-cell stage of zygotic development, and then again in 
the primordial germ cells (PGCs) of the developing embryo (Kangaspeska et al., 
2008; Mayer et al., 2000; Metivier et al., 2008; Oswald et al., 2000; Santos et al., 
2002). Histone modifications also undergo global changes during development; 
during spermatogenesis, the majority of histone proteins are replaced by protamines 
throughout the genome and then restored after fertilisation (Hammoud et al., 2009; 
Torres-Padilla et al., 2006).  
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Figure 1-1: Overview of epigenetic modifications within the mammalian genome. Non-coding 
RNA molecules, chemical modifications of histone proteins within nucleosomes and methylation of 
cytosine bases all contribute to the layer of transcriptional control over the genome known as the 
epigenome. Image courtesy of: Sawan et al., Mutation Research 642 (1-2), 1-13 (2008).  
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1.2 DNA methylation  
1.2.1 5’-methylcytosine  
Methylation at the carbon-5 (5’) position of cytosine is a post-replication 
modification of DNA present in most eukaryotes, including all vertebrates and plant 
species, and many prokaryotes (Goll and Bestor, 2005; Suzuki and Bird, 2008). DNA 
methylation is critical for normal development and plays a role in an array of cellular 
processes such as chromatin remodelling and transcriptional regulation, X 
chromosome inactivation, genomic imprinting and transposon silencing (Bird, 2007; 
Kiefer, 2007). 5mC is strongly associated with heterochromatic regions of the 
genome where it functions as a permanent, silencing epigenetic modification 
(Hashimshony et al., 2003; Jaenisch, 1997; Walsh et al., 1998). The localisation of 
5mC at promoters usually results in transcriptional silencing and it has therefore 
traditionally been regarded as a repressive epigenetic mark (Cedar and Bergman, 
2009; Siegfried et al., 1999; Tiwari et al., 2008; Zhang et al., 2005), although DNA 
methylation is frequently correlated with active coding regions and tissue-specific 
gene expression (Futscher et al., 2002; Grunau et al., 2000; Kumar and Biswas, 
1988; Ngô et al., 1996; Song et al., 2005). For example, 5mC is found in the gene 
body of actively transcribed genes in both plants and mammals (Ball et al., 2009; 
Hellman and Chess, 2007; Zhang et al., 2006).  
DNA methylation is arguably the best understood and most widely studied 
epigenetic modification in mammalian cells; the mechanisms controlling the 
establishment and maintenance of DNA methylation patterns are well characterised 
and functional studies have shown that DNA methylation is essential for normal 
development and cellular differentiation (Jackson et al., 2004). The DNA 
methyltransferase (DNMT) family of enzymes are responsible for the establishment 
and maintenance of 5mC modifications in the genome (Bestor, 2000; Goll and 
Bestor, 2005). DNMT3A and DNMT3B are known as the de novo 
methyltransferases and establish DNA methylation patterns during gametogenesis 
and early embryonic development (Okano et al., 1999), whilst DNMT1 has been 
identified as a maintenance methyltransferase that conserves DNA methylation 
patterns on daughter DNA strands during replication (Lei et al., 1996; Li et al., 
1992). DNMT1 associates with the replication fork during DNA synthesis through 
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binding to PCNA and UHRF1 and preferentially targets hemi-methylated DNA sites 
to restore 5mC on daughter strands; loss of either DNMT1 or UHRF1 triggers 
passive DNA demethylation (Bostick et al., 2007; Chuang et al., 1997; Sharif et al., 
2007). The two remaining DNMT enzymes, DNMT3L and DNMT2, retain 
significant structural homology to the other DNMT enzymes but contain no 
detectable DNA methylation activity (Yoder and Bestor, 1998). DNMT2, now more 
commonly known as tRNA aspartic acid methyltransferase 1 (TRDMT1), instead 
functions as an RNA methyltransferase (Goll et al., 2006), whilst DNMT3L acts as a 
regulator of de novo methylation through its interaction with DNMT3A and 
DNMT3B (Chen et al., 2005; Jia et al., 2007; Suetake et al., 2004). DNMT3L is 
essential for the establishment of mammalian germline imprinting and is thought to 
directly recruit DNMT3A2 (an isoform of DNMT3A present in germ cells) to DNA 
through its specific binding to the unmethylated histone H3K4 (Bourc’his et al., 
2001; Hata et al., 2002; Ooi et al., 2007). 
1.2.2 5’-hydroxymethylcytosine and further oxidative derivatives  
More recently, the ten-eleven translocation (TET) proteins have been identified as 2-
oxoglutarate- and iron-dependent dioxygenases that are capable of converting 5mC 
to its further oxidation products: 5-hydroxymethylcytosine (5hmC), 5-formylcytosine 
(5fC) and 5-carboxylcytosine (5caC) (He et al., 2011; Ito et al., 2011; Tahiliani et al., 
2009).  
5hmC was first identified at physiologically relevant levels in mouse ESCs, Purkinje 
neurons, and granule cells in the brain, with levels ranging from 0.03% (in ESCs) to 
0.6% (in Purkinje cells) of total nucleotides, up to 40% as abundant as 5mC 
(Kriaucionis and Heintz, 2009; Tahiliani et al., 2009). 5hmC has since been 
identified in a wide variety of mammalian tissues and cell lines, suggesting that 
5hmC may be a biologically relevant epigenetic modification in its own right with 
unique gene regulatory functions. However, the highest enrichment levels are 
consistently found in tissues of the CNS, where 5hmC accounts for approximately 
0.3 - 0.7% of the total cytosine content of the cells (Globisch et al., 2010a; Li and 
Liu, 2011; Song et al., 2011b; Szwagierczak et al., 2010). 5hmC levels in adult 
mNSCs have been found to be similar to that of mESCs, at around 0.04% of total 
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nucleotides, whilst an age-dependent increase in global 5hmC is observed in mouse 
cerebellum. 5hmC comprises 0.1% of total nucleotides at postnatal day 7, reaching a 
maximum of 0.4% at 2.5 months old (Song et al., 2011b). 
5fC and 5caC have also been detected within mammalian DNA, but at levels at least 
10-fold lower than that of 5hmC. A sensitive high-performance liquid 
chromatography-mass spectrometry (HPLC-MS) method was able to detect 5fC, but 
not 5caC, in mESC DNA at levels of 0.02% of the total deoxyguanosine (dG) 
content, around 20-fold lower than 5hmC (0.39%/dG) and over 200-fold lower than 
the 5mC content (5%/dG) of the DNA sample (Pfaffeneder et al., 2011). Another 
study utilising an HPLC-MS assay was able to quantify both the 5fC and 5caC 
content of mESC DNA (Ito et al., 2011). 5caC was present at a level of 3 5caC per 
106 C bases, approximately 7-fold lower than 5fC and over 400-fold lower than the 
5hmC content of the DNA sample. Nuclear extracts from mESCs have been shown 
to contain a specific thymine DNA glycosylase (TDG) activity that is able to excise 
5fC and 5caC from DNA substrates, but not 5hmC, 5mC or unmodified C, perhaps 
explaining why neither 5fC or 5caC appear to accumulate to significant levels within 
genomic DNA (He et al., 2011; Zhang et al., 2012). 
 
Figure 1-2: The chemical structure of cytosine modifications present in mammalian DNA. A 
methyl (CH3) group may be added to the 5’ position of the cytosine pyrimidine ring by the DNMT 
enzymes, which can then undergo iterative oxidation reactions by the TET enzymes to produce a 
primary alcohol (5hmC), aldehyde (5fC) or carboxylic acid (5caC). Image courtesy of: Hill et al., 
Genomics 104 (5), 324-333 (2014).  
1.2.3 The genomic context of 5mC 
In mammalian somatic tissue, over 99% of all 5’-methylcytosine (5mC) bases occur 
in the context of CpG dinucleotides, although a significant proportion of non-CpG 
methylation has been found within ESCs and adult neurons, making up around 25% 
and 53% of all 5mC, respectively (Bernstein et al., 2007; Lister et al., 2009, 2013). 
CpG sites make up approximately 1-4% of mammalian DNA and around 70% are 
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methylated (Bird et al., 1985; Ehrlich et al., 1982; Lister et al., 2011). CpG sites are 
generally depleted within the genome due to the susceptibility of 5mC to mutation 
via deamination to produce thymine, but certain areas of high CpG density, known as 
CpG islands (CGIs), remain protected as they are largely unmethylated in the germ 
line (Barker et al., 1984; Bird, 1980). Although definitions vary, CGIs are usually 
characterised by a minimum GC content of 50-55%, a minimum observed:expected 
CpG ratio of 0.60-0.65 and a defined sequence length, often between 200-1000bp 
(Bird, 1986; Gardiner-Garden and Frommer, 1987; Illingworth and Bird, 2009; Takai 
and Jones, 2002). It has been estimated that there are over 25,000 CGIs in the human 
genome and around 23,000 CGIs in the mouse genome, although these regions show 
a lower average CpG density in mouse (Illingworth et al., 2010). Over 50% of gene 
promoter regions are associated with CGIs (Antequera and Bird, 1993; Bird, 1987) 
and methylation events at these CGIs are highly correlated with chromatin 
accessibility and gene transcription states, indicating a regulatory role for 5mC at 
these promoter-associated regions (Deaton and Bird, 2011).  
Between 40-60 million 5mC bases are found within mammalian DNA, making up 
around 4-6% of all cytosines. 5mC is widespread in its genomic location and is 
found both in gene bodies and more distal regions. Approximately 80% of CpG 
methylation is concentrated in repeat DNA sequences such as satellites, whilst CGIs 
and transcriptional start sites (TSS) are frequently depleted of 5mC (Bird, 1986; 
Ehrlich et al., 1982). Within intragenic regions, similar levels of relatively high 
methylated CpG density are found in introns, exons and 3’ UTR regions, with levels 
decreasing in the 5’ UTR region as you move nearer the TSS, which shows minimal 
methylation. Levels of 5mC then increase again as you move upstream of the TSS, 
returning to similar gene body methylation levels around 2kb upstream of the TSS. 
Non-CpG methylation within ESCs is also enriched in the gene body and depleted at 
the TSS, with 15-20% higher 5mC levels observed in exons over introns and the 
3’UTR. Unlike CpG methylation, non-CpG 5mC levels in ESCs are around 50% 
lower in the regions flanking the TSS (5’ UTR and promoter) than in the gene body. 
However, both CpG and non-CpG methylation are relatively depleted at transcription 
factor (TF) binding sites and active enhancer regions. Non-CpG methylation density 
in the gene body is positively correlated to gene expression, whilst no correlation is 
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detected with CpG methylation density (Lister et al., 2009). This is in contrast with 
gene body CpG methylation in differentiated somatic cells, where a positive 
correlation to gene expression levels has been observed in human fibroblast and B-
lymphocyte cell lines (Ball et al., 2009; Lister et al., 2009).  
1.2.4 The genomic context of 5hmC  
Initial reports of high levels of 5hmC in ESCs (compared to negligible levels in most 
somatic tissues) led to speculation that 5hmC may be responsible for the high 
proportion of non-CpG methylation detected in ESCs through bisulphite-based 
assays. Some of the first genome-wide 5hmC profiles generated by hMeDIP-seq 
reported extensive enrichment of strand-specific 5hmC in CAG sequences, as well as 
CA and CT repeat regions (Ficz et al., 2011; Matarese et al., 2011; Williams et al., 
2011). However, the development of single-base resolution methods of 5hmC 
detection have revealed that around 99% of 5hmC is found in the CpG context (both 
in mouse and human ESCs and brain tissue), suggesting that previous reports of non-
CpG 5hmC were probably due to technical limitations and/or bias of the affinity 
enrichment assays used (Booth et al., 2012; Lister et al., 2013; Wen et al., 2014; Yu 
et al., 2012). Nevertheless, contradictions remain in the current body of literature 
concerning genomic 5hmC distribution, particularly regarding suggestions of strand 
asymmetry, repeat element enrichment and the precise relationship between 5mC 
and 5hmC coexisting at the same loci. Further technological advances in 5hmC 
detection methods will no doubt be needed to resolve these ambiguities.  
The first genome-wide maps of 5hmC in both mouse ESC and cerebellum DNA, 
using affinity enrichment techniques coupled to sequencing, found enrichment 
concentrated in intragenic regions, with little or no detectable 5hmC in repeat regions 
(Pastor et al., 2011; Song et al., 2011b; Williams et al., 2011; Wu et al., 2011). 
Particularly high 5hmC enrichment within exons was also observed in ESCs, as has 
previously been observed for 5mC (Pastor et al., 2011; Williams et al., 2011; Wu et 
al., 2011). Indeed, the presence of 5hmC appears to require pre-existing 5mC, after it 
was shown that triple DMNT knockout cells lack both 5mC and 5hmC in the genome 
(Ficz et al., 2011; Williams et al., 2011).  5hmC levels within the gene body show a 
positive correlation to gene expression, suggesting a possible role for 5hmC in 
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promoting transcriptional activity, perhaps counteracting the repressive action of 
5mC without needing to demethylate (Song et al., 2011b; Wu et al., 2011). Although 
the majority of 5hmC-enriched regions were also enriched for CpG sequences, a 
relatively high level of strand-biased CpH and CAG sequence were also identified in 
5hmC enrichment profiles, suggesting that 5hmC may be present in a strand-specific, 
non-CpG context. (Ficz et al., 2011; Matarese et al., 2011; Pastor et al., 2011).  
Depletion of 5hmC around the TSS, transcriptional termination sites (TTS) and distal 
intergenic regions was observed compared to proximal upstream and downstream 
regions, using a glucosylation-based enrichment assay in mouse cerebellum, Purkinje 
cells, granule cells and Bergmann glial cell DNA (Mellen et al., 2012; Song et al., 
2011b). However, enrichment for 5hmC at the TSS was seen in mESCs using both 
glucosylation-based and CMS-based enrichment assays (see section 1.4.2), 
predominantly at a subset of promoter-associated CGIs of transcriptionally inactive 
genes characterized by bivalent histone domains and low 5mC levels (Pastor et al., 
2011; Wu et al., 2011). Similarly, two hMeDIP-seq datasets also found slight 5hmC 
enrichment at the TSS and promoter-associated CGIs (Ficz et al., 2011; Williams et 
al., 2011), with a particular enrichment of 5hmC at TET1-bound TSS: between 35-
50% of all genes enriched for 5hmC at the TSS were also bound by TET1 (Williams 
et al., 2011). 5hmC enrichment has also been reported at H3K4me1-marked 
enhancers (Pastor et al., 2011), the promoters of long interspersed nuclear elements 
(LINE1), CTCF and pluripotency transcription factor (TF) binding sites (Ficz et al., 
2011), suggesting a link between 5hmC and transcriptional regulation in ESCs. 
A similar genomic 5hmC distribution was detected in human frontal lobe brain tissue 
using an immunoprecipitation technique coupled to NimbleGen 720k CpG island 
plus promoter arrays (Jin et al., 2011a). The majority of 5hmC was found at 
promoters (55-59%) whilst a significant proportion of 5hmC was enriched in 
intragenic regions (35-38%). Only 6% of total 5hmC was identified in intergenic 
regions, suggesting selective targeting of 5hmC to genes.  
5hmC identification at single-base resolution has since been made possible due to the 
development of two methods of selective chemical conversion of 5hmC bases within 
DNA, oxidative bisulphite sequencing (oxBS-seq) and TET-assisted bisulphite 
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sequencing (TAB-seq), which allow quantitative 5hmC mapping (see section 1.4.3 
for details). Using a reduced representation oxBS-seq method that targeted CGI-
containing genomic DNA from mESCs, the highest 5hmC levels were found in both 
intragenic and intergenic CGIs and the lowest levels at TSS-associated CGIs, 
supporting previous reports of intragenic 5hmC enrichment. A total of 800 out of 
12,660 CGIs covered by the sequencing data (averaging 120 reads per CpG) were 
found to contain 5hmC, with an average level of 3.3% (Booth et al., 2012). Within 
CGIs, 5hmC was identified only within the CpG context and both 5mC and 5hmC 
levels across all CGIs were negatively correlated to CpG density. In addition, the 
highest 5hmC levels were found at CGIs with intermediate levels of 5mC (25-75%), 
and significant amounts of 5hmC were also observed at LINE1 elements, as noted by 
Ficz et al. (2011).  
Overall, these results were confirmed by 5hmC maps generated by TAB-seq for both 
human H1 ESCs and mouse E14 ESCs, although the sensitivity of this method was 
slighter lower due to a reduced sequencing depth of 26.5 (Yu et al., 2012). 5hmC 
was found predominantly at CpG dinucleotides, with 99.9% of 5hmC identified in 
the CpG context in H1 cells and 98.7% in E14 cells, and displayed greatest 
enrichment in regions with the lowest CpG density. Within genic regions, 5hmC 
enrichment was inversely correlated to expression levels, as previously noted (Booth 
et al., 2012; Pastor et al., 2011).  Analysis of 5hmC distribution within genomic 
features, however, revealed differing patterns of enrichment from previous studies. 
Approximately half of all 5hmC bases were located at distal-regulatory elements, 
including p300 and CTCF binding sites, enhancers and DNase1 hypersensitive sites. 
The highest absolute levels of 5hmC were found at distal-regulatory elements, 
compared to either proximal-promoter regions or intragenic regions, which showed 
the lowest 5hmC levels. However, the number of 5hmC bases in genic regions may 
have been underestimated due to insufficient sequencing depth, due to the very low 
5hmC levels within genic regions (3-4%). An inverse relationship was noted between 
5mC and 5hmC content, indicating that the strongest DNA demethylation is 
occurring at distal regulatory sites that show high 5hmC levels and reciprocally low 
5mC. 
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The median abundance of 5hmC at enriched sites was measured at 20.9%, compared 
to a median of 59.0% for 5mC. Interestingly, 5hmC was found to show extensive 
strand asymmetry, unlike 5mC (Yu et al., 2012). Only 21.0% of 5hmCs were located 
within symmetrically modified CpG sites, whilst 91.8% of 5mC were symmetrically 
distributed, supporting earlier findings from hMeDIP-seq profiles (Ficz et al., 2011). 
In addition, low but significant enrichment of 5hmC was found in multiple repeat 
elements, including short interspersed nuclear elements (SINE), LINE1, and long 
terminal repeats (LTRs), with 5hmC levels falling between 3-12% and comparable to 
that seen in promoter regions.  
1.2.5 Proposed mechanisms of DNA demethylating activity 
Dynamic changes in DNA methylation patterns are frequently observed during 
development and are important determinants in cell fate specification and cellular 
reprogramming in germ cells (Liang et al., 2011; Meissner et al., 2008a; Suzuki and 
Bird, 2008). Evidence for both locus-specific and genome-wide DNA demethylation 
events have originated from studies of early embryogenesis. In the fertilised oocyte, 
the paternal pronucleus undergoes a global wave of DNA demethylation prior to 
pronuclear fusion, suggesting the existence of an active mechanism of 5mC erasure 
that is independent of DNA replication (Hajkova et al., 2002; Oswald et al., 2000; 
Santos et al., 2002). The maternal pronucleus also undergoes extensive global DNA 
demethylation, albeit more slowly during the first few cleavage divisions of the early 
embryo, due to a replication-dependent, passive dilution of 5mC (Rougier et al., 
1998).  
The recent identification of 5-hydroxymethylcytosine and further oxidation products 
of 5-methylcytosine has led to the suggestion that they represent intermediates of a 
DNA demethylation mechanism initiated by the TET enzyme family (Bhutani et al., 
2011; Wu and Zhang, 2010). DNMT1 shows a reduced binding preference for 5hmC 
compared to 5mC, suggesting that oxidation of 5mC to 5hmC by the TET proteins 
may be a method of disrupting the maintenance methylation machinery and 
triggering passive demethylation through the dilution of 5mC during successive 
rounds of DNA replication (Tahiliani et al., 2009). 5hmC immunostaining of mitotic 
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chromosomes in pre-implantation embryos provided further support of such a 
replication-dependent, passive demethylation mechanism (Inoue and Zhang, 2011).  
However, the precise mechanisms governing active DNA demethylation have been 
more difficult to elucidate. No mammalian proteins have so far been identified with 
5mC-specific DNA base-excision repair demethylase activity analogous to the DNA 
glycosylases found in plants, but the base-excision repair (BER) pathway has been 
shown to play an essential role during in vivo active DNA demethylation in 
mammals (Hajkova et al., 2010). Thymine DNA glycosylase (TDG)-deficient 
embryos are non-viable and characterised by severe epigenetic abnormalities, 
highlighting the importance of TDG in normal development (Cortázar et al., 2011; 
Cortellino et al., 2011). Two main pathways have been proposed to modify 5mC to a 
suitable TDG substrate: TET-mediated oxidation and deamination to thymine by the 
AID (activation induced cytidine deaminase) or APOBEC (apolipoprotein B mRNA 
editing enzyme, catalytic polypeptide-like) proteins (Figure 1-3). 
A TET- and TDG-mediated mechanism was proposed after the discovery of the TET 
family of enzymes in mammalian cells and their ability to catalyse the sequential 
oxidation of 5mC in both the CpG and non-CpG context in vitro to 5hmC, 5fC and 
5caC, followed by thymine DNA glycosylase-mediated excision repair (Guo et al., 
2011; Ito et al., 2011; Tahiliani et al., 2009). TDG specifically recognizes both 5fC 
and 5caC bases (but neither 5mC or 5hmC) within duplex DNA, suggesting a 
mechanistic link for both TET and TDG to active DNA demethylation (He et al., 
2011; Maiti and Drohat, 2011; Zhang et al., 2012). The preference of TDG for 
removing 5fC and 5caC from C:G pairings, despite the greatly reduced numbers of 
5fC/5caC within the genome compared to unmodified or methylated C, was 
explained though the observation that TDG base-excision activity is dependant on N-
glycosidic bond stability and that 5fC/5caC have the lowest energy barriers for N-
glycosidic bond cleavage than either 5hmC, 5mC or unmodified C (Bennett et al., 
2006; Williams and Wang, 2012). Several other observations have strengthened the 
view that TET/TDG-mediated excision represents the most likely mechanism behind 
active DNA demethylation: TET3 knockdown results in only partial demethylation 
of the paternal pronucleus in fertilised oocytes and eventual embryonic lethality (Gu 
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et al., 2011); TDG knockdown in mESCs results in an accumulation of global 5caC 
levels, whilst TDG overexpression reduces 5caC (He et al., 2011); and TET1 activity 
is essential for the erasure of paternal genomic imprints in PGCs (Yamaguchi et al., 
2013). 
It has also been suggested that the oxidised methyl group could be directly removed 
by a 5caC-specific decarboxylase, although the existence of such an enzyme remains 
unknown (Schiesser et al., 2012). There is some evidence for an alternative 
mechanism of active DNA demethylation involving TDG and the AID/APOBEC 
enzyme complex, whereby either 5mC or 5hmC undergo deamination to thymine and 
5-hydroxymethyluracil, respectively, followed by TDG-mediated BER. 
 
Figure 1-3: Schematic of proposed DNA demethylation pathways and their enzymatic 
components. DNA demethylation may occur either through the passive dilution of 5mC through 
replication (A), or through a replication-independent active mechanism involving TET oxidation to 
5hmC (B). 5hmC may then undergo either deamination by the AID/APOBEC enzymes to 5hmU (C) 
or further oxidation to 5fC/5cacC (D). TDG-mediated BER pathway can target either 5fC, 5caCor 
5hmU substrates and restore an unmodified C:G pairing in duplex DNA (E). Image adapted from: 
Song et al., Nature Biotechnology 30(11), 1107-1116 (2012).  
TDG is known to recognise both thymine (T)-G and uracil (U)-G mismatches within 
DNA and excise the mismatched base, thus restoring normal C-G base pairing 
(Neddermann and Jiricny, 1993, 1994). It has been proposed that 5mC deamination 
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by the AID/APOBEC enzyme complex to T, followed by TDG-mediated excision 
repair, could be a method of active DNA demethylation. The AID enzyme appears to 
be required for active DNA demethylation during both experimental cellular 
reprogramming of somatic cells and during in vivo reprogramming of PGCs (Bhutani 
et al., 2010; Popp et al., 2010). TDG is also able to recognize and excise 5-
hydroxymethyluracil (5hmU)-G mismatches, suggesting that deamination of 5hmC 
could be a possible demethylation mechanism (Cortellino et al., 2011; Guo et al., 
2011). However, 5hmC deamination has not so far been detected either in vivo or in 
vitro by the AID/APOBEC deaminases, which also show a much reduced preference 
for 5mC substrates over unmodified C (Nabel et al., 2012; Rangam et al., 2012). 
Moreover, AID deficiency does not result in embryonic lethality, unlike TDG (Popp 
et al., 2010). Given the critical role of 5mC in development, active DNA 
demethylation must entail an alternative AID-independent mechanism. 
1.3 5mC profiling methods 
1.3.1 Restriction enzyme-based assays 
Changes in DNA methylation patterns have been implicated in a wide variety of 
developmental and disease processes, driving the rapid development of novel 
methods of methylome analysis (Beck and Rakyan, 2008; Brena et al., 2006). DNA 
methylation profiling typically relies on an initial 5mC-dependent treatment, such as 
restriction enzyme digestion, affinity enrichment or bisulphite conversion, coupled to 
a detection method such as PCR amplification, microarray hybridisation or DNA 
sequencing (Laird, 2010).  
The first example of DNA methylation detection in the late 1970s used methylation-
sensitive restriction enzyme digestion of DNA, followed by analysis using gel 
electrophoresis and Southern blotting, to show that methylation in mammalian DNA 
occurs predominantly in the CpG context (Gautier et al., 1977). Commonly used 
restriction enzymes to interrogate 5mC include HpaII and MspI, a pair of 
isoschizomers with the same recognition site CCGG but differential methylation 
sensitivity: HpaII is inhibited by methylation of the second cytosine in the 
recognition sequence (CmeCGG), whereas MspI is not. DNA cleavage with HpaII 
and MspI in separate assays and comparison of the resulting fragment sizes allows 
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for the discrimination of methylated from unmethylated DNA. Locus-specific, 
quantitative 5mC detection may also be achieved by combining restriction enzyme 
digestion with PCR across the recognition sequence, although this method is prone to 
false positive readings due to incomplete HpaII digestion (Singer-Sam et al., 1990). 
Nevertheless, differential enzymatic 5mC sensitivity forms the basis of more recently 
developed genome-wide detection methods such as the HELP assay (HpaII tiny 
fragment enrichment by ligation-mediated PCR) and Methyl-Seq, which combine 
restriction enzyme digestion of genomic DNA with microarray hybridisation and 
next-generation sequencing, respectively, to identify methylated loci (Brunner et al., 
2009; Khulan et al., 2006). 
1.3.2 Affinity enrichment-based assays 
Affinity enrichment techniques use either antibodies raised against 5mC or the 
methyl-binding domain (MBD) of MECP2, a methylation-specific CpG-binding 
protein, to efficiently precipitate 5mC-containing DNA fragments. The first 
demonstration of a 5mC affinity enrichment assay used an MBD column (containing 
a MECP2-bound nickel-agarose matrix) to fractionate human genomic DNA 
according to its methylated CpG content (Cross et al., 1994). Alternative MBD 
proteins with higher affinity for methylated CpG sites were subsequently engineered 
(Jørgensen et al., 2006) and used for profiling captured DNA on microarrays (Keshet 
et al., 2006). MBD enrichment may be coupled with PCR for targeted, locus-specific 
5mC detection or coupled with array hybridisation for genome-wide analysis 
(Gebhard et al., 2006a, 2006b). The methylated CpG island recovery assay (MIRA) 
is a similar technique for MBD-mediated enrichment (using an MBD2/MSB3L1 
complex) that may be coupled to arrays or next-generation sequencing for 5mC 
analysis (Rauch and Pfeifer, 2005; Rauch et al., 2006, 2007). 
Enrichment using an anti-5mC antibody, termed methylated DNA 
immunoprecipitation (MeDIP), was used to produce the first genome-wide 5mC 
profiles in mammalian DNA in combination with tiling microarray hybridisation 
(Weber et al., 2005). The advent of next generation, high-throughput DNA 
sequencing has allowed for genome-wide 5mC profiling using both MeDIP and 
MBD enrichment strategies without being restricted by either the species-specificity 
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of a microarray or to the small subset of genomic loci typically represented 
(Brinkman et al., 2010; Down et al., 2008; Serre et al., 2009). MeDIP-seq has 
become a well-established method of generating methylomes in a efficient, cost-
effective manner that in amenable to high-throughput sample processing and 
automation of the experimental protocol (Butcher and Beck, 2010). Both MeDIP-seq 
and MBD-seq offer moderate genomic resolution of 100-300bp, depending on DNA 
fragment size and sequencing read length, and can accurately identify differentially 
methylated regions (DMRs) between samples, but may only be used to infer relative 
methylation differences rather than quantitative differences because the detected 
5mC signals are strongly influenced by sequencing depth. In addition, both 
enrichment methods exhibit bias towards CpG-dense regions of the genome, 
potentially underestimating the proportion of 5mC in areas of low CpG content 
(Bock et al., 2010; Harris et al., 2010; Li et al., 2010a).  
1.3.3 Sodium bisulphite-based assays 
Sodium bisulphite sequencing (BS-seq) is considered the gold standard for genome-
wide DNA methylation profiling, combining BS conversion of DNA with next-
generating sequencing technology to produce single-base resolution DNA 
methylomes (Cokus et al., 2008; Frommer et al., 1992). BS conversion can 
differentiate methylated from unmethylated cytosines in the genome but does not 
discriminate between 5mC and 5hmC, which are protected from conversion to uracil 
and are both read as cytosine after sequencing (Huang et al., 2010; Jin et al., 2010; 
Nestor et al., 2010). The first single-base-resolution, mammalian DNA methylome 
was generated using BS-seq for human ESCs and foetal fibroblasts (Lister et al., 
2009) and similar studies have since employed BS-seq to profile 5mC in a wise 
variety of samples, including human cancers, cord blood, peripheral blood 
mononuclear cells and mouse frontal cortex (Berman et al., 2011; Heyn et al., 2012; 
Hon et al., 2012; Li et al., 2010b; Xie et al., 2012). However, BS-seq requires much 
deeper sequencing to generate 5mC profiles with comparable CpG coverage to those 
obtained through affinity-enrichment methods, substantially increasing the cost per 
methylome. Whilst assays such as MeDIP- and MBD-seq produce DNA libraries 
covering only highly-methylated genomic regions, thus concentrating the sequencing 
effort only on potential regions of interest, BS-seq datasets cover the entire genome 
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and the majority of sequencing reads end up mapping to unmethylated genomic 
regions and are effectively discarded (Robinson et al., 2010). 
Reduced representation bisulphite sequencing (RRBS) employs a similar 
experimental method to profile DNA methylation in a defined subset of CG-rich 
genomic regions. RRBS covers less than 10% of all CpG sites and is typically 
restricted to CpG islands and promoter regions, but allows for a much more cost-
effective genome-wide 5mC analysis than whole genome BS-seq, making it suitable 
for profiling multiple DNA samples (Bock et al., 2010; Gu et al., 2010; Meissner et 
al., 2005, 2008b).   
BS-converted DNA is not easily interrogated through standard array hybridization 
techniques in the same way as affinity-enriched or endonuclease-digested DNA 
because the lower sequence complexity results in frequent mismatches and decreased 
binding specificity. However, several specialised arrays have been developed 
specifically for the detection of genome-wide DNA methylation at single-base 
resolution. The Infinium HumanMethylation450 (450K) BeadChip provides the most 
comprehensive genome coverage of the currently available arrays, interrogating 
485,577 CpG sites, 3,091 non-CpG sites and 65 random SNPs, and is arguably the 
most widely used DNA methylation profiling microarray. Sample preparation 
requires minimal hands-on time and each BeadChip consists of 12 arrays for DNA 
hybridisation, making this method suitable for analysing large cohorts. The probes 
cover 99% of all RefSeq genes and target multiple transcripts, covering a total of 
29,246 transcripts with an average of 17.9 probes each (Bibikova et al., 2011). 
Probes were designed to target multiple gene features, including promoters, gene 
bodies, the first exon, 5’ and 3’ UTRs (Figure 1-4A). In addition, 96% of all CpG 
islands are covered by the array’s probes, where CpG islands are defined as 500bp 
windows with a GC base composition over 55% and an observed:expected CpG ratio 
over 0.65, totalling 26,658 targeted CpG islands with an average of 5.63 probes each 
(Figure 1-4B).  
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Figure 1-4: Infinium 450K array probe distribution and design. A) Typical probe representation 
of each gene transcript. B) Typical probe representation of regions of differential CpG context. Image 
courtesy of: Bibikova et al., Genomics 98(4), 288-295 (2011).   
The 450K platform has been extensively validated against other technologies as a 
highly sensitive and reproducible 5mC profiling method and is also compatible with 
formalin-fixed, paraffin-embedded (FFPE) tissue samples (Dedeurwaerder et al., 
2011; Roessler et al., 2012; Sandoval et al., 2011). The moderate genome coverage 
of the Infinium 450K array compared to other sequencing-based assays, such as 
RRBS-seq, is counterbalanced by the substantially lower cost, higher sample 
throughput and less complex data analysis inherent in this assay, which has 
established itself as the current platform of choice for population-based epigenetic 
analyses, such as epigenome-wide association studies (Liu et al., 2013b; Michels et 
al., 2013; Rakyan et al., 2011; Tsai and Bell, 2015). However, conventional 450K 
protocols depend on BS conversion of DNA and therefore cannot be used to 
discriminate 5mC from 5hmC within the genome. The popularity of the 450K array 
for epigenetic studies made it an attractive candidate for adaptation to 5hmC analysis 
after the emergence of oxidative bisulphite (oxBS) chemistry (Booth et al., 2012). 
This method is explored further in Chapter 5. 
For locus-specific detection, combined bisulphite restriction analysis (COBRA) 
relies on restriction enzyme digestion of BS-converted DNA followed by gel 
electrophoresis, electroblotting and oligonucleotide hybridisation to quantify 5mC at 
particular recognition sites (Xiong and Laird, 1997). This method is suitable for use 
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with FFPE tissue samples and small amounts of starting DNA, but is labour-
intensive and limited to assaying a defined set of restriction sites. Similarly, 
methylation-specific PCR (MSP) of BS-converted DNA using methylation-sensitive 
primers followed by gel electrophoresis may be used for semi-quantitative 
assessment of 5mC levels and is sensitive enough to detect very low 5mC levels 
(0.1%), but it is also a fairly labour-intensive method and therefore not suitable for 
large-scale analyses (Herman et al., 1996). For high-throughput, quantitative PCR-
based 5mC detection, MethyLight assays can rapidly and accurately identify 
methylated DNA loci using real-time, fluorescence-based TaqMan® technology 
(Eads et al., 2000). Locus-specific BS-seq can be used to interrogate 5mC by 
sequencing PCR products amplified from BS-converted DNA, allowing strand-
specific, single-base resolution of 5mC. However, this method but requires cloning 
of PCR amplicons followed by individual sequencing of multiple clones in order to 
provide adequate sensitivity towards 5mC (Frommer et al., 1992).  
Pyrosequencing technology allows accurate, quantitative measurement of 5mC at 
individual CpG sites in a strand-specific manner (Dejeux et al., 2009; Ronaghi et al., 
1996; Tost and Gut, 2007). Pyrosequencing analysis of DNA methylation relies on 
BS conversion of DNA samples followed by PCR amplification of the target 
sequence using biotin-labelled primer pairs. These amplicons are then subjected to a 
real-time DNA sequencing-by-synthesis method, which relies on a cascade of 
enzymatic reactions following incorporation of a nucleotide in the newly synthesised 
DNA strand to generate visible light in a manner proportional to the number of added 
nucleotides. Only one type of nucleotide is present in the reaction well at any one 
time and unincorporated nucleotides are degraded rapidly, allowing consecutive 
addition of the four nucleotides to the reaction wells. The intensity of the light 
generated for each nucleotide type is measured and used to determine the sequence 
of the template DNA strand (Figure 1-5).  
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Figure 1-5: The pyrosequencing reaction mechanism (left) and output Pyrogram (right) 
showing the confirmed DNA sequence.  Image courtesy of: England and Pettersson, Nature 
Methods 2 (2005). 
DNA methylation analysis by pyrosequencing (BS-pyroseq) has been extensively 
used for targeted DNA methylation analysis of candidate genomic regions (Baba et 
al., 2010; White et al., 2006; Xinarianos et al., 2006), as well as a validation tool for 
5mC signal detected using other analysis methods (Choufani et al., 2011; Feber et 
al., 2011; Mirmohammadsadegh et al., 2006; Schatz et al., 2004). 
1.4 5hmC profiling methods  
1.4.1 Global 5hmC detection 
Studies concerning the newly identified oxidative derivatives of 5mC have been 
hampered by the lack of appropriate methods to identify and profile these 
modifications; the first 5hmC detection methods allowed only quantification of 
global 5hmC levels in genomic DNA. Thin-layer chromatography (TLC) assays 
were first used to confirm the presence of 5hmC in the DNA of mouse Purkinje 
neurons and granule cells at levels of 0.59% and 0.23% of the total dG content, 
respectively, whilst 5hmC levels in ESCs were measured at 0.032% of all bases, 
slightly lower than in the neuronal cells (Kriaucionis and Heintz, 2009; Tahiliani et 
al., 2009). Restriction enzyme-based methods have been used to quantify 5hmC in 
various mouse and human tissues, although these are limited to assaying 5hmC in 
specific recognition sequences (Kinney et al., 2011; Szwagierczak et al., 2010). 
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Several methods have employed anti-5hmC antibodies to measure global 5hmC, 
including immunostaining, dot-blots and enzyme-linked immunosorbent assays 
(ELISA). Immunostaining of fixed tissue samples (Hackett et al., 2012; Haffner et 
al., 2011; Jin et al., 2011b; Lian et al., 2012; Ruzov et al., 2011; Szulwach et al., 
2011a) and immuno dot-blots using anti-5hmC antibodies (Jin et al., 2011a; Nestor et 
al., 2012) are perhaps the most widely used methods for quick and easy assessment 
of the relative distribution of 5hmC across a wide range of cell and tissue types. 
However, the most sensitive and accurate 5hmC quantification method is 
undoubtedly liquid chromatography-mass spectrometry (LC-MS), which has been 
used to measure 5hmC in various mouse tissues and cell lines (Globisch et al., 
2010a; Jin et al., 2011b; Kraus et al., 2012; Munzel et al., 2010).  
1.4.2 Locus-specific detection 
The first developments in locus-specific 5hmC detection were centred around 
affinity-based DNA enrichment methods followed by PCR, microarray or 
sequencing analysis (Matarese et al., 2011). The first genome-wide profile of 5hmC 
used selective chemical labelling of 5hmC coupled to high-throughput sequencing to 
map 5hmC in the cerebellum of postnatal day 7 and 2.5-month old mice (Song et al., 
2011b; Szulwach et al., 2011a, 2011b). This method uses a ß-glucotransferase (ß-
GT) enzyme from T4 bacteriophages to label 5hmC with a customised glucose 
moiety (UDP-6-N3-glucose), resulting in ß-glucosyl-5-hydroxymethylcytosine 
(5gmC). Click chemistry is then used for biotinylation of the azide group of 5gmC, 
allowing high-affinity purification of the biotin-labelled DNA fragments using 
avidin. Other methods using selective glusosylation and biotin-labelling have been 
developed which do not require the engineering of a modified glucose moiety. The 
GLIB (glusosylation, periodate oxidation and biotinylation) method uses ß-GT to 
glucosylate 5hmC with UDP-glucose, followed by oxidation by sodium periodate to 
an aldehyde derivative, which can be biotinylated using aldehyde-reactive probes for 
selective pull-down of 5hmC-containing DNA for sequencing analysis (Pastor et al., 
2011). Similarly, glycosylation of genomic DNA can be combined with restriction-
enzyme digestion to detect both 5mC and 5hmC. The MspI restriction endonuclease 
is methylation-insensitive and cleaves CCGG sites containing C, 5mC or 5hmC at 
the internal cytosine position, but glucosylation of 5hmC protects this site from MspI 
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digestion (Huang et al., 1982; Josse and Kornberg, 1962; Waalwijk and Flavell, 
1978). Therefore comparison of MspI digestion patterns between glycosylated and 
untreated DNA can be used to quantify the 5hmC content of DNA at CCGG loci. 
Digestion with HpaII, an isoschizomer of MspI that cannot cleave CCCGG sites 
when 5mC, 5hmC or 5gmC is present at the internal cytosine position, can provide a 
measure of the total methylated content of DNA. As a consequence, digestion of 
glucosylated and untreated DNA in parallel with either MspI or HpaII may be used 
to quantify 5mC levels by subtraction of the MspI-generated 5hmC estimate from the 
HpaII estimate of total methylation. Digested DNA may then be analysed using gel 
electrophoresis or PCR amplification using primers flanking a CCGG recognition 
site of interest to assess global levels of 5hmC and 5mC (Davis and Vaisvila, 2011; 
Kinney et al., 2011). Alternatively, digested DNA may be hybridised to a tiling 
microarray for genome-wide, single-base resolution of modified bases at CCGG sites 
(Khare et al., 2012).   
Antibody-based immunoprecipitation of hydroxymethylated DNA fragments 
(hMeDIP) was also quickly developed as an alternative enrichment strategy for 
5hmC profiling, based on well-established MeDIP protocols for 5mC profiling. The 
first hMeDIP-seq profiles were generated for wild-type (WT) and mutant mESCs 
and differentiating embryoid bodies (EBs) using antibodies raised against 5hmC 
(Ficz et al., 2011; Williams et al., 2011). 5hmC has since been mapped in a variety of 
cell lines and tissue types using hMeDIP-seq, including mouse PGCs, mouse NPCs, 
human ESCs, in vitro derived human NSCs and dopamine neurons, and human 
melanoma samples (Hackett et al., 2012; Kim et al., 2014; Lian et al., 2012; Stroud 
et al., 2011; Tan et al., 2013). 5hmC-containing DNA fragments captured using 
hMeDIP assays have also been interrogated through hybridization to tiling 
microarrays for analysis of specific genomic features. For example, 5hmC was 
mapped in human frontal lobe DNA using the NimbleGen 720K microarray, which 
covers just over 720,000 CpG sites within CpG islands and promoter regions (Jin et 
al., 2011a), the NimbleGen 72K ENCODE microarray was used to determine 5hmC 
enrichment across over 72,000 biologically significant genomic regions, as defined 
by the ENCODE project, in several normal human tissues, including brain, colon and 
liver (Nestor et al., 2012), and 5hmC was mapped in WT and Tet1-knockdown 
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mESCs using NimbleGen whole-genome tiling arrays (Wu et al., 2011). A related 
IP-based method uses an antibody raised against 5-methylenesulphonate (CMS), the 
product of BS conversion of 5hmC, to pull down CMS-containing DNA fragments 
after BS conversion for subsequent analysis using sequencing, PCR or microarrays 
(Huang et al., 2012; Pastor et al., 2011).  
1.4.3 Single-base resolution detection 
After publication of several genome-wide 5hmC profiles using a variety of affinity-
purification methods, a modification of the traditional bisulphite conversion 
chemistry made it possible to profile 5hmC at single-base resolution in DNA, 
resulting in the first quantitative mapping of 5hmC in mESCs (Booth et al., 2012). 
This selective chemical conversion method, termed oxBS chemistry, includes a DNA 
oxidation step using potassium perruthenate prior to bisulphite conversion. Oxidation 
results in the conversion of all 5hmC modifications to 5fC, whilst leaving 5mC 
unchanged. 5fC behaves as unmodified C during subsequent sodium bisulphite 
treatment and is fully converted into uracil. Therefore, under oxBS conditions, only 
5mC bases are detected as cytosine after sequencing. Subtraction of the oxBS-
generated cytosine readout from BS-only datasets allows detection of 5hmC sites. An 
alternative method for single-base resolution of 5hmC has also been developed, 
termed TET-assisted bisulphite sequencing (TAB-seq), which also uses a selective 
oxidation step prior to BS conversion in order to discriminate 5mC from 5hmC (Yu 
et al., 2012). DNA is first treated with ß-GT to glucosylate 5hmC residues, before 
using an excess recombinant TET1 protein to fully oxidise the remaining 5mC bases 
to 5caC, whilst 5gmC is protected from further oxidation. BS treatment leads to the 
conversion of all 5caC (originally 5mC) and unmodified C to uracil, whilst 5gmC 
remains protected. After sequencing, only 5gmC positions (originally 5hmC) bases 
will be read as C, whilst all original 5mC and C positions will be read as thymine 
(T), allowing quantitative base-resolution analysis of 5hmC in one sequencing 
reaction. TAB-seq has since been used to profile 5hmC in both human and mouse 
foetal and adult frontal cortex (Lister et al., 2013; Wen et al., 2014). In addition, 
single molecule real-time (SMRT) sequencing technology can differentiate between 
C, 5mC and 5hmC in DNA and has been applied to genome-wide 
hydroxymethylome profiling in an mESC sample (Flusberg et al., 2010; Song et al., 
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2011a). SMRT sequencing is a sequencing-by-synthesis method that monitors the 
continuous incorporation of phospholabelled nucleotides in newly synthesised DNA 
molecules through the detection of fluorescent pulse emissions. Measurement of the 
interpulse duration allows differentiation between modified cytosine bases, although 
5hmC labelling with ß-GT and biotin followed by selective enrichment of 5hmC-
containing DNA prior to SMRT sequencing greatly increases the detection 
confidence of this method and reduces the sequencing cost per sample.  
1.5 DNA methylation in cell-fate specification 
DNA methylation is thought to be essential for maintaining the phenotypic plasticity 
of a cell in response to both environmental and developmental cues (Feinberg, 2007). 
The transition from a pluripotent state to a terminally differentiated cell type 
coincides with many tissue-specific alterations in DNA methylation that have been 
linked to the regulation of gene expression and alternative transcription (Irizarry et 
al., 2009; Shiota et al., 2002). Greater differences in DNA methylation levels have 
been found between tissue types than between individuals; for example, 7.1% of all 
CpG sites show differential 5mC levels between dermal fibroblasts and CD4+ 
lymphocytes, compared to differences of only 0.275% and 0.1% between individuals 
of different age and gender, respectively (Eckhardt et al., 2006). These differentially 
methylated regions fall within both intragenic and intergenic regions and are 
preferentially located at highly evolutionarily conserved sequences, suggesting a 
potential regulatory function.  
DNA methylation at CpG-rich promoter regions varies considerably depending on 
cell and tissue type, suggesting a role in regulating these changing transcriptional 
profiles during development. Gains in promoter-associated 5mC during development 
are usually associated with silencing of the corresponding gene, as shown by studies 
of X chromosome inactivation (Mohandas et al., 1981). An in vitro model of 
neurogenesis demonstrated that mESCs gain CpG-rich promoter methylation during 
lineage commitment as they differentiate into radial-glial progenitor cells and then 
into postmitotic neurons. This de novo methylation occurred in approximately 2-3% 
of all interrogated promoters (around 350 out of 15,000), mostly during the transition 
from mESCs to neuronal progenitor cells, with few further 5mC gains observed in 
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the differentiation to neurons. In contrast, loss of methylation is seen only at 0.1% 
(or 22) of the promoters tested. Promoter-associated 5mC gains were also enriched at 
pluripotency-specific genes, including Oct4, Nanog, Sox2 and Zfp42, suggesting 
methylation functions primarily as a repressive mark to suppress the pluripotent 
potential of cell during development (Mohn et al., 2008).  
An array-based analysis of over 14,000 CGIs in human brain, blood, spleen and 
muscle tissue revealed that less than 10% of all CGIs within promoters are 
methylated in somatic tissues, but around half of these CGIs show extensive tissue-
specific differential methylation patterns and many are associated with genes 
essential in development, such as homeobox genes (Illingworth et al., 2008). In 
addition, a MeDIP-based analysis of 5mC in four different mouse tissues (brain, 
heart, liver and testis) found that most detected regions of 5mC within promoters and 
CGIs were also tissue-specific differentially methylated regions (T-DMRs), whereas 
around 10-fold fewer loci were uniformly methylated in all four tissues (460 
compared to 4,686 T-DMRs), supporting a functional role for 5mC in regulating 
tissue specification development (Liang et al., 2011). The application of genome-
wide RRBS-seq in a variety of pluripotent and terminally differentiated cells allowed 
5mC profiling at around 5% of all CpG sites (approximately 1 million CpGs) in both 
CpG-rich and CpG-poor regions of the genome. Approximately 8% of all CpG sites 
became hypermethylated and 2% lost methylation upon ESC differentiation; most of 
these differentially methylated CpG sites associated occurred at putative distal 
regulatory elements up to 100kb away from annotated promoters (Meissner et al., 
2008a). More recently, this observation has been supported by single-base resolution 
microarray analysis of 5mC at over 4.5 million CpG sites in a variety of human and 
mouse tissues, which revealed that the greatest tissue-specific methylation variation 
is located mostly outside of promoters, in CpG island shores that are located within 
2kb of CGIs. Over half of CGI shores are in intergenic regions, over 2kb away from 
the nearest annotated gene (Irizarry et al., 2009).  
Changes in the non-CpG content of cells have also been implicated in differentiation 
processes; nearly 25% of all methylated cytosines in H1 ESCs are found in non-CpG 
context, almost all of which seem to be lost upon differentiation via six days of 
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BMP4 exposure (Lister et al., 2009). This observation indicates such global DNA 
methylation changes are necessary for the switching of cell fates; in this instance, 
non-CpG methylation may be a distinguishing feature of stem cells and a significant 
contributor towards establishing pluripotency. 
1.5.1 The potential role of 5hmC in neural development 
The discovery of 5hmC as a stable modification in mammalian DNA has led to the 
hypothesis that this modified cytosine may exert its own gene regulatory function 
within the genome in an analogous manner to 5mC. It appears there is a correlation 
between global 5hmC levels and differentiation potential: the 5hmC content of DNA 
increases as a cell loses its proliferative capacity and transitions from a pluripotent, 
stem cell-like state to a fully differentiated cell type (Haffner et al., 2011; Nestor et 
al., 2012; Orr et al., 2012). Elevated levels of 5hmC have consistently been found in 
tissues of the CNS, where the 5hmC content of DNA is around ten-fold higher than 
in other somatic tissues or proliferating cell lines (Globisch et al., 2010b; Kriaucionis 
and Heintz, 2009; Song et al., 2011b). In addition, global 5hmC levels in the mouse 
cerebellum increase during aging, rising from approximately 0.1% of total 
nucleotides at postnatal day 7, when extensive cell proliferation is occurring in 
developing brain, to 0.4% at 2.5 months of age (Song et al., 2011b), with a similar 
increase of approximately 4-fold being detected between postnatal day 7 and 6-
week-old mouse cerebellum (Szulwach et al., 2011a). Unpublished data from Song et 
al. (2011) also suggests 5hmC levels increase during the in vitro differentiation of 
adult mNSCs.  
It has previously been shown that active DNA demethylation is integral to neuronal 
function and plays a role in learning and memory formation. Locus-specific active 
DNA demethylation of the brain-derived neurotrophic factor (BDNF) promoter 
occurs in response to neuronal stimulation, releasing promoter-bound MECP2 and 
resulting in upregulation of BDNF, a key regulator of synaptic plasticity 
(Martinowich et al., 2003; Yoshii and Constantine-Paton, 2010). MECP2 has also 
been demonstrated to bind 5hmC and 5mC with similar affinities and is the principal 
5hmC-binding protein in mouse brain (Mellen et al., 2012), which supports the 
previous findings of both MECP2 and 5hmC being preferentially located in regions 
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of highly accessible chromatin and elevated gene expression (Song et al., 2011b; 
Thambirajah et al., 2012). 5hmC analysis in mouse models of Rett syndrome, a 
neurological disorder characterized by MECP2 mutations, found that 5hmC levels in 
the cerebellum are inversely correlated with MECP2 dosage and that MECP2 
binding to 5mC can inhibit TET1-mediated oxidation of 5mC (Szulwach et al., 
2011a). Furthermore, combined MeDIP- and hMeDIP-seq analysis of the epigenetic 
changes occurring within the anterior HOXA cluster (HOXA1-6) during the neural 
differentiation of a human embryonal carcinoma cell line showed that 5mC to 5hmC 
conversion was a critical factor in the activation of this gene set (Bocker et al., 2012). 
Taken together, these observations all suggest a unique role for 5hmC in 
transcriptional regulation during neurodevelopment and brain maturation.  
1.5.2 Development of the central nervous system 
Neurons and macroglia are the two main cell types present in the brain and spinal 
cord, which together make up the mammalian CNS. These organs originate from a 
multipotent, self-renewing NSC population present in the neural tube of the 
developing embryo, which is comprised of a single layer of neuroepithelial cells 
showing strong apical-basal polarity (Götz and Huttner, 2005). CNS development 
occurs under strict spatiotemporal control, with embryonic neurogenesis taking place 
before the onset of gliogenesis. Initially, neuroepithelial cells undergo an expansion 
phase of symmetric cell divisions, before switching to asymmetric divisions which 
each produce a neuronal cell and a daughter stem cell (Figure 1-6). As neurogenesis 
progresses, neuroepithelial cells are gradually replaced by radial glial cells and basal 
progenitor cells, two further NSC subtypes with restricted lineage potential (Temple, 
2001).  
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Figure 1-6: Neurogenesis in the developing mouse CNS. Neural development in the mammalian 
CNS is divided into three major phases that encompasses an NSC expansion phase, a neurogenic 
phase and a gliogenic phase. Abbreviations: E10-17 = embryonic day 10-17. NP = neural progenitors 
(neuroepithelial cells). IKNM = interkinetic nuclear migration; MZ =marginal zone; VZ = ventricular 
zone; SVZ = subventricular zone; SEZ = subependymal zone; PP= preplate; SP =subplate; CP = 
cortical plate; CR = Cajal-Retzius neuron; L1-L6= neuronal layers; UL Pyr = upper layer pyramidal 
neurons; DL Pyr = deep layer pyramidal neurons; RGC = radial glial cell; IPC = intermediate 
progenitor cell; Ast = astrocytes; EL = ependymal cells; BV = blood vessels. Image adapted from: 
Kwan et al., Development 139, 1535-1546 (2012). 
Concomitant with the onset of neuronal differentiation is the transition of the 
neuroepithelium into a multi-layered tissue. Neurons migrate towards the basal 
surface, forming a neuronal layer, whilst the most apical cell layer containing radial 
glial and basal progenitor cells is referred to as the ventricular zone (VZ). Radial 
glial cells and basal progenitor cells continue to divide asymmetrically to produce 
both neurons and daughter stem cells, before finally switching to symmetric, 
neurogenic cell division towards the end of neurogenesis. The switch from 
neurogenesis to gliogenesis coincides with the development of a subventricular zone 
(SVZ), a new cell layer basal to the VZ formed by a subset of basal progenitors 
(Götz and Huttner, 2005; Temple, 2001). Gliogenesis occurs mostly in the SVZ of 
the developing telencephalon, resulting in the formation of the two main types of 
macroglial cell: astrocytes and oligodendrocytes. The SVZ remains in the lateral 
ventricle of the adult mammalian brain and is a source of adult NSCs (Lois and 
Alvarez-Buylla, 1993; Reynolds and Weiss, 1992). 
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1.5.3 Neural development in the adult mammalian brain 
A subset of cells in the mammalian CNS have been found to retain NSC-like 
properties throughout adulthood and can differentiate to produce both neurons and 
glia (Lois and Alvarez-Buylla, 1993; Morshead et al., 1994; Reynolds and Weiss, 
1992; Weiss et al., 1996). They can be found in either the SVZ of the lateral ventricle 
(Figure 1-7) or in the subgranular zone (SGZ) of the hippocampus. Adult NSCs in 
the lateral ventricle can differentiate to produce interneurons, which migrate to the 
olfactory bulb, whilst NSCs of the hippocampus produce granule cells, which reside 
in the dentate gyrus (Alvarez-Buylla and Lim, 2004). These cells are known to show 
the structural and molecular properties of astrocytes and are often described as 
astroglial or radial glial cells (Doetsch et al., 1999). Adult NSCs have been 
successfully isolated from the adult mouse brain and established in vitro, where they 
may be induced to differentiate into the three major neural lineages (astrocytes, 
oligodendrocytes and neurons), providing a useful and convenient source of neural 
stem cells for research into neurodevelopmental and disease processes (Glaser et al., 
2007; Pollard et al., 2006). 
 
Figure 1-7: Location of NSCs in the adult mouse brain. (A) Cross-section of an adult mouse brain 
shown the location of the lateral ventricles (LV), where NSCs are found. (B) The SVZ layer in the 
wall of the LV. (C) The interrelationship of the 3 major cell types found in the SVZ. B cells are 
astrocyte-like cells that behave as NSCs, have self-renewing and differentiation capacity and are 
frequently GFAP-positive. They can generate C cells, a type of transit-amplifying cell that 
differentiate into A cells (neuroblasts), which can migrate to the olfactory bulb and function as 
interneurons. Both C and A cells are GFAP-negative. Image courtesy of: Alvarez-Buylla and Lim, 
Neuron 41(5), 683-686 (2004). 
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1.5.4 The role of astrocytes in the central nervous system 
Astrocytes are a diverse group of glial cells present throughout the CNS that are 
divided into two main subgroups, protoplasmic and fibrous astrocytes, based on 
differences in morphology and location within the brain (Sofroniew and Vinters, 
2010). Protoplasmic astrocytes are found in grey matter and are linked to neuronal 
cell bodies and synapses, whilst fibrous astrocytes are located within white matter 
and are typically linked to neuronal axons. Traditionally, glial cells have been 
thought to outnumber neurons by a factor of ten, but more recently a study of cell 
number in human brain tissue found approximately equal numbers of neurons and 
glia (Azevedo et al., 2009), although ratios vary dramatically between different brain 
regions. The cerebral cortex had the highest glial-to-neuron ratio at approximately 
4:1, whereas this ratio is reversed in the cerebellum.  
The functions of astrocytes are not well understood, but it is generally accepted that 
astrocytes play a critical function in the regulation of metabolism within the CNS. 
Astrocytes contain glycogen granules that serve as the main energy stores for 
neuronal cells and may be transferred to adjacent cells during periods of high 
synaptic activity or hypoglycaemia (Brown et al., 2004; Pellerin et al., 2007; 
Voutsinos-Porche et al., 2003). Astrocytic processes form connections to both blood 
vessels and neurons, allowing the regulation of local blood flow in response to 
neuronal activity (Iadecola and Nedergaard, 2007; Koehler et al., 2009). There is also 
evidence for a role in synaptic plasticity and signalling. Astrocytes express cell-
surface receptors for many neurotransmitter molecules and may release chemical 
signals of their own into the extracellular space, including glutamate, d-serine and 
ATP, which may regulate the function of neighbouring neurons (Haydon and 
Carmignoto, 2006). Astrocytic processes have also been shown to physically interact 
with many thousands of neuronal synapses and dendrite branches, providing a 
mechanism through which they may influence synaptic transmission and regulate the 
homeostasis of synaptic interstitial fluid (Halassa et al., 2007; Ogata and Kosaka, 
2002). Astrocytes are also thought to be important in guiding neuronal axon 
migration in the developing CNS (Powell and Geller, 1999) and to contribute to 
normal myelination of axons within white matter (Lutz et al., 2009). The 
increasingly diverse range of observed astrocytic functions suggests they are not 
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simply neuronal support cells but instead represent a group of highly specialised 
neural cells with critical importance in the healthy CNS. 
1.6 Aberrant DNA methylation phenotypes and disease 
Alongside changes in the distribution of histone modification and chromatin-
modifying proteins, aberrant DNA methylation has been linked to a host of 
developmental abnormalities and disease states (Feinberg, 2007). The importance of 
normal methylation patterns in development is highlighted by the embryonic lethal 
phenotype observed in embryos with homozygous mutation of DNMT1 (Li et al., 
1992). The epigenetic deregulation observed in many human disease states is often 
the result of genetic mutations that result in loss of imprinting or inactivation of a 
core component of the DNA methylation machinery, such as the DNMT enzymes or 
MBD proteins. These locus-specific mutations have been linked to many 
developmental disorders that frequently manifest as neurological disease, including 
Prader-Willi and Angelman syndrome (Buiting et al., 1995; Horsthemke and Buiting, 
2006), Rett syndrome (Guy et al., 2001; Psoni et al., 2012), Huntington’s disease (Ng 
et al., 2013), Alzheimer’s disease (Irier and Jin, 2012) and ICF 
(immunodeficiency, centromere instability and facial anomalies) syndrome (Xu et 
al., 1999). 5mC deregulation is also commonly observed during tumourigenesis, both 
in the form of global and site-specific hypo- and hyper-methylation events that are 
associated with the transcriptional deregulation and epigenetic plasticity observed in 
cancer cells (Feinberg and Vogelstein, 1983; Jones and Baylin, 2007). Promoter 
hypermethylation is observed at many tumour suppressor genes that are silenced in 
cancer, such as the retinoblastoma gene RB and the cyclin-dependent kinase 
inhibitors CDKN2A and CDKN2B (Greger et al., 1989; Herman et al., 1997), whilst 
many oncogenes are activated by hypomethylation, including HRAS and the cyclin 
D2 gene, CCND2 (Feinberg and Tycko, 2004; Feinberg and Vogelstein, 1983; 
Wilson et al., 2007). 
 Recently, 5hmC regulation has also been implicated in disease progression, 
particularly cancer. Global hypo-hydroxymethylation has been observed in many 
cancer tissues compared to their normal counterparts (Haffner et al., 2011; Jin et al., 
2011b; Kraus et al., 2012; Kudo et al., 2012; Lian et al., 2012; Yang et al., 2012) and 
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has also been associated with poorer prognosis and reduced survival in MDS, 
glioblastoma and melanoma (Lian et al., 2012; Liu et al., 2013a; Orr et al., 2012). 
Mutations in either isocitrate dehydrogenase genes 1 and 2 (IDH1/2) are often 
observed in astrocytomas, glioblastomas and acute myeloid leukaemia (AML), 
leading to TET2 inhibition and a hypermethylation phenotype, with corresponding 
hypo-hydroxymethylation (Figueroa et al., 2010). Reduced expression of TET1 and 
TET2 have also been extensively reported in various cancers, including AML, 
myelodysplastic syndrome (MDS), glioblastoma, prostate and breast cancer, further 
linking the 5hmC pathway to disease progression (Abdel-Wahab et al., 2009; 
Delhommeau et al., 2009; Hsu et al., 2012; Langemeijer et al., 2009; Muller et al., 
2012). 
1.7 DNA methylation as a therapeutic target 
Given the widespread epigenetic deregulation seen in many disease phenotypes, the 
restoration of normal DNA methylation patterning is a promising avenue of research 
in the development of multiple therapies. So far, the U.S. Food and Drug 
Administration (FDA) have approved two DNA demethylating drugs for clinical use 
in the treatment of MDS and AML (Kaminskas et al., 2005; Kantarjian et al., 2006). 
5-azacytidine (5-aza) and 5-aza-2’-deoxycytidine (DAC), also known by their trade 
names Vidaza and Dacogen, respectively, are cytosine analogues that incorporate 
into newly synthesised DNA molecules, where they act as DNMT inhibitors through 
irreversible covalent binding of the enzyme, thereby depleting the cell of active 
DNMT (Figure 1-8). However, it is unknown whether their therapeutic usefulness 
stems from an ability to truly reprogram cancerous cells or if these DNA 
demethylating agents simply trigger cell death due to cytotoxicity (Kaiser, 2010).  
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Figure 1-8: Mechanism of action of 5’-azacytidine and 5-aza-2’-deoxycytidine as a DNA 
demethylating agent. The molecule labelled “Z” represents the cytosine analogues 5-aza and DAC. 
The cytosine analogues incorporate into newly synthesised daughter strands, where they may 
covalently bind DNMT molecules, sequestering their enzymatic activity. The DNA demethylation 
activity of these epigenetic drugs depends on DNA replication, allowing selective targeting of 
proliferating cells. Image courtesy of Egger et al., Nature 429, 457-463 (2004).  
Whilst shown to be effective in treating certain cancers, these DNA demethylation 
drugs are thought to be non-specific in both their cellular and genomic targets and 
there is concern that they may induce hypomethylation at normally methylated sites, 
potentially activating oncogenes in normal tissue, as seen in mouse models of 
induced hypomethylation (Gaudet et al., 2003). However evidence is emerging that 
these DNMT inhibitors act in a non-random and reproducible manner, preferentially 
targeting CpG dinucleotides outside of CGIs, whilst other genomic regions are 
consistently resistant to DNA demethylation (Hagemann et al., 2011). The potential 
of developing targeted DNA demethylating agents is explored in Chapter 5. 
Interestingly, treatment with cytosine analogues may also affect 5hmC levels, as 
noted in a recent study using DAC treatment in a leukaemia cell line, which observed 
both increased global 5hmC and increased TET1 binding in DNA (Chowdhury et al., 
2015). As reduced 5hmC levels have emerged as a frequent hallmark of cancer, this 
study provides an alternative mechanism through which DNA demethylating agents 
may be exerting their therapeutic capacity and warrants further investigation into the 
Initial clinical trials used increasingly cytotoxic doses of these
agents, even though the induction of gene expression shows a bell-
shaped response curve44. Exciting new clinical trials have shown that
low doses of these agents might be efficacious in treating  myeloid
dysplastic syndrome and other leukaemias47. In addition, azanucleo-
sides are being tested for the treatment of haemoglobinopathies48, in
which the aim is to cause the demethylation of the promoters of the
fetal globin genes that have become silenced in the patient as part of
normal development, leading to an increase in haemoglobin F to
correct the anaemia that characterizes these diseases.
A disadvantage of the azanucleosides is their instability in aque-
ous solutions, but this might be overcome by the use of other ana-
logues, such as zebularine or 5-fluoro-2!-deoxycytidine, which also
inhibit DNA methylation after incorporation into DNA and might
be orally active49. Procainamide, which is used to treat cardiac
arrhythmias, is also an inhibitor of DNA methylation50. In addition,
natural products derived from tea51 and from sponges52 have shown
activity in vitro. Clinical trials with antisense oligonucleotides that
target the DNA methyltransferases are also underway53.
Epigenetic silencing is almost universally associated with histone
deacetylation, which is catalysed by at least three classes of HDACs in
human cells. The HDACs are partly redundant in function, and a
growing series of small molecules has been designed to inhibit their
activities either globally or more specifically (Table 2). HDAC
inhibitors can induce differentiation, growth arrest and/or apoptosis
in transformed cells in culture and in tumours. The driving hypothe-
sis is that accumulation of acetylated proteins, particularly histones,
results in the induction of genes and the upregulation of others that
have become epigenetically silenced. In particular, the gene encoding
p21, which is a cell-cycle kinase inhibitor, is commonly upregulated
in tumour cells treated with these agents in the absence of p53 (ref.
54). This is important in terms of cancer therapy, because many can-
cers have no functional p53 and are therefore unable to arrest cells in a
p53-dependent fashion. Different HDAC inhibitors are being used
intravenously or orally in several phase I and II clinical trials55, in
which changes in histone acetylation have been documented.
Because there are many different HDACs, it will be important in the
future to design therapies that can target individual enzymes and
thus increase the precision of this approach.
Coupling therapies
The links between histone modification and DNA methylation (see
Fig. 1) have encouraged investigators to think about dual therapies
insight review articles
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Table 2 Epigenetic drugs
Target Drug Clinical trials
DNA methylation 5-Azacytidine Phase I/II/III
5-Aza-2!-deoxycytidine Phase I/II/III
FCDR
Zebularine
Procainamide
EGCG Phase I
Psammaplin A
Antisense oligomers Phase I
Histone deacetylase Many55, including:
Phenylbutyric acid Phase I/II
SAHA Phase I/II
Depsipeptide Phase I/II
Valproic acid Phase I/II
EGCG, epigallocatechin-3-gallate; FCDR, 5-fluoro-2!-deoxycytidine; SAHA, suberoylanilide
hydroxamic acid.
Figure 2 Mechanism of action of nucleoside
analogue inhibitors. Deoxynucleoside analogues
such as 5-aza-2!-deoxycytidine (depicted by Z) are
converted into the triphosphate inside S-phase cells
and are incorporated in place of cytosine into DNA.
Ribonucleosides such as 5-azacytidine or
zebularine are reduced at the diphosphate level by
ribonucleotide reductase for incorporation (not
shown). Once in DNA, the fraudulent bases form
covalent bonds with DNA methyltransferases
(DNMTs), resulting in the depletion of active
enzymes and the demethylation of DNA. Pink
circles, methylated CpG; cream circles,
unmethylated CpG.
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Epigenetic therapy
The fact that many human diseases, including cancer, have an epi-
genetic aetiology has encouraged the development of a new thera-
peutic option that might be termed ‘epigenetic therapy.’ Many agents
have been discovered that alter methylation patterns on DNA or the
modification of histones, and several of these agents are currently
being tested in clinical trials (Table 2).
Inhibitors of DNA methylation rapidly reactivate the expression
of genes that have undergone epigenetic silencing, particularly if this
silencing has occurred in a pathological situation. The prototype
inhibitors, 5-azacytidine (5-aza-CR) and 5-aza-2!-deoxycytidine
(5-aza-CdR), were initially developed as cytotoxic agents42, but it was
subsequently discovered that they are powerful inhibitors of DNA
methylation and induce gene expression and differentiation in cultured
cells43,44. Both nucleoside analogues are converted to the deoxy-
nucleotide triphosphates and are then incorporated in place of cyto-
sine into replicating DNA (Fig. 2). They are therefore active only in
S-phase cells43, where they serve as powerful mechanism-based
inhibitors of DNA methylation44. DNA methyltransferases get trapped
on DNA containing modified bases such as azacytosine, 5-fluoro-
cytosine, pseudoisocytosine or zebularine, resulting in the formation
of heritably demethylated DNA44,45. Covalent attachment of the
various DNA methyltransferases to DNA might well be responsible
for the cytotoxicities of these agents, particularly at high doses46.
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possibility of using 5hmC and the TET enzyme family as novel targets in the 
development of epigenetic therapies. 
1.8 Project aims 
1) Investigation into 5mC and 5hmC dynamics during neural differentiation 
using genome-wide, MeDIP- and hMeDIP-seq profiling methods to analyse 
the changing distribution of both modifications and explore the potential 
function of 5hmC in the mammalian genome. 
2) Development of a novel method for 5hmC detection at single-base resolution 
through adaptation of oxidative bisulphite chemistry for use in combination 
with the Infinium HumanMethylation450 BeadChip.  
3) Assessment of the potential use of photocaged DNMT inhibitors for targeted 
DNA demethylation treatment using an in vitro cell culture assay combined 
with genome-wide 5mC analysis. 
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Chapter 2 Materials and methods 
2.1 Cell lines  
The JM8 cell line (WT agouti C57BL/6N mouse ESCs) was obtained from the 
laboratory of Dr William Skarnes (Sanger Institute, Hinxton, Cambridge) and a 
Sox1-GFP knock-in E14Tg2a  (46C) mouse ESC line was obtained from the 
laboratory of Dr Paul Bertone (EMBL-EBI, Hinxton, Cambridge). Both were 
cultured according to the protocol described in section 2.3. Primary mouse NSCs 
were previously isolated from the subventricular zone of an adult mouse brain 
(C57BL/6N strain) and established in culture by Dr Stefano Bartesaghi at the 
Samantha Dickson Brain Cancer Unit of Professor Paolo Salomoni (UCL Cancer 
Institute, University College London). These cells were cultured as described in 
section 2.3.4. The Saos-2 human osteosarcoma cell line was obtained from the 
laboratory of Dr Sandra Strauss (UCL Cancer Institute, University College London) 
and cultured as described in section 2.3.6. 
2.2 Tissue samples 
Two 6-month old, WT C57BL/6N female mice were sacrificed using CO2 euthanasia 
for the dissection of brain tissue samples. Tissue samples were taken from the cortex, 
cerebellum and olfactory bulb of both mice to serve as biological replicates.  
All human tissue samples were handled in accordance with the ethical standards of 
the Helsinki declaration (1964, 2008) of the World Medical Association. Human 
brain genomic DNA from a 33 year-old male was obtained from AMSBIO 
(#D1234035, lot #B701205; referred to as ‘brain1’). Human frontal cortex DNA was 
collected from a 54-year-old female according to ethical approval obtained from the 
Berkshire Local Research Ethics Committee (REC 08/H0505/165), with informed 
written consent (referred to as ‘brain2’). Pooled (male and female) whole blood 
DNA was obtained from blood donations of volunteers from the UCL Cancer 
Institute. 
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2.3 Cell culture 
2.3.1 Cell counting 
In order to calculate accurate cell seeding densities when passaging, cell numbers 
were quantified using a Vi-CELL XR (Beckman Coulter) automated cell viability 
analyser, which uses the trypan blue exclusion method to count viable cells within a 
500µl volume. 
2.3.2 Embryonic stem cell culture 
Preparation of plastic culture dishes: 2% gelatin solution (Sigma-Aldrich; #G1393-
100ML) was diluted to 0.1% with 1X Dulbecco’s phosphate-buffered saline (DPBS; 
Gibco; #14190-169) and stored at 4°C. All plasticware used for mESC culture was 
first coated with a 0.1% gelatin solution for 30 minutes at room temperature. Excess 
gelatin solution was aspirated from the surface and let to air dry for approximately 1 
minute before cell seeding.  
Cell expansion: JM8 and 46C cells were initially cultured as an adherent monolayer 
in LIF- and serum-containing growth medium, comprising of knockout DMEM 
(Gibco; #10829-018), 2mM L-glutamine (Gibco; #25030-081), 100µM ß-
mercaptoethanol (Gibco; #21985-023), 10% foetal bovine serum (FBS) (Gibco; 
10500-064) and 103 U/ml LIF (Millipore; #ESG1106). After a couple of passages, 
both mESC cell lines were switched to serum- and LIF-free “3i” medium using 
iSTEM (StemCells, Inc.; #SCS-SF-ES-01) and subsequently expanded solely under 
these conditions. All cells were incubated at 37°C in 5% CO2.  
Cell passaging: 30 minutes prior to passaging, aliquots of Accutase (Sigma-Aldrich; 
#A6964) and growth medium were pre-warmed in a water bath at 37°C and 1X 
DPBS solution equilibrated to room temperature. New plasticware was coated with 
0.1% gelatin solution and left at room temperature for a minimum of 30 minutes 
under a culture hood until needed. To passage mESCs, all growth media was 
aspirated from the culture flask and retained for use as ‘wash media’ in subsequent 
steps. The flask’s surface was washed gently with 1X DPBS, taking care not to 
disrupt the cell layer. The remaining DPBS was aspirated away and pre-warmed 
Accutase added to the flask (approximately 0.8ml for a T25 flask, or 2.5ml for a T75 
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flask). The flask was tilted gently to ensure the entire cell surface was covered with 
Accutase solution, before returning the flask to an incubator (37°C, 5% CO2) for a 
maximum of 5 minutes. Cells were observed under a microscope to check for 
detachment and then a small amount of ‘wash media’ (2ml for a T25 flask, 5-10ml 
for a T75 flask) was added back to the flask to resuspend the detached cells. The cell 
suspension was then transferred to a new 15ml falcon tube and spun down for 3 
minutes at 1200rpm to pellet the cells. The remaining supernatant was aspirated 
away and the cell pellet dissociated and resuspended in fresh growth media. The cells 
were then split 1:6 in freshly-coated culture flasks or plates, as needed. Finally, all 
flasks were topped up with pre-warmed growth media to a total volume of 5ml for 
T25 flasks, or 15ml for T75 flasks.  
Cell freezing: To freeze down cell aliquots, freezing medium was prepared by adding 
10% DMSO to growth medium (at room temperature) immediately prior to use. 
Cells were dissociated after reaching approximately 70-80% confluence and spun 
down to a pellet as described above, before being resuspended in freezing medium in 
the appropriate volume: 
Plasticware Freezing media volume Number of cryovials needed 
6-well plate 1ml (per well) 2 
25cm2 flask 2.5ml 3 
75cm2 flask 7.5ml 9 
 
0.5ml of the resulting cell suspension was transferred into each cryovial and 
immediately placed on dry ice for 10 minutes, before being transferred to a -80°C 
freezer overnight. The next day, cryovials were transferred to liquid nitrogen for 
long-term storage.  
2.3.3 Neural differentiation 
Generation of a stable, self-renewing mNSC line: Neural differentiation of mESCs 
was performed using the Sox1-GFP knock-in E14Tg2a (46C) mESC line in order to 
monitor the appearance of SOX1-positive neural precursor cells. 46C mESCs 
growing under 3i conditions were dissociated, spun down and resuspended in RHB-
A media (without growth factors or serum) and replated at 1 x 104 cells/cm2 in 
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gelatin-coated T25 flasks. Media was exchanged every other day and cells were 
monitored daily for the appearance of GFP (indicating Sox1 expression) using a 
fluorescence microscope, which typically occurred around day 7-8 of differentiation 
and peaked at day 10, when neural rosette structures were clearly visible throughout 
the culture. At this stage, cells were dissociated with Accutase, spun down and 
resuspended in freshly prepared RHB-A media with 10ng/ml EGF and FGF-2. Cells 
were then replated on laminin-coated plasticware at the same cell density and 
expanded as embryonic mNSCs, following the protocol described in section 2.3.4. 
Growth factor concentrations were increased to 20ng/ml for one or two passages if 
cells exhibited low viability upon this replating step. 
Continuous neuronal differentiation: three variations on a neuronal differentiation 
protocol were tested to produce terminally differentiated neurons from mESC 
cultures, referred to as methods A, B and C (see Chapter 3). In method A, mESCs 
grown under 3i conditions were replated in RHB-A media (without supplements) at 
0.5-1.5 x 104 cells/cm2 on gelatin-coated plasticware to initiate differentiation. Cells 
were maintained under these differentiation conditions for 3 weeks, when no further 
changes in cell morphology or cell number were observed. In method B, mESCs 
were replated in RHB-A (without supplements) at 0.5-1.5 x 104 cells/cm2 on gelatin-
coated plasticware to initiate differentiation and monitored for Sox1-GFP expression, 
upon which they were dissociated, resuspended in fresh RHB-A and replated on a 
laminin-coated substrate at 4-5 x 104 cells/cm2 and monitored for the appearance of 
neuronal morphology, such as axonal projections and dendritic branches. In method 
C, stably renewing embryonic mNSCs are derived as described above and cultured in 
RHB-A with FGF-2 and EGF, before being replated at approximately 2-3 x 104 
cells/cm2 (approximately 6.5 x 105 cells in a T25 flask) on a laminin substrate and 
withdrawing EGF from the expansion media. Cells are maintained in these 
conditions for 7 days, before withdrawing FGF-2 from the media and continuing the 
culture in RHB-A only for a further 7 days (minimum) and monitored for the 
appearance of neuronal-like cells. 
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2.3.4 Neural stem cell culture 
Preparation of cell culture reagents: A 1:100 dilution of laminin (1mg/ml, Sigma-
Aldrich) was prepared in sterile-filtered 1X DPBS and 5ml aliquots of the resulting 
1µg/ml solution stored at -20ºC. Recombinant human FGF-basic (FGF-2, 
PeproTech; #100-18B) was reconstituted in 10µl 5mM Tris (pH 7-7.6) and diluted 
1:100 in a 0.1% solution of bovine serum albumin (BSA) made up in 1X DPBS. The 
resulting10µg/ml FGF-2 solution was stored in aliquots at -20ºC and used at a final 
concentration of 10ng/ml. Recombinant human EGF (EGF, PeproTech; #AF-100-15) 
was reconstituted in 100µl sterile H2O and a 1:100 dilution prepared in 0.1% BSA 
solution (diluted in 1X DPBS). The resulting 10µg/ml EGF solution was stored in 
aliquots at -20ºC and used at a final concentration of 10ng/ml.  
Preparation of plastic culture dishes: All new flasks and tissue culture plates were 
coated with a 1µg/ml laminin solution (approximately 1ml added to a T25 flask) for 
a minimum of three hours at room temperature prior to cell seeding. All plasticware 
was placed on a bench-top orbital shaker for the incubation period to ensure all 
surfaces were evenly coated with laminin.  
Cell expansion: Primary and embryonic mNSCs were grown as adherent monolayers 
in laminin-coated flasks. Expansion medium was comprised of RHB-A (StemCells, 
Inc.; SCS-SF-NB-01), a serum-free chemically defined neural stem cell medium, 
along with epidermal growth factor (EGF, PeproTech; #AF-100-15) and fibroblast 
growth factor (FGF-2, PeproTech; #100-18B), both at a final concentration of 
10ng/ml. All cells were incubated at 37°C in 5% CO2. 
Cell passaging: mNSCs were passaged after reaching 75-90% confluence and 
typically split 1:5 into freshly-coated laminin flasks using the same procedure as 
previously described for mESCs in 2.3.2.   
Cell freezing: Both primary and embryonic mNSCs were frozen down as described 
for mESCs in section 2.3.2, using freezing medium comprised of RHB-A, 10ng/ml 
FGF-2, 10ng/ml EGF and 10% DMSO. 
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2.3.5 Astrocytic differentiation 
Astrocytic differentiation of stably self-renewing embryonic or adult mNSCs was 
triggered through the simultaneous withdrawal of EGF and FGF-2 and addition of 
10% FBS (Gibco; #10500-064) to RHB-A media. Aliquots of 10% FBS-containing 
differentiation media were sterile-filtered using a 0.2µm filter prior to use. After 
aspiration of the mNSC expansion media, mNSC cultures were washed gently with 
1X DPBS prior to addition of the differentiation media, taking care not to let cells 
dry out. Differentiation was initiated when mNSCs cells were at 50-75% confluence 
within a tissue culture plate flask or plate. Differentiation media was exchanged 
every third day for the duration of the differentiation period and cells were collected 
for DNA extraction (or fixed in paraformaldehyde for immunostaining) 14 days after 
initiating differentiation.  
2.3.6 Saos-2 cell culture 
The Saos-2 cell line was grown as an adherent monolayer in RPMI-1640 medium 
(Lonza; #12-702F) supplemented with 10% FBS (Gibco; #10500-064) on uncoated 
tissue culture plasticware. Cells were passaged as described above for mESCs (see 
section 2.3.2), although Trypsin (Gibco; #25300-062) was used in the place of 
Accutase to dissociate cells during passaging.  
2.3.7 Saos-2 cell line treatments with cytosine analogues  
Cytosine analogues: 5-aza and DAC compounds were purchased from Sigma-
Aldrich (#A2385 and #A3656, respectively). Caged-DAC and caged-aza compounds 
were synthesised by Mikiembo Kukwikila and Ha Phuong Nguyen (Department of 
Chemistry, University College London) and provided as 10mM solutions in 
acetonitrile. Unless otherwise stated, all compounds were stored as 1mM solutions at 
-20°C and diluted to 100µM in acetonitrile just prior to use. 
In vitro cell treatments: Saos-2 cells were seeded into 24-well tissue culture plates at 
an initial density of approximately 10,000 cells per well 24 hours before the first 
treatment dose. 500µl of culture media was added per well and exchanged every 24 
hours for fresh media, prior to addition of a new treatment dose. 100µM solutions of 
5’-azacytidine (5-aza), 5’-aza-2’-deoxycytidine (DAC) caged-aza and caged-DAC 
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compounds were added directly to fresh growth media in the appropriate wells every 
24 hours for the duration of the treatment period. Irradiation of uncovered tissue 
culture plates was carried out at 365nm for one hour immediately after the required 
compound dosage was added to the media. A 65µW/cm2 UV lamp (Mineralight; 
#UVGL-58) was used to irradiate uncovered 24-well culture plates at room 
temperature under a culture hood, within a UV black box. Control plates that were 
not receiving irradiation treatment were incubated at room temperature under the 
culture hood for the duration of the 1-hour treatment. Care was taken to minimise 
light exposure to these control cells by covering the plates in foil.  
2.3.8 Live cell imaging 
A live cell imaging system was used to monitor the 5-aza, DAC, caged-aza and 
caged-DAC treatments to Saos-2 cells (see Chapter 5, section 5.3). Cells were 
monitored using an IncuCyte (Essen BioScience), which allowed multiple cell 
confluence measurements and phase contrast images to be taken in each well of 
multi-well culture plate once every two hours. 
2.4 EdU assay 
EdU incorporation assays were performed using the Click-iT EdU Imaging Kit 
(Molecular Probes; #C10086) with Alexa Fluor 488, 594 and 647 azides according to 
the manufacturer’s instructions, with a few minor modifications. For analysis of 
mESCs and mNSCs, cells were seeded into 4-well plates under expansion conditions 
(see section 2.3.2 and 2.3.4, respectively) 24 hours prior to EdU labelling. For 
analysis of astrocytes, 40-60,000 mNSCs were seeded per well of laminin-coated 4-
well plates, incubated in expansion media for 24 hours and subsequently switched to 
differentiation media for 14 days (see section 2.3.5) prior to addition of EdU. A 
20µM EdU solution was freshly prepared through a 1:500 dilution of 10mM EdU in 
pre-warmed culture media. Cells were incubated with 20µM EdU at 37°C for 2 hours 
before fixation at room temperature for 10 minutes in 4% paraformaldehyde (PFA), 
prepared using a 1:3 mixture of 16% PFA (Alfa Aesar; #43368) with 1X DPBS. 
After aspiration of the PFA solution, cells were gently washed twice with 0.1% 
PBST, composed of 0.1% Triton X-100 (Sigma-Aldrich) dissolved in 1X DPBS 
solution. For permeabilisation, approximately 200µl of fresh 0.1% PBST was added 
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to each well and incubated for 20 minutes at room temperature prior to addition of 
200µl per well of the Click-iT reaction cocktail, prepared as described in the 
manufacturer’s protocol. Cells were covered with foil and incubated in the dark for 
one hour at room temperature and then washed twice with 0.1% PBST. Cells were 
then subjected to immunocytochemical staining (as described in section 2.5) for the 
appropriate phenotypic markers (OCT4 for mESCs, nestin for mNSCs and GFAP for 
astrocytes) prior to visualisation. 
2.5 Immunocytochemistry 
Cells were plated as an adherent monolayer at the desired density in 4-well tissue 
culture plates (Thermo Scientific Nunc; #176740) and incubated at 37°C for a 
minimum of 24 hours prior to fixation. For immunostaining of mESCs and mNSCs, 
between 50-70,000 cells were typically seeded into each well 24 hours prior to 
fixation. For immunostaining of astrocytes, mNSCs were seeded at a lower density 
(between 30-50,000 cells per well) and incubated in expansion media for 24 hours 
before undergoing differentiation for 14 days prior to fixation (see section 2.3.5 for 
further details). For immunocytochemical analysis, growth media was aspirated from 
the surface of the cells and each well washed twice with 1X DPBS, taking care not to 
disturb the cell layer.  
After aspirating away the remaining wash solution, 200µl of 4% PFA (prepared as 
described in section 2.4) was added to each well and incubated at room temperature 
for 10 minutes. After aspirating off the remaining fixative, cells were gently washed 
twice with 1X DPBS before addition of 200µl of freshly prepared 0.1% PBST to 
each well for permeabilisation. Cells were incubated in 0.1% PBST for a minimum 
of 5 minutes at room temperature (or stored at 4°C for up to 1 week) before 
proceeding with immunostaining. 
Immunocytochemical staining was performed by aspiration of the 0.1% PBST 
solution and addition of 200µl blocking solution (0.1% PBST with 4% FBS and 1% 
BSA) to each well. Fixated cells were incubated with block solution for one hour at 
room temperature, before replacing block solution with primary antibody dilutions 
made up using fresh block solution (e.g. 1.5µl of Ab to 1500µl blocking solution for 
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a 1:1000 dilution). Primary antibodies used for immunocytochemical analysis were a 
rabbit anti-GFAP IgG antibody (Sigma-Aldrich; #G9269), a mouse anti-nestin IgG1 
antibody (Millipore; #MAB353), both at a 1:800 dilution, and a mouse anti-Oct-3/4 
(C-10) IgG2b antibody (Santa Cruz Biotechnology, Inc.; #sc-5279), at a 1:400 
dilution. Cells were covered with foil and incubated with the primary antibody 
solution overnight at 4°C.  
After aspiration of the primary antibody solution, cells were gently washed twice 
with 0.1% PBST, taking care not to let the cells dry out between steps. 200µl of a 
secondary antibody dilution (in block solution) was then added to each well. 
Secondary antibodies used for immunocytochemical analysis were an Alexa Fluor 
488 donkey anti-rabbit IgG (H+L) antibody (Invitrogen; #A21206) and an Alexa 
Fluor 555 goat anti-mouse IgG (Invitrogen; #A21422), both at a final dilution of 
1:1000. Cells were covered with foil and incubated at room temperature for 45 
minutes before aspirating the antibody solution and washing twice with 0.1% PBST. 
DAPI counterstaining was performed by incubating cells with a 1:10,000 DAPI 
dilution in 0.1% PBST for approximately 10 seconds before quickly aspirating away 
all remaining solution. A final wash with 0.1% PBST was performed before covering 
each well with fresh 0.1% PBST for visualisation or storage at 4°C. Immunostaining 
was visualised using an Axio Observer Z1 (Carl Zeiss, Ltd.) fluorescence 
microscope and images taken using AxioVision software. 
2.6 DNA extraction 
DNA samples for MeDIP- and hMeDIP-seq analysis were prepared from frozen cell 
pellets (approximately 3 x 107 cells) using a DNA/RNA dual extraction protocol 
(Qiagen AllPrep DNA/RNA Mini Kit; #80204). In order to maximise yield, the 
extraction protocol was performed on 3 separate aliquots per cell sample due to the 
large amount of available starting material. First, cell pellets were thawed on ice 
before being re-suspended in 1800µl RLT plus buffer, pipette-mixed thoroughly and 
then divided into 3 x 600µl samples for subsequent processing. Each 600µl cell 
suspension was transferred to an individual QIAshredder spin column (Qiagen; 
#79654) and spun at maximum speed (13,200rpm, or 16,100 x g) in an Eppendorf 
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microcentrifuge. The lysate was then used for dual DNA/RNA extraction according 
to the manufacturer’s instructions.  
DNA extraction from mouse and human tissues was performed using the DNeasy 
Blood & Tissue Kit (Qiagen; #69504) according to the manufacturer’s 
recommendations.  
2.7 Enzyme-linked immunosorbent assays (ELISA)  
A 5mC ELISA assay (5-mC DNA ELISA Kit, Zymo Research; #D5325) was 
performed according to manufacturer’s instructions, with the DNA-coated plate 
incubated at 4ºC overnight rather than at 37ºC for 1 hour. After addition of HRP 
developer, the plate was incubated at room temperature for 1 hour prior to 
absorbance measurements. Final absorbance readings were measured at 450nm on a 
VarioSkan Flash multimode platereader (Thermo Scientific). 
2.8 MeDIP- and hMeDIP-seq 
2.8.1 DNA quantification 
DNA samples were quantified using a NanoDrop 1000 spectrophotometer and 
aliquots of approximately 100ng were analysed using agarose gel electrophoresis to 
check that all samples contained high-molecular weight (>10kb) DNA and were free 
from RNA contamination. Quantification of low concentration DNA samples was 
carried out using the Qubit High Sensitivity fluorometric assay kit (Invitrogen; 
#Q32851).  
2.8.2 DNA shearing 
DNA samples were sonicated using a Biorupter (Diagenode) in 1.5ml TPX 
polymethylpentene microtubes (Diagenode; #M-50001). 1.5µg DNA was added to 
each tube in a total volume of 150µl elution buffer. Each sample was sonicated on 
the ‘high’ setting (320W) for a total of four 15-minute cycles (30 seconds on, 30 
seconds off) followed by an additional 5-minute cycle. Between cycles, the 
sonication bath was cooled with ice for 5 minutes to prevent overheating. All 
sonicated DNA samples were run on an Agilent Bioanalyzer 2100 using a High 
 56 
Sensitivity DNA chip at a 1:10 dilution to check the majority of fragments fell within 
the desired range of 150-350bp.  
2.8.3 Library preparation (part 1) 
MeDIP and hMeDIP DNA libraries were prepared using the NEBNext DNA Library 
Prep Master Mix Set for Ilumina (New England Biolabs; #E6040L) and the 
Multiplexing Sample Preparation Oligonucleotide Kit (Illumina; #PE-400-1001). 
Sonicated DNA underwent DNA end repair, dA-tailing and adapter ligation reactions 
according to the manufacturer’s protocol and using Illumina Index paired-end (PE) 
adapters. DNA purification steps were performed using Agencourt AMPure XP 
(Beckman Coulter; #A63881) beads and the final elution step was performed in a 
final volume of 40µl buffer EB (Qiagen; #19086).  
2.8.4 DNA immunoprecipitation 
The DNA immunoprecipitation steps were automated on an SX-8G IP-Star using the 
Auto MeDIP kit (Diagenode; #AF-Auto01-0100) and Auto hMeDIP kit (Diagenode; 
#AF-Auto02-0016), according to the manufacturer’s instructions, with one minor 
modification for the auto MeDIP reactions: two lambda DNA fragments, one 
unmethylated (“20CpG”) and one fully methylated (“15CpG”), were added to each 
sample at a concentration of 0.2pM to act as spiked-in control DNA. For auto 
hMeDIP reactions, the spike-in DNA controls provided by the Diagenode kit were 
used as recommended by the manufacturer. The longer immunoselection step (15 
hours over 5 hours) at 4°C was selected for the auto MeDIP reactions 
(“MeDIP_19h_DIB” program) and the recommended 10 hour immunoseletion step 
at 4°C was selected for the auto hMeDIP reactions (“hMeDIP_14h_DIB”) on the IP-
Star. After the incubations were complete, all samples were removed from the IP-
Star and the tubes containing either the immunoprecipitated sample DNA or the 
input DNA were placed in a magnetic rack to capture the DNA-bound beads for a 
minimum of 15 minutes. The supernatant fractions were transferred to new tubes and 
labelled as either ‘input’ or ‘IP’ as appropriate before proceeding to the first quality 
control step (QC1). 4.5µl of each DNA sample was set aside for QC1 and the 
remaining DNA was purified using Agencourt Ampure XP beads and eluted in 22µl 
buffer EB. 
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2.8.5 Quality control  (part 1) 
DNA recovery of hydroxymethylated, methylated and unmethylated spiked-in DNA 
and specificity of the antibody immunoprecipitation was tested using quantitative 
PCR (qPCR). The primer sequences used for QC1 of MeDIP samples (corresponding 
to the ‘20CpG’ and ‘15CpG’ lambda DNA fragments) are listed in Supplementary 
Table 1. The primer used for QC1 of hMeDIP samples were provided in the auto 
hMeDIP kit. 4.5µl of each DNA library and its respective input DNA was diluted to 
10µl in ultra-pure H2O. Triplicate qPCR reactions were set up on ice in 96-well 
plates for each DNA library as follows: 6.25µl MESA BLUE qPCR MasterMix Plus 
for SYBR (Eurogentec; #RT-SY2X-03+WOUB), 0.625µl forward primer (10µM), 
0.625µl reverse primer (10µM), 3.75µl ultra-pure H2O, and 1.25µl template DNA. 
The qPCR plates were run on a 7300 Real Time PCR System (Applied Biosystems) 
on the following program: 95ºC for 15min, 40 cycles of 95ºC for 15s and 60ºC for 
1min, followed by melt curve analysis. The percentage recovery for each spiked-in 
DNA fragment was calculated as follows: 
!"#!"#$% % = 2!"(!"#$%&'" !"#$% !"!!"#$% !") × 100 
AE refers to the amplification efficiency of the primer pair (e.g. 100% = 1) and Ct 
represents the cycle threshold calculated from the qPCR results. The MeDIP Ct refers 
to the cycle threshold calculated for the sample DNA (either MeDIP or hMeDIP 
libraries). The Ct value of the input DNA must be adjusted to reflect the differing 
amounts of DNA that are included for input compared to the IP reactions, as only 
10% of the total library-prepped DNA sample is used as input. This is achieved as 
follows: 
!"#$%&'" !"#$% !" = !"#$% !" − log [2!" 10 ] 
Finally, specificity of the antibody towards its respective modification (either 5mC or 
5hmC) was calculated as follows: 
!"#$%&%$%'( = 1− !"#$%"!&!"#$%!!"#$%&!"#$%"!&!"#!!"#$%&  
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Successfully prepared MeDIP and hMeDIP libraries all had a specificity ≥ 95%.  
2.8.6 Library preparation (part 2) 
Immunoprecipitated DNA samples underwent adapter-mediated PCR amplification 
in order to generate suitable libraries for next-generation sequencing using the 2X 
KAPA HiFi HotStart ReadyMix (Kapa Biosystems; #KK2601) and the primers 
provided by the Multiplexing Sample Preparation Oligonucleotide Kit (Illumina; 
#PE-400-1001). 22µl of purified MeDIP or hMeDIP DNA was used as template 
DNA in a final reaction volume of 50µl. A PCR reaction was set up for each library 
as follows: 1µl of PCR Primer InPE 1.0 (25µM), 1µl of PCR Primer InPE 2.0 
(0.5µM), 1µl of PCR Primer Index (25µM), 25µl of KAPA HiFi HotStart ReadyMix 
and 22µl template DNA. The PCR reaction was incubated on a thermal cycler under 
the following conditions: 98ºC for 45s, 15 cycles of 98ºC for 15s, 65ºC for 30s, 72ºC 
for 30s, followed by a final extension at 72ºC for 5min and hold at 4ºC. DNA was 
purified using Ampure XP beads and eluted in 18µl buffer EB.  
2.8.7 Library size selection 
PCR-amplified, purified MeDIP and hMeDIP DNA samples were loaded onto a 2% 
agarose gel and analysed by gel electrophoresis (1hr 40min at 100V). 3 wells were 
left empty on either side of each sample to prevent cross-contamination during gel 
excision. In addition, each sample was separated by a 50bp DNA ladder (New 
England Biolabs) in order to facilitate accurate library size selection. The gel was 
transferred to a UV transilluminator and a gel band corresponding to 300-350bp was 
excised for each DNA library and collected in a 2ml DNA LoBind tubes (Eppendorf; 
#0030108.078). In addition, bands corresponding to 250-300bp and 350-400bp DNA 
size ranges were also excised to serve as back-up libraries. The DNA was extracted 
from each gel band using the MinElute Gel Extraction Kit (Qiagen; #28604) 
according to the manufacturer’s protocol, using an overnight incubation in Buffer 
QG at 4ºC in order to ensure full dissolution of the gel slice. DNA was eluted in 10µl 
buffer EB.  
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2.8.8 Quality control (part 2) 
The fold-enrichment ratio of hydroxymethylated and methylated DNA fragments 
present within the hMeDIP and MeDIP DNA libraries, respectively, was calculated 
using primers to assay known hydroxymethylated, methylated and unmethylated 
regions in the endogenous genomic DNA using qPCR. Primer pairs used for 
hMeDIP QC2 were provided in the Auto hMeDIP kit (Diagenode; #AF-Auto02-
0016). MeDIP QC2 primer pairs are listed in Supplementary Table 1; the 5mC status 
of these two amplified regions had been previously validated in mESC DNA by past 
lab members. 1µl of size-selected and purified DNA was diluted to 10µl using ultra-
pure H2O for use as template DNA in the qPCR reactions. All qPCR reactions were 
assayed in triplicate as described in section 2.8.5. The fold-enrichment ratio was 
calculated for two regions per DNA library (methylated and unmethylated, or 
hydroxymethylated and unmethylated) as follows: 
!"#$ − !"#$%ℎ!"#$ !"#$% =  2!"(!"!"#$%_!"#!!!"!"#$%_!"#!)2!!(!"!"#$%_!"#$%!!!"!"#$%_!"#$%!) 
where AE represents the amplification efficiency of the primer pair in question, 
expressed as a number (e.g. 100% efficiency = 1). Fold-enrichment ratios ≥ 25 were 
considered suitable for progressing with DNA sequencing (Taiwo et al., 2012).  
2.8.9 DNA sequencing 
MeDIP and hMeDIP libraries were subjected to next-generation DNA sequencing 
using 100 base pair paired-end reads on an Illumina HiSeq 2000 according to 
manufacturer’s instructions by the sequencing facility at Illumina (Cambridge, UK).  
2.8.10 Sequencing data analysis 
Analysis of the raw sequencing fastq data files was performed by Dr Gareth Wilson 
(Medical Genomics, UCL Cancer Institute, University College London) using the 
MeDUSA analysis pipeline (Wilson et al., 2012). Briefly, the MeDUSA pipeline was 
used to align the sequencing reads to the reference genome mm10 using the 
Burrows-Wheeler alignment tool (BWA), followed by filtering of clonal and 
unpaired reads with SAMtools. 5mC and 5hmC peaks were defined using MACS 
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(q>10) (Zhang et al., 2008) prior to DMR calling between biological cohorts using 
500bp windows. 
2.9 Infinium HumanMethylation450 BeadChip 
2.9.1 Bisulphite conversion 
Bisulphite (BS) conversion of Saos-2 cell line DNA samples for 450K methylation 
profiling (see Chapter 5, sections 5.3.4 and 5.3.6) was performed using the EZ DNA 
Methylation Kit (Zymo Research; #D5001) according to manufacturer’s instructions. 
500ng of input genomic DNA was used per conversion and all samples were 
incubated with BS reagent using the thermal cycling conditions specifically 
recommended for the Illumina Infinium 450K analysis, consisting of 16 cycles of 
95°C for 30s plus 50°C for 60min, followed by holding samples at 4°C until DNA 
purification. DNA was eluted in a final volume of 12µl and stored at -80°C until 
BeadChip processing. 
2.9.2 Bisulphite conversion efficiency  
BS conversion efficiency was assessed for all Soas-2 DNA samples prior to 450K 
analysis (see Chapter 5, section 5.3.6) in order to confirm successful, complete 
conversion of the DNA sample. Conversion efficiency was assessed by qPCR using 
two primer pairs designed around the same 133bp sequence located at chr7:5571729-
5571861 (hg19 assembly), approximately 1kb upstream of the ACTB gene. One 
primer pair (“Actin positive”) specifically amplifies BS-converted DNA only; the 
second primer pair (“Actin negative”) specifically amplifies unconverted DNA only 
(see Supplementary Table 1 for primer sequences). Each DNA sample was assayed 
by qPCR in triplicate for both primer pairs. All qPCR reactions were set up in a final 
volume of 12.5µl as follows: 6.25µl MESA Blue qPCR MasterMix Plus for SYBR 
(Eurogentec; #RT-SY2X-03+WOUB), 0.625µl forward primer (10µM), 0.625µl 
reverse primer (10µM), 3.75µl ultra-pure H2O, and 1.25µl template DNA. The qPCR 
plates were run on a 7300 Real Time PCR System (Applied Biosystems) on the 
following program: 95ºC for 10min, 40 cycles of 95ºC for 15s and 60ºC for 1min, 
followed by melt curve analysis. BS conversion efficiency was calculated as follows: 
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!"#$%&'("# !""#$#!"#$ % = 1− 11+ 2∆!" × 100 
A conversion efficiency of ≥ 99% was obtained for all samples. 
2.9.3 Oxidative bisulphite conversion 
Oxidative bisulphite (oxBS) conversion of human brain DNA samples was 
performed using either a “low input” or “high input” protocol (see Chapter 5, section 
5.2.4). 
2.9.3.1 Low-input protocol 
1µg DNA per sample was processed using a trial version of the TrueMethyl 24 kit 
(CEGX). Samples were split evenly into two aliquots of 500ng and processed 
through either the BS-only or oxBS conversion workflow. Each aliquot was 
subjected to an initial buffer exchange step using a spin column format and eluted in 
ultra-pure water. The full eluate (∼22µl per sample) was carried forward. Samples 
were denatured using the provided denaturing solution for 30 min at 37 °C, in a total 
reaction volume of 24µl and immediately taken forward to oxidation. 1µl of the 
provided oxidant solution was added to each sample undergoing the oxBS workflow 
only (1µl of ultra-pure water was added to BS-only samples for mock oxidation). All 
samples were incubated for 30 min at 40 °C. Oxidised samples were equilibrated to 
room temperature before proceeding immediately to BS conversion. BS reagent 
solution was prepared as described in the TrueMethyl protocol and 170µl was added 
to each 25µl oxidation reaction mixture. Finally, 5µl of BS additive was added to 
each reaction, bringing the total volume to 200µl. All reactions were incubated using 
BS-specific thermal cycling conditions. Converted DNAs were purified using the 
provided spin columns and 4µl of each sample eluate was used as input into the 
Infinium 450K array. 
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2.9.3.2 High-input protocol 
4µg DNA per sample was processed using the TrueMethyl protocol for 450K 
analysis (Version 1.1, CEGX). The protocol was performed as described, with two 
minor alterations. First, the initial shearing step of DNA was performed using a 
Bioruptor  (Diagenode). The DNA was diluted into a total volume of 50µl in 1.5 ml 
microtubes and sonicated for 30 seconds on setting ‘H’. 10µl was set aside for 
visualisation on a 2% agarose gel to confirm correct DNA fragmentation (all 
<10 kb). The remaining 40µl (∼3.2µg) sheared DNA was then split into 2 × 20µl 
aliquots and purified using Agencourt AMPure XP beads using a modified protocol 
described in TrueMethyl 24 Kit User Guide (Appendix 3, version 3.1, CEGX). Each 
sample was eluted in 20µl ultra-pure water and quantified using a NanoDrop 1000 
spectrophotometer. The the spike-in CEGX digestion control was added at a level of 
0.5% w/w and then DNA samples were processed either through the oxBS or BS-
only workflow as outlined in the TrueMethyl 24 Kit User Guide. 7µl of the final 
eluate was used as input into the Infinium 450K array, made possible by adding 1µl 
of 0.4 N NaOH to each sample rather than the standard 4µl of 0.1 N NaOH when 
setting up the MSA4 plate during BeadChip processing. 
2.9.4 Taq1 digestion control 
For assessment of the extent of oxBS conversion, the spike-in digestion control was 
PCR amplified from both oxBS and BS-only DNA conversions and subjected to 
Taq1 restriction endonuclease digestion. The digestion control contains a single Taq1 
recognition site (5’-TCGA-3’) with 5hmC in the internal CpG site. After successful 
oxBS conversion and PCR amplification, the internal 5hmC should have undergone 
complete conversion to T, rendering the amplicon resistant to Taq1 digestion. The 
BS-converted and PCR-amplified digestion control should retain the internal CpG 
site and therefore undergo cleavage by Taq1.  
PCR amplification of the BS- and oxBS-converted DNA (see section 2.7.2) was 
carried out with DreamTaq DNA polymerase (Thermo Scientific; #EP0701). Each 
reaction was set up as follows: 1µl DNA as template, 60µl 10X DreamTaq Buffer, 
24µl dNTP mix (10mM), 6µl digestion control forward primer (100µM), 6µl 
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digestion control reverse primer (100µM), 480µl ultra-pure H2O, and 12µl 
DreamTaq DNA polymerase (5U/µl).  All reactions were incubated on a thermal 
cycler under the following conditions: 95°C for 120s followed by 40 cycles of 95°C 
for 30s, 60°C for 30s, and 72°C for 15s. PCR reactions were purified using the 
QIAquick PCR Purification Kit (Qiagen; #28104) and eluted in 50µl EB (provided 
with kit). Purified DNA was quantified using a NanoDrop 1000 spectrophotometer 
and concentration adjusted to 10ng/µl using ultra-pure H2O.  
Each DNA sample was subsequently digested by the Taq1 restriction endonuclease 
(Promega; #R6151) in a final reaction volume of 20µl containing: 10µl of template 
DNA (10ng/µl), 2µl of 10X RE Buffer, 4µl of Taq1 (10U/µl), 0.2µl BSA (10µg/µl) 
and 3.8µl ultra-pure H2O. Positive and negative control reactions were carried out in 
parallel, with either 5µl of cutting control DNA (20ng/µl; provided by TrueMethyl 
kit) replacing the amplified DNA sample or without the addition of Taq1 DNA 
polymerase. Each control reaction was made up to a final volume of 20 µl with 
additional ultra-pure H2O. All digestion reactions were incubated on a thermal cycler 
at 65°C for 18 hours followed by an inactivation step at 80°C for 20 minutes. 
Reaction products were analysed by gel electrophoresis using a 2% agarose gel. 
2.9.5 BeadChip processing 
BS-converted and oxBS-converted DNA samples were interrogated on Illumina 
Infinium HumanMethylation450 BeadChips following the manufacturer’s 
recommendations by UCL Genomics (Institute of Child Health Microarray and Next 
Generation Sequencing Facility, University College London). This required the use 
of 4µl of eluted DNA and 4 µl of 0.1N NaOH per sample. However, an optimisation 
of the TrueMethyl protocol, referred to as the “high-input” protocol in Chapter 5 
(section 5.2.4), required that oxBS-converted samples were processed on the 450K 
BeadChip using 7µl of eluted DNA and 1 µl of 0.4N NaOH per sample in order to 
maximise the amount of DNA interrogated on the arrays. This applied to a total of 
four samples (2 BS-converted replicates and 2 oxBS-converted replicates of the 
“brain1” DNA sample).  
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2.9.6 Data analysis 
The human brain samples subjected to the oxBS protocol (see Chapter 5, section 5.2) 
were analysed independently of the Saos-2 cell line dataset (see Chapter 5, section 
5.3) processed under a standard BS conversion protocol. Raw IDAT files were 
obtained from UCL Genomics and processed using ChAMP, a 450K analysis 
pipeline implemented with the statistical software package R (v.3.0.1) (Morris et al., 
2014). Probes were filtered by their raw intensity values using a detection p-value 
threshold of 0.01 and normalised using SWAN (Makismovic et al., 2012). For the 
human brain samples, an additional probe-filtering step was implemented: probes 
corresponding to the X and Y chromosomes were removed from the dataset as both 
male and female samples were being analysed.  
2.10 Pyrosequencing 
DNA underwent oxBS conversion using the TrueMethyl 24 Kit followed by 
pyrosequencing analysis (“oxBS-pyroseq”) on a PyroMark Q96 MD system 
(Qiagen) to quantify both 5mC and 5hmC at individual CpG sites. 
2.10.1 Primer design 
A subset of differentially methylated regions called from MeDIP-seq and hMeDIP-
seq datasets were selected for validation based their statistical significance. Regions 
falling within repetitive DNA sequence were excluded because they could not be 
uniquely targeted and amplified through PCR. For oxBS-450K validation, 50bp 
windows containing at least two CpG sites identified as containing the highest levels 
of 5hmC in the ‘brain1’ sample (5hmC ≥ 30%) were selected for oxBS-pyroseq.  
PyroMark Assay Design software (v.2.0.1.15) was used to design and select the most 
suitable primers for each pyrosequencing assay. Final primer lists used for 
pyrosequencing analysis in validation experiments are detailed in Supplementary 
Table 1. All custom-designed primers were ordered from Sigma-Aldrich. 
2.10.2 Primer standard curves 
Methylated DNA standard curves for each primer pair were generated to check for 
primer bias due to the 5mC content of DNA samples. A control DNA sample (pooled 
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human blood sample; see section 2.2) was used to generate fully unmethylated and 
fully methylated DNA aliquots that were then mixed at differing ratios to create 
pools of 0, 20, 40, 60, 80 and 100% methylated DNA.  
Fully unmethylated DNA was generated by undergoing two successive rounds of 
whole genome amplification (WGA) using the REPLI-g Midi Kit (Qiagen; 
#150043), according to the manufacturer’s protocol. The WGA reaction mix was 
incubated for 16 hours at 30°C in order to maximise the DNA yield.  
Fully methylated DNA was generated by treatment with M.SssI, a CpG 
methyltransferase (New England Biolabs; # M0226L). In vitro methylation reactions 
were set up in a final volume of 50µl as follows: 5µl 10X NEBuffer 2, 5µl SAM 
(1600µM), 10µl template DNA (300ng/µl), 27.5µl ultra-pure H2O and 2.5µl M.SssI 
(4U/µl). Reaction mixes were incubated on a thermal cycler for 1 hour at 37°C 
followed by 20 minutes at 65°C to inactivate the enzyme.  
The methylation status of the fully unmethylated and methylated control DNA 
samples were assessed through digestion with three different methylation-sensitive 
restriction endonucleases: HpaII (New England Biolabs; #R0171L), HpyCH4IV 
(New England Biolabs; # R0619L) and BstUI (New England Biolabs; #R0518L). 
Digestion reactions were set up for each control DNA sample in a final volume of 
40µl as follows: 10µl control DNA (~50ng/µl), 24µl ultra-pure H2O, 4µl NEBuffer1, 
1µl HpaII (10U/µl) and 1µl HpyCH4IV (10U/µl). Negative control reactions without 
either enzyme were also set up for each control DNA sample. All reactions were 
incubated on a thermal cycler for 1 hour at 37°C, before adding 1µl BstUI (10U/µl) 
to each (with the exception of negative controls) and incubating for a further 1 hour 
at 60°C. After the incubation, reaction mixes were analysed on a 2% agarose gel to 
check for digestion. Only WGA control DNA was visibly digested, whilst M.SssI-
treated DNA and both negative controls remained as a high molecular weight, tight 
DNA band (>10kb) after gel electrophoresis.   
The remaining WGA and M.SssI-treated DNA were purified using Agencourt 
Ampure XP beads, eluted in 100µl buffer EB (Qiagen) and the concentration 
adjusted to 50ng/µl each and checked using a Qubit dsDNA broad range assay kit 
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(Invitrogen; #Q32853). Next, six different pools of 0, 20, 40, 60, 80 and 100% 
methylated DNA were made up by mixing differing ratios of WGA and M.SssI-
treated DNA in a final volume of 20µl (i.e. 1µg DNA per mixture) and then 
subjecting each sample to BS conversion using the EZ DNA Methylation Kit (Zymo 
Research; ##D5001), according to the manufacturer’s protocol. All samples were 
eluted in a final volume of 40µl M-elution buffer and adjusted to a 10ng/µl final 
concentration. 
PyroMark PCR reactions for each primer pair (see section 2.10.1) were set up in 
triplicate on the six different BS-converted, control DNA samples (0, 20, 40, 60, 80 
and 100% 5mC), each in a final volume of 25µl and set up as follows: 23µl of a PCR 
mastermix (12.5µl PyroMark PCR mastermix, 2µl MgCl2 (25mM), 2.5µl 10X 
CoralLoad, 6µl H2O), 1µl DNA template, 0.5µl forward primer (5µM) and 0.5µl 
reverse primer (5µM). PCR plates were incubated on a thermal cycler under the 
following conditions: 95°C for 15min, 13 cycles of 94°C for 30s, 66°C for 30s (-
0.5°C per cycle) and 72°C for 30s, followed by 50 cycles of 94°C for 30s, 56°C for 
30s, 72°C for 30s, and then a final extension of 72°C for 10min. 
Finally, each PCR product was subject to pyrosequencing analysis (in triplicate) on a 
PyroMark Q96 MD system, according to the manufacturer’s protocol (see section 
2.10.6 for further details). Standard curves were generated for each primer pair by 
plotting expected methylation scores against pyrosequencing-derived measurements 
of methylation score (Supplementary Figure 1) and the final pyrosequencing results 
adjusted based on correlation between observed and expected 5mC scores. 
2.10.3 DNA extraction 
DNA was purified from in vitro cultured cell samples for oxBS-pyroseq analysis 
using the DNeasy Blood & Tissue Kit (Qiagen; #69504), according to 
manufacturer’s instructions. 
2.10.4 Oxidative bisulphite conversion of DNA 
4µg of each DNA sample was diluted in ultra-pure H2O to a final volume of 150µl 
and sonicated for 30 seconds using a Biorupter (Diagenode) on the “high” setting. 
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Each sample was then purified using the Zymo Clean and Concentrator-25 kit, 
following the manufacturer’s instructions, and eluted in 45µl ultra-pure H2O. 
Purified DNA was quantified using a NanoDrop 1000 spectrophotometer and the 
spike-in CEGX digestion control was added to each sample at a level of 0.5% w/w. 
Each sample was then split into two aliquots of 22.5µl and processed through the 
high-input TrueMethyl protocol as described previously (see section 2.9.3).  
2.10.5 PCR amplification  
PCR reactions were set up in 96-well plates using the PyroMark PCR kit (Qiagen; 
#978703). Each PCR was run in triplicate on both oxBS- and BS-converted DNA for 
each primer pair. PCR reactions were carried out in a final volume of 25µl and 
contained 23µl of a PCR mastermix (12.5µl PyroMark PCR mastermix, 2µl MgCl2 
(25mM), 2.5µl 10X CoralLoad, 6µl H2O), 1µl DNA template, 0.5µl forward primer 
(5µM) and 0.5µl reverse primer (5µM), one of which was biotinylated on the 5’ end 
(see section 2.10.1). PCR plates were incubated on a thermal cycler under the 
following conditions: 95°C for 15min, 13 cycles of 94°C for 30s, 66°C for 30s (-
0.5°C per cycle) and 72°C for 30s, followed by 50 cycles of 94°C for 30s, 56°C for 
30s, 72°C for 30s, and then a final extension of 72°C for 10min.  
2.10.6 Sequencing run 
PCR amplicons were prepared for sequencing through immobilisation to 
streptavidin- and sepharose-coated agarose beads. Each reaction was set up in a final 
volume of 70µl within a 96-well plate format (“plate 1”). Each well contained: 10µl 
of biotinylated PCR product, 40µl PyroMark binding buffer (Qiagen; #979006), 28µl 
ultra-pure H2O and 2µl streptavidin sepharose high performance agarose beads (GE 
Healthcare; #17-5113-01). The plate was sealed with a polyolefin film (Starlab; 
#E2796-9795) and agitated for 10 minutes on a microplate shaker (SciQuip; 
#SP2260-MP). 
Next, a 96-well PyroMark Q96 plate (Qiagen; #979101), referred to as plate 2, was 
set up containing the sequencing primers corresponding to each of the biotinylated 
PCR amplicons present in plate 1. First, 10µM sequencing primer stocks were 
diluted to 0.3µM in PyroMark annealing buffer (Qiagen; #979009) and then 12µl of 
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each sequencing primer was dispensed into the appropriate well of plate 2, taking 
care not to scratch the lower surface of the well.  
The PyroMark Q96 Vacuum Workstation was set up according to the manufacturer’s 
recommendations for capture of the amplicon-bead complexes in plate 1, followed 
by several wash steps and denaturation (using 0.2M NaOH) in order to generate 
single-stranded DNA fragments suitable for pyrosequencing. Finally, the single-
stranded DNA fragments were dispensed into plate 2 in order to mix with their 
corresponding sequencing primer. Plate 2 was sealed and placed in a heating block at 
85ºC for 5 minutes before cooling to room temperature, in order to ensure primer 
annealing to the template DNA strands. 
Pyrosequencing assays were analysed on a PyroMark Q96 MD system and the data 
output analysed using Pyro Q-CpG software (v.1.0.9). Methylation scores at each 
CpG site were normalised against a linear calibration curve (see section 2.10.2). 5mC 
levels were obtained from the oxBS-converted methylation scores, whilst 5hmC 
levels calculated by subtraction of oxBS from BS-only methylation scores.  
2.11 LC-MS analysis 
Liquid chromatography-mass spectrometry (LC-MS) analysis was performed by 
Martin Bachman (Department of Chemistry, University of Cambridge) as follows: 
500ng of genomic DNA was incubated with 5 U of DNA Degradase Plus (Zymo 
Research; #E2020) at 37°C for 3 hours. The resulting mixture of 2'-deoxynucleosides 
was analysed on a Triple Quad 6500 mass spectrometer (AB Sciex) fitted with an 
Infinity 1290 LC system (Agilent) and an Acquity UPLC HSS T3 column (Waters), 
using a gradient of water and acetonitrile with 0.1% formic acid. External calibration 
was performed using synthetic standards, and for accurate quantification, all samples 
and standards were spiked with isotopically labelled nucleosides.  
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Chapter 3 Development of an in vitro culture and phenotyping 
model of neural differentiation  
3.1 Introduction 
The central aim of this project was to investigate the potential function of 5hmC 
through profiling of both 5mC and 5hmC in parallel during the differentiation of 
mouse embryonic stem cells (mESCs) down a neural lineage. Unlike 5mC, global 
5hmC levels vary widely between somatic tissue types and are highest in the CNS, 
where it has been found in the range of 0.3 to 0.8% of all cytosines (Globisch et al., 
2010; Kriaucionis and Heintz, 2009; Munzel et al., 2010; Nestor et al., 2011). Lower 
but nevertheless significant levels of 5hmC have also been observed in mouse ESCs, 
ranging from 0.032% (Tahiliani et al., 2009) to 0.047% of total nucleotides (Song et 
al., 2011). In addition to non-neural somatic tissues, the lowest levels of 5hmC are 
observed in cells with high proliferative capacity, including blood, immortalized cell 
lines such as HeLa, HEK293FT and HCT116 and numerous cancers (Haffner et al., 
2011; Li and Liu, 2011; Song et al., 2011). Even if present at very low global levels, 
5hmC may still have biological relevance if it shows a clustered, rather than random, 
distribution throughout the genome, such as marking hotspots of DNA demethylation 
activity.  
An association between differentiation stage and 5hmC level has also been noted 
through immunohistochemical staining of stratified epithelial cells in various 
embryonic and adult tissues, where undifferentiated basal cells showed reduced 
5hmC staining as compared to differentiated apical cells (Haffner et al., 2011). The 
apparent inverse correlation between 5hmC levels and proliferative capacity led to 
the hypothesis that the most significant changes to 5hmC distribution (in the form of 
5hmC gains) may occur during normal CNS development, as pluripotent stem cells 
undergo lineage commitment to terminally differentiated neural cells.  
Although high levels of 5hmC had been measured in various mouse tissue types of 
the CNS, including cortex, hippocampus, cerebellum and hypothalamus, there was 
little information available on variations in 5hmC distribution amongst neural cell 
subtypes. Purkinje and granule cell neurons have been shown to contain some of the 
highest recorded levels of 5hmC at 0.6 and 0.2% of all nucleotides, respectively, but 
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comparable data for either astrocytes or oligodendrocytes was not yet available 
(Kriaucionis and Heintz, 2009). However, it seemed unlikely that neurons alone 
could be responsible for the high 5hmC signal observed in CNS tissues. The mouse 
neocortex, for example, has a glial-to-neuronal ratio of approximately 3:1 (Fu et al., 
2012) and contains the highest global 5hmC levels of any tissue. On the other hand, 
neurons outnumber glial cells by approximately 4:1 in the mouse cerebellum (the 
most neuron-dense tissue of the CNS) and yet 5hmC levels are up to 50% lower here 
than in cortical tissue (Globisch et al., 2010; Munzel et al., 2010; Szwagierczak et al., 
2010), suggesting that glial cells are likely to contribute to global 5hmC levels to 
some degree. In the absence of any concrete data on the differences in 5hmC content 
between neurons and glia, the relative ease of in vitro differentiation of the various 
neural subtypes was taken into account in order to determine a suitable cell culture 
model for further analysis.  
Fully differentiated neural cells may be derived in culture from either ESCs (via an 
intermediary neural precursor stage) or from primary neural stem cells (NSCs) 
isolated from the embryonic or adult brain (Figure 3-1). Neural precursors may be 
maintained in culture as either floating neurospheres or as an adherent monolayer 
upon addition of growth factors. The first example of isolated primary NSCs were 
propagated in culture as floating neurospheres (Reynolds and Weiss, 1992), 
heterogeneous spherical clusters of cells comprising of neurons, oligodendrocytes 
and astrocytes in addition to neural progenitors (Bez et al., 2003; Suslov et al., 2002). 
It is thought that the differentiated neural cells provide a cellular niche that allows for 
the maintenance of an NSC subpopulation within the neurosphere.  
More recently, successful expansion of ESC-derived NSCs in adherent conditions 
has been demonstrated, resulting in a homogenous population of cells with stable, 
long-term properties of self-renewal and tripotent differentiation capacity (Conti et 
al., 2005; Glaser et al., 2007; Ying et al., 2003). Alternatively, primary neural stem 
cells may be isolated from the subventricular zone (SVZ) of the foetal adult brain 
and established in adherent monoculture under the same conditions as embryonic-
derived NSCs, retaining the capacity to produce differentiated neuronal and glial 
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cells throughout many passages (Conti et al., 2005; Kriegstein and Alvarez-Buylla, 
2009; Pollard et al., 2006).  
 
Figure 3-1: Overview of in vitro neural stem cell systems. Neural progenitors may be derived 
through the in vitro differentiation of ESCs and iPSCs or isolated from foetal and adult brain. Neural 
progenitors may be expanded within neurospheres (a heterogeneous cell mass) or as a homogeneous, 
adherent monolayer before undergoing further neural lineage differentiation. Image courtesy of: Conti 
L, Cattaneo E. 2010. Nature Reviews Neuroscience 11, 176-187. 
The astrocytic differentiation of neural stem cells is well established and produces 
homogeneous cultures of functional, mature astrocytes after just 48 hours of 
exposure to serum (Brunet et al., 2004; Sauvageot and Stiles, 2002). These cells 
uniformly express glial fibrillary acidic protein (GFAP), a type of intermediate 
filament protein present in mature astrocytes (Jacque et al., 1978), generally accepted 
as the prevailing  immunocytochemical (ICC) marker of this cell type and whose 
expression is induced by serum exposure (Eng et al., 2000; Sakai et al., 1990).  
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Although many protocols for the in vitro production of neurons are available, they 
are technically challenging, difficult to reproduce and result in highly variable yields 
of neuronal cells. Neuronal differentiation is often accompanied by high rates of cell 
death and results in heterogeneous cell cultures comprising both neurons and glial 
cells, requiring further cell sorting or lineage selection to isolate a particular neural 
subtype (Gaspard et al., 2008; Kim et al., 2002; Ying and Smith, 2003). More 
recently, efficient generation of neurons in high yield (90% or more) have been 
reported from adherent, monolayer mESC cultures, although these neurons display 
heterogeneity in both marker expression and physiological function (Li et al., 2009).  
The in vitro generation of oligodendrocytes from either ESCs or NSCs has 
traditionally proved more difficult to achieve. An initial protocol for the generation 
of differentiated glial cells expressing the oligodendrocyte-specific markers O4 and 
2′, 3′-cyclic nucleotide 3′-phosphodiesterase (CNP) from rat ESCs reported 
heterogeneous populations comprising of approximately equal percentages (30-40%) 
of oligodendrocytes and astrocytes (Brüstle et al., 1999). Others have employed 
floating ‘oligosphere’ cultures to produce > 90% mature oligodendrocytes from 
mESCs. This multi-step procedure involves a combination of embryoid body (EB) 
formation, induction with retinoic acid and transfer into a defined oligosphere 
medium to form free-floating cell clusters that may dissociated and replated to 
encourage differentiation into mature oligodendrocytes (Liu et al., 2000). More 
recently, differentiated oligodendrocytes have been derived in adherent monolayers 
using a stably transfected CNP-ßgeo mESC line followed by a neomycine selection 
step to produce glial precursors that could be further differentiated into 
galactocerebroside-positive oligodendrocytes at yields of 80 ± 7% (Glaser et al., 
2005). A simpler protocol starting from a stably renewing mNSC population has also 
been demonstrated, but results in heterogeneous populations of neural cells 
comprising of approximately 20% oligodendrocytes, 40% astrocytes and 10% 
neurons (Glaser et al., 2007).  
Astrocytes were therefore deemed to be the most suitable differentiated cell type for 
analysis, as large numbers of homogeneous cells may be easily and efficiently 
produced through in vitro differentiation of mNSCs. In order to elucidate the precise 
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changes that occur in genomic 5hmC and 5mC distribution along the neural 
differentiation pathway, a combined MeDIP- and hMeDIP-seq approach was used to 
profile the DNA methylome at three defined cellular stages: mESCs, mNSCs and 
fully differentiated astrocytes. This chapter describes the in vitro cell culture model 
used to generate these cells for 5mC/5hmC DNA profiling.  
3.2 Establishment of mouse embryonic stem cells in culture 
JM8, a wild-type (WT) C57BL/6N mESC line, was initially established in culture 
using a LIF- and serum-containing growth medium in the absence of feeder cells 
(Pettitt et al., 2009; Smith, 1991). However, considerable spontaneous differentiation 
was observed under these growth conditions (Figure 3-2A), which did not improve 
during subsequent passaging.  
It has previously been observed that mESCs cultured in traditional LIF- and serum-
containing medium exhibit cellular heterogeneity in transcription factor expression 
(Chambers et al., 2007; Hayashi et al., 2008; Payer et al., 2006; Toyooka et al., 
2008). Several positive regulators of pluripotency (including NANOG, STELLA, 
OCT4 and KLF4) are present in varying concentration amongst subpopulations of 
mESCs, resulting in differences in self-renewal and differentiation capacity. These 
subpopulations appear to represent interconvertible cell states resulting from 
continuous, stochastic fluctuations in transcription factor expression and associated 
epigenetic modifications. This presents a problem for studies employing epigenetic 
and gene expression profiling methods, potentially confounding any downstream 
comparative analysis performed on datasets derived from such samples. 
In order to improve the homogeneity of the mESC culture and ensure they 
represented a truly undifferentiated population of cells, an alternative ‘3i’ culture 
method was tested. ‘3i’ refers to LIF- and serum-free growth media that relies on the 
addition of three small-molecule inhibitors SU5402, PD184352 and CHIR99021 to 
block mESC differentiation (Ying et al., 2008). These inhibitors target FGF receptor 
tyrosine kinases, the mitogen-activated protein kinase (MAPK) pathway and 
glycogen synthase kinase-3 (GSK3), respectively. Under these conditions, mESCs 
express uniformly high levels of Nanog, Klf4 and Rex1 and are thought to represent a 
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developmentally neutral, ‘ground state’ of pluripotency, maintaining the capacity for 
continuous self-renewal and tripotent differentiation (Wray et al., 2010).  
When re-plated in 3i medium (iSTEM®, StemCells Inc.; #SCS-SF-ES-01), the JM8 
mESCs exhibited an immediate change in cellular morphology. Cells grew as 
uniform colonies with little or no visible differentiation (Figure 3-2B).  
 
Figure 3-2: Phase contrast images of JM8 mESCs grown in adherent conditions in (A) LIF- and 
serum-containing media and (B) 3i media. In both conditions shown above, mESCs are plated on 
gelatin-coated plasticware. Significant numbers of differentiated cells are observed in condition (A), 
characterised by flat, irregularly shaped morphology and large cytoplasm. mESC colonies, in contrast, 
are characterised by small, compact cells with large nucleus-to-cytoplasm ratios. Colonies are usually 
circular and have a slightly raised, dome-shaped appearance.  
3.2.1 Embryonic stem cell phenotyping  
JM8 cells grown in either 3i or LIF- and serum-containing media underwent 
paraformaldehyde (PFA) fixation and subsequent immunostaining using an anti-
OCT-3/4 monoclonal antibody (Santa Cruz Biotechnology, Inc.; #sc-5279), a well-
established marker of ESCs (Nichols et al., 1998; Niwa et al., 2000).  Uniform, 
positive Oct4 expression was observed for all mESC colonies kept in both growth 
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media conditions (Figure 3-3A and B), although several isolated OCT4-negative 
cells were observed surrounding the mESC colonies (indicated by DAPI nuclear 
counterstaining) when grown in LIF and serum, indicating the presence of some 
differentiating cells. No immunoreactivity against the neural progenitor cell markers 
nestin and SOX1 was detected, providing confidence that these cells were truly ESCs 
(Figure 3-3C-D). 
 
Figure 3-3: Immunostaining of mESCs grown in two alternate culture conditions. (A) Cells 
maintained in LIF- and serum-free ‘3i’ medium and stained for OCT4 (red). (B) Cells maintained in 
LIF- and serum-containing expansion medium and stained for OCT4 (red). (C) mESCs grown under 
3i conditions were uniformly nestin-negative (red). (D) mESCs  grown under 3i conditions were 
uniformly SOX1-negative (green). DAPI nuclear counterstaining is shown in blue.  
3.2.2 Embryonic stem cell proliferation analysis 
Whilst mESCs grown under 3i conditions were able to undergo frequent passaging 
with no observable reduction in growth rate, an EdU assay (Click-iT® EdU Imaging 
Kit, Molecular Probes™; #C10086) was performed to confirm the proliferative 
capacity of this cell type. EdU, a thymidine analogue, is incorporated into newly 
synthesized DNA during S-phase of the cell cycle and may be detected through 
immunostaining with an anti-EdU primary antibody and fluorescent (Alexa Fluor® 
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594) secondary antibody. mESCs were incubated with media containing 10µM EdU 
for two hours before being fixated in 4% PFA and immunostained (Figure 3-4). 
Although the boundaries of individual cells and their nuclei were not clearly 
discernible due to the three-dimensional, dome-shaped nature of the mESC colonies, 
widespread EdU staining was observed in approximately half of all DAPI-
counterstained nuclei. 
 
Figure 3-4: Comparison of EdU and OCT4 immunostaining of mESCs. Panel 1 shows mESCs 
stained for EdU (red). Panel 2 shows mESCs stained for OCT4 (red). All images show nuclei 
counterstained with DAPI (blue). Uniform OCT4 stained was observed across all mESC colonies, 
whist approximately 50% of mESCs were positive for EdU incorporation.  
3.3 Primary neural stem cell culture and differentiation 
A WT mNSC line derived from an adult C57BL/6N mouse was grown as an 
adherent monolayer on laminin-coated plasticware. NSC expansion medium was 
comprised of RHB-A®, a serum-free, chemically defined culture medium 
(StemCells, Inc.; #SCS-SF-NB-01), in combination with epidermal growth factor 
(EGF) and basic fibroblast growth factor (FGF-2), each at a final concentration of 
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10ng/ml. These cells showed a doubling time of approximately 24 hours and could 
be passaged extensively without any apparent change in morphology or growth rate.  
Cell phenotype was confirmed by immunofluorescence for a combination of neural 
markers. Individual wells of 4-well culture dishes, seeded with P7 mNSCs, were 
stained with either anti-nestin (#ab6142) or anti-GFAP (#G9269) antibodies (Figure 
3-5, 1A-B). Cells were immunoreactive for nestin, a distinguishing marker of NSCs, 
and GFAP-negative (Wiese et al., 2004). 
Withdrawal of growth factors from the RHB-A media and addition of 10% foetal 
bovine serum (Gibco®; #10500-064) triggered the differentiation of mNSCs down 
the glial lineage to produce astrocytes, resulting in flat, stellate-like cells after just 24 
hours. Cells were kept in this differentiation medium, without re-plating or 
passaging, for two weeks before harvesting the cells for DNA extraction. 
Immunostaining conducted in parallel revealed 100% of the cells were GFAP-
positive after this two-week exposure to serum (Figure 3-5, 2A-B). In addition, no 
nestin immunoreactivity was detected above background signal, suggesting that a 
homogeneous population of astrocytes had been achieved under these culture 
conditions.  
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Figure 3-5: ICC staining of primary mNSCs and differentiated astrocytes. Panel 1: mNSCs under 
proliferating conditions showed uniform nestin expression (1A) without any visible GFAP expression 
(1B). Panel 2: After 14 days of differentiation through exposure to serum, mNSCs had adopted typical 
astrocytic morphology and were broadly nestin-negative (2A) and GFAP-positive (2B). 
3.3.1 Neural stem cell and astrocyte proliferation analysis 
The proliferative capacity of mNSCs was monitored using an automated live cell 
imaging system (IncuCyte™, Essen Biosciences) that took cell density 
measurements every 2 hours over a one-week period, resulting in an exponential 
growth pattern after an initial phase of minimal cell growth, likely due to low 
seeding densities (Figure 3-6A). Incubation with EdU confirmed that a high 
proportion of cells (~40%) were in S-phase under these expansion conditions  
(Figure 3-6C).  
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Figure 3-6: Investigating the proliferative potential of mNSCs and differentiated astrocytes. (A) 
Cell density measurements of primary mNSCs in expansion conditions over a one-week period show 
a typical sigmoid growth curve. Error bars represent the standard deviation between 3 replicate 
measurements. (B) Total cell counts of mNSCs grown in either expansion conditions (red) or 
differentiation conditions (green) over a 6-day period. Error bars represent the standard deviation 
between 3 replicate measurements. (C) Approximately 40% of all nuclei stained positive for EdU, 
indicating active proliferation in the mNSC culture. Nuclear EdU staining is shown in white; nestin 
staining is shown in red. (D) No nuclear EdU staining was visible in the astrocyte culture; GFAP 
staining is shown in green. DAPI nuclear counterstaining is shown in blue (both images).  
In contrast, cell division was strongly repressed in differentiating mNSCs upon 
switching growth factors for serum in the culture medium. Serum is known to be a 
potent inhibitor of proliferation and was used at high levels (10%) for astrocytic 
differentiation. The effect of serum on cell proliferation was assessed by counting 
total cell numbers for six consecutive days after switching from expansion medium 
to serum-containing differentiation medium. Individual wells of 6 x 6-well plates 
were seeded with approximately 0.3 x 106 mNSCs in either expansion or serum-
containing medium (3 wells per condition). After 24 hours, cells were collected from 
each well of the first plate and counted using an automated cell viability analyser 
(Vi-CELL® XR, Beckman Coulter) that excludes dead cells using trypan blue 
staining. These measurements were repeated every 24 hours for a total of 6 days and 
mean cell counts calculated for each culture condition (Figure 3-6B). Cells exposed 
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to expansion medium displayed fairly linear cell growth until day 4, after which a 
slight decrease in cell count was observed for the remaining 2 days due to 
overcrowding of the culture dish. Cells exposed to serum, however, exhibited 
complete absence of growth from day 1. Some cell death was observed under these 
differentiation conditions as cell numbers decreased slightly over the 6-day culture 
period. In addition, an EDU assay performed on astrocyte cultures 2 weeks after 
initiating differentiation showed no visible incorporation of EdU (Figure 3-6D), 
confirming the fully differentiated status of these cells. 
3.4 Neural differentiation of embryonic stem cells 
A knock-in Sox1-GFP reporter mESC line, originally derived from E14Tg2a.IV cells 
(Ying et al., 2003), was used in place of WT mESCs in order to facilitate the 
monitoring of the neural differentiation process.  
Neural precursor cells were successfully generated from mESCs by replating at 1 x 
104 cells/cm2 in RHB-A media. RHB-A has been shown to achieve more efficient 
neural commitment of mESCs than N2B27, the conventional serum-free medium 
described by Ying and Smith (2003) in the first demonstration of neural induction in 
a feeder-free, adherent monolayer mESC culture (Abranches et al., 2009; Diogo et 
al., 2008). Differentiating mESCs were monitored for the appearance of SOX1-
positive neural precursors (Figure 3-7A-F). Sox1-GFP expression was first visible by 
day 7 alongside nestin (Figure 3-7G-H), whilst a characteristic neural rosette 
structure was apparent by day 10 (Figure 3-8), in parallel with widespread Sox1-GFP 
expression.  
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Figure 3-7: mESCs undergoing neural induction over 10 days. (A) Live imaging at day 0; mESCs 
under 3i culture conditions form typical spherical colonies. (B) Live imaging at day 3 of neural 
induction, after replating mESCs in RHB-A media. (C) Live imaging at day 5 of neural induction; 
significant amounts of cell death was visible at this stage. (D) ICC staining shows that nestin 
expression is minimal at day 6 but becomes widespread by day 7 (G). (E) Live imaging at day 7 of 
neural induction; elongated, bipolar cells appeared to be proliferating rapidly, outgrowing a 
subpopulation of flattened cells. Sox1-GFP expression is apparent (H) but levels are not significantly 
above those of background fluorescence; neural precursor cells are not yet arranged as rosette 
structures. (F) Live cell imaging at day 10 of neural induction; neural rosettes began to form within 
the culture alongside strong and widespread Sox1 expression (I) localized to cells within neural 
rosettes.   
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Figure 3-8: Live cell imaging at Day 10 of mESC differentiation. Phase contrast imaging (left 
panel) shows the formation of neural rosette structures within the culture dish. Fluorescence imaging 
(central panel) shows strong endogenous GFP expression concentrated within the neural rosettes.  
Differentiating mESCs cultures were dissociated at day 10, re-suspended in fresh 
RHB-A medium containing EGF and FGF-2 and replated onto laminin-coated 
plasticware. Some initial cell death and cellular heterogeneity was seen upon this re-
plating step, including cells with a more flattened, multipolar non-neural 
morphology. However, an adherent, SOX1-negative cell population rapidly outgrew 
these differentiated cells and subsequent passaging resulted in uniform cultures of 
elongated bipolar cells. These cells formed a lattice structure in the culture dish at 
higher densities, typical of neural stem cells (Figure 3-9B), and were maintained in 
culture through multiple (>8) passages without any loss in proliferation capacity or 
morphological change. ICC analysis confirmed these cells to be uniformly nestin-
positive and GFAP-negative, in agreement with a neural stem cell identity (Figure 
3-9C and D). 
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Figure 3-9: ESC-derived mNSCs in expansion medium. (1A) Live cell imaging of ‘day 10’ 
differentiated mESCs replated in neural stem cell expansion medium. (1B) ESC-derived mNSCs after 
three passages in expansion medium. (2A) ESC-derived mNSCs showed uniform nestin 
immunoreactivity (red). (2B) mNSCs were negative  for  GFAP immunoreactivity (green). DAPI 
nuclear counterstaining is shown (blue) in panel 2. 
Astrocyte differentiation of embryonic-derived mNSCs was induced using the same 
culture conditions described previously for primary cells, through withdrawal of 
EGF and FGF-2 and addition to 10% serum to the neural culture medium (RHB-A). 
Cells were maintained under these conditions for 2 weeks before either ICC staining 
or cell harvesting for DNA extraction (Figure 3-10). 
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Figure 3-10: Differentiation of embryonic-derived mNSCs to astrocytes. (1A) After only 24 hours 
of differentiation using 10% serum-containing media, a distinctive glial morphology is observed. (1B) 
ICC analysis after differentiation for 24 hours shows cells broadly expressing the astrocytic cell 
marker GFAP (green). (2A) After 2 weeks of serum exposure, no significant differences in cellular 
morphology are observed. (2B) Cells remain uniformly GFAP-positive (green).  
3.5 Neuronal differentiation of mNSCs 
Whilst the focus of this project was on the 5mC and 5hmC dynamics associated with 
astrocytic fate determination, comparison of global 5hmC levels in astrocytes to 
other neural lineages was also desirable as it was unclear whether the significant 
5hmC content associated with CNS tissue was restricted to a particular neural 
subtype. In an attempt to generate mature neurons in vitro, the Sox1-GFP mESC line 
was used to assess three variations of a neuronal differentiation protocol (Figure 
3-11). In the first method (A), mESC colonies growing under 3i conditions are 
dissociated, re-suspended in fresh RHB-A medium and seeded onto a gelatin-coated 
surface at a density of 0.5-1.5 x 104 cells/cm2. The cells are then left to undergo 
continuous differentiation in these conditions without further re-plating or changes to 
media composition (Ying and Smith, 2003). This protocol generated a high 
percentage of neuronal-like cells with thin, elongated processes extending throughout 
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the culture dish (Figure 3-12A-D), although cells with glial morphology were also 
observed in low numbers throughout the culture. These cells were maintained under 
differentiation conditions until day 21, when they were harvested for DNA 
extraction. However, cells at this stage of differentiation did not survive replating for 
ICC analysis, so the phenotype of these neuronal cells could not be accurately 
assessed. 
 
Figure 3-11: Neuronal differentiation of mNSCs. An outline of three culture methods attempted for 
the in vitro generation of differentiated neurons. SOX1-positive neural precursors were generated 
from mESCs as described in section 3.4. Methods (A) and (B) are based on the protocol from Ying 
and Smith, 2003. Method (C) is based on the protocol from Conti et al. 2005.  
In a variation of the above protocol, cells may undergo a replating step at the neural 
precursor stage to promote a higher proportion of neuronal differentiation (method 
B). When SOX1-positive neural precursors are detected amongst the differentiating 
cell population (around day 7-10), they are dissociated and re-plated at slightly lower 
density (4-5 x 104 cells/cm2) in RHB-A medium on a laminin substrate (Lorincz, 
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2006). The use of laminin over gelatin promotes increased cell attachment and re-
plating is thought to promote a greater proportion of neuronal differentiation by 
disrupting cell-to-cell contacts and reducing cell density in the culture dish, thereby 
reducing the effects of autocrine factors released from neighbouring cells that 
promote an undifferentiated state. However, few cells successfully reattached upon 
replating on day 10 and did not display the characteristic morphology of neural 
precursors, instead appearing as a heterogeneous and somewhat differentiated 
population (Figure 3-12E-F). No further visible neuronal differentiation took place 
and cells failed to survive in culture past a few days. 
The final method (C) relies on the generation of intermediary pluripotent progenitors 
prior to full neuronal differentiation. A stably renewing mNSC population is first 
established from the initial mESC culture, as described in section 3.4, before 
sequentially withdrawing growth factors to induce a neuronal cell fate, resulting in a 
final cell population containing 30 - 40% MAP2- and NeuN-positive neuronal cells 
(Conti et al., 2005). In this protocol, stably renewing mNSCs are dissociated, 
resuspended in RHB-A media containing FGF-2 only and replated at a density of 2-3 
x 104 cells/cm2. After 7 days of differentiation under these conditions, FGF-2 is 
withdrawn from the media and cells undergo a further 7 days of differentiation to 
induce a neuronal cell fate. Although this method did result in neuronal-like cells 
with long processes, cell yields were extremely low due to widespread cell death, 
making this method unsuitable for the generation of sufficient quantities of neurons 
necessary for downstream DNA methylation analysis (Figure 3-13).  
 87 
 
Figure 3-12: Continuous neural differentiation of mESCs as an adherent monolayer in RHB-A 
with and without a replating step. (A-B)	 Day	 14	 of continuous neural induction on a gelatin 
substrate; cells grew long processes and started to form a lattice structure within the culture dish, 
suggesting the onset of a neuronal cell identity. (C-D) Day 17 of continuous neural induction on a 
gelatin substrate. Neuronal morphology had become more widespread; some flattened non-neuronal 
cells remained in the culture dish.  (E-F) Day 13 of neural induction after replating neural progenitors 
onto laminin on day 10. Very few cells survived the replating step and displayed heterogeneous 
morphology upon attachment.  
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Figure 3-13: Live cell imaging of an embryonic-derived mNSC population undergoing neuronal 
differentiation through sequential growth factor withdrawal. Self-renewing mNSCs were replated 
in RHB-A with FGF-2 (10ng/ml) only to initiate differentiation. (1A) Day 4 of EGF withdrawal. (1B) 
Day 7 of EGF withdrawal. FGF-2 was withdrawn on this day and differentiation continued in RHB-A 
medium only. (2A & 2B) Day 14 of EGF withdrawal/Day 7 of FGF-2 withdrawal. Significant cell 
death was observed upon FGF-2 withdrawal, with only a few adherent cells remaining at the end of 
the 14-day differentiation period.  
3.6 Discussion 
An in vitro culture model was successfully developed and established for the 
generation of three defined cell populations: mESCs, mNSCs and astrocytes. 
Phenotypes were confirmed using a combination of morphological observation, ICC 
staining and proliferation analysis, performed in parallel to the expansion and/or 
differentiation of the corresponding cells for collection (Table 3-1).  
Cell samples for methylome and hydroxymethylome analysis were all derived from 
the WT C57BL/6N mouse strain. Both stem cell populations (mESCs and primary 
mNSCs) were expanded separately in vitro and harvested for DNA extraction. 
Astrocytes were differentiated directly from primary mNSCs and harvested after a 
two-week culture in 10% serum-containing medium to ensure full differentiation. 
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10% serum exposure for a minimum of 48 hours is a traditional method for the in 
vitro production of astrocytes and is sufficient for the induction of two characteristic 
astrocyte markers, GFAP and glutamine synthetase, concomitant with the 
downregulation of nestin (Brunet et al., 2010; Loo et al., 1995; Sakai et al., 1990), 
although mature, morphologically homogeneous cultures of GFAP-expressing 
astrocytes have been previously derived in culture after 48 hours in the presence of 
just 1% serum (Conti et al., 2005).  
In addition, the neural differentiation of Sox1-GFP mESCs in adherent monolayer 
conditions permitted the generation of embryonic-derived mNSCs, astrocytes and 
neuronal-like cells. These alternatively derived cell populations were used for 
validation of the genome-wide 5mC and 5hmC profiling data in order to assess 
whether observed DNA methylation changes between mESCs and primary neural 
cells could be recapitulated under in vitro differentiation culture conditions.  
Cell Type MeDIP/hMeDIP-
seq analysis 
oxBS-pyroseq 
analysis 
LC-MS 
analysis 
WT C57BL/6N mESCs  
✓ ✓ 
WT C57BL/6N adult mNSCs  
✓  ✓ 
WT C57BL/6N astrocytes 
✓  ✓ 
E14Tg2a.IV Sox1-GFP 
mESCs  ✓ ✓ 
E14Tg2a.IV Sox1-GFP 
mNSCs   ✓ ✓ 
E14Tg2a.IV Sox1-GFP 
astrocytes   ✓ ✓ 
 
Table 3-1: Summary of all cell culture samples collected for subsequent DNA analysis. 
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Chapter 4 Methylome and hydroxymethylome analysis of neural 
differentiation  
Work carried out in collaboration: 
MeDIP- and hMeDIP-seq DNA libraries were sequenced on an Illumina HiSeq 2000 
at Illumina Cambridge Ltd, UK. Bioinformatics analysis of raw sequencing data 
using the MEDIPS pipeline was carried out by Dr Gareth Wilson (UCL Cancer 
Institute). LC-MS analyses of genomic DNA samples were performed by Martin 
Bachman (Department of Chemistry, University of Cambridge).  
4.1 Introduction 
DNA methylation at the 5’ position of cytosine is a well-characterised epigenetic 
modification in mammalian DNA and is known to play an important role in a diverse 
range of cellular processes, including genomic imprinting, X-chromosome 
inactivation, retrotransposon gene silencing and tissue-specific gene regulation (Bird, 
2002; Reik, 2007). 5-methylcytosine (5mC) is thought to be a heritable, stable 
epigenetic modification that nevertheless undergoes dynamic changes during normal 
development in both somatic and germ line tissues (Hajkova et al., 2002; Meissner et 
al., 2008).  
DNA methylation patterns are established and maintained by the DNA 
methyltransferase (DNMT) family of enzymes. Knockout studies in mice targeting 
the DNMT gene family have shown that homozygous deletion of either the 
maintenance methyltransferase DNMT1 or the de novo methyltransferases 
DNMT3A/B results in embryonic or early postnatal lethality, suggesting a critical 
functional role for 5mC in normal development (Li et al., 1992; Okano et al., 1999). 
DNMT3A and DNMT3B display distinct expression patterns in the developing 
central nervous system (CNS), with DNMT3B highly expressed during early 
neurogenesis (E11-E15), whilst DNMT3A levels are initially low but increase during 
early postnatal development within postmitotic neurons before being downregulated 
in the mature adult CNS (Feng et al., 2005).  
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5mC-mediated transcriptional regulation has been widely implicated in CNS 
development and mutations in methyl-CpG binding domain (MBD) proteins have 
been linked to neurological disorders such as Rett Syndrome (Goto et al., 1994; Guy 
et al., 2001). There is also increasing evidence supporting a role for 5mC in the 
dynamic regulation of gene expression patterns underlying neural plasticity (Feng et 
al., 2007; Hsieh and Gage, 2004). Neuronal activity has been shown to trigger 
changes in DNA methylation, MBD protein binding affinity and gene transcription 
levels, suggesting that 5mC-mediated chromatin remodelling is critical for normal 
neuronal gene regulation (Chen et al., 2003; Martinowich et al., 2003).  
The recent discovery of 5-hydroxymethylcytosine (5hmC), an oxidation product of 
5mC catalysed by the ten-eleven-translocation (TET) hydroxylase enzymes, as a 
novel constituent of mammalian DNA has opened up new avenues of research into 
the role of DNA methylation in health and disease (Kriaucionis and Heintz, 2009; 
Tahiliani et al., 2009). There is particular interest surrounding the potential function 
of 5hmC in CNS development due to the unusually high levels of 5hmC recorded in 
both human and mouse brain compared to other somatic tissues, immortalised cell 
lines and stem cells (Globisch et al., 2010; Munzel et al., 2010; Song et al., 2011). 
However, few methods were available at the time for the accurate quantification and 
profiling of this novel cytosine modification, although two methods (oxBS-seq and 
TAB-seq) have subsequently been developed for single-base-resolution 5hmC 
sequencing (Booth et al., 2012; Yu et al., 2012). Sodium bisulphite conversion 
coupled to high-throughput sequencing (BS-seq) is considered the gold standard for 
DNA methylation profiling and allows single base resolution of 5mC (Lister et al., 
2009) but cannot discriminate between 5mC and 5hmC, leading to potential 
overestimation of the 5mC content of DNA (Huang et al., 2010; Nestor et al., 2010). 
Several enrichment-based techniques quickly emerged for genome-wide 5hmC 
profiling, including hMeDIP (Ficz et al., 2011; Stroud et al., 2011; Williams et al., 
2011; Wu et al., 2011), anti-CMS and GLIB (Pastor et al., 2011), all of which can be 
used to immunoprecipitate 5hmC-containing DNA fragments for sequence analysis 
using arrays or high-throughput sequencing.  
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In order to explore the 5mC/5hmC changes that occur along astrocytic lineage 
differentiation, genome-wide 5mC and 5hmC analysis was performed for three time 
points at defined cellular stages: mESCs, primary mNSCs and in vitro differentiated 
astrocytes. MeDIP-seq is a well established genome-wide profiling method offering 
moderate resolution (100-300bp) at significantly lower cost than single-base 
resolution, whole-genome profiling methods such as BS-seq (Down et al., 2008; 
Weber et al., 2005). MeDIP-seq may also be automated for higher throughput and 
increased reproducibility between samples (Butcher and Beck, 2010). Automated 
MeDIP- and hMeDIP-seq assays were therefore selected for methylation profiling on 
the basis of reliability and specificity towards either 5mC or 5hmC (depending on the 
antibody used), whilst enabling ease of comparison between the final datasets due to 
similar experimental protocols. 
4.2 Genome-wide DNA methylation profiling of neural differentiation 
Genome-wide 5mC and 5hmC profiles were generated for three distinct cell types 
(mESCs, mNSCs and astrocytes) in triplicate using a combined MeDIP- and 
hMeDIP-seq approach, resulting in a total of nine methylomes and nine 
hydroxymethylomes. MeDIP- and hMeDIP-seq DNA libraries were sequenced on an 
Illumina HiSeq 2000 (100bp paired-end reads) and the resulting fastq data files were 
processed using the MeDUSA analysis pipeline (Wilson et al., 2012). Briefly, raw 
sequencing reads were aligned to the mm10 reference genome using BWA (Li and 
Durbin, 2009), filtered for redundant and unpaired reads using SAMtools (Li et al., 
2009) and normalised for fragment length, resulting in final read counts in the range 
of 9.5 to 20 million uniquely-mapped paired-end reads per DNA library (Table 4-1, 
column 2). The final percentages of uniquely mapped reads were lower than 
expected, likely due to the existence of PCR duplicates arising during library 
amplification. Individual methylation and hydroxymethylation peaks were defined 
using MACS (Zhang et al., 2008).  
The correlation between MeDIP- and hMeDIP-seq replicates was calculated to 
provide an estimate of concordance in genome-wide sequence coverage within each 
biological sample (Supplementary Table 2). The correlations were very high between 
replicates for all three samples (mESCs, mNSCs and astrocytes) and both types of 
 93 
DNA sequencing library (MeDIP and hMeDIP). For hMeDIP-seq libraries, 
correlations were all > 0.95, whilst MeDIP-seq correlations were slightly lower (> 
0.86).  
Sample type  
High quality, 
aligned read 
count (mean) 
Final non-
redundant read 
count (mean) 
Final alignment 
rate (%) 
MeDIP-seq    
Astrocytes  39,617,891 13,109,040 33.1% 
Neural stem cells 42,833,593 9,487,916 22.2% 
Embryonic stem cells 56,426,103 17,781,913 31.5% 
hMeDIP-seq    
Astrocytes 40,290,816 18,142,576 45.0% 
Neural stem cells 33,902,991 19,982,046 58.9% 
Embryonic stem cells 33,062,430 17,798,058 53.8% 
Table 4-1: Sequencing read counts for MeDIP and hMeDIP libraries. Three distinct DNA 
libraries were prepared and sequenced for each sample type and read counts shown in the table above 
represent the mean value of three replicates. 
Dynamic changes in 5mC and 5hmC distribution were assessed through the 
identification of differentially methylated and hydroxymethylated regions (DMRs 
and hDMRs, respectively) associated with two defined stages of neural 
differentiation: mESCs to mNSCs, and mNSCs to astrocytes. These regions were 
defined as 500bp windows of differential enrichment between triplicate methylation 
or hydroxymethylation peak-sets, using a stringent false discovery rate (FDR) of 5%.  
Most observed changes occurred in the transition from an embryonic to neural stem 
cell fate, with a total of 5,925 DMRs and 321 hDMRs found between these two cell 
types. In contrast, just 140 DMRs and 2 hDMRs were called between mNSCs and 
astrocytes (Table 4-2). The majority of DMRs (90%) called between mESCs and 
mNSCs represented gains in methylation at this transition (hyper-DMRs). All 140 
DMRs observed between mNSCs and astrocytes also represented hypermethylation, 
suggesting a pattern of increasing genome-wide methylation as a cell transitions 
from a pluripotent to terminally differentiated cell fate.  
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Overall, the total number of hDMRs detected between the different 
hydroxymethylomes was approximately 20-fold less than the number of DMRs, 
perhaps reflecting the significantly lower amounts of global 5hmC observed in 
mammalian genomic DNA compared to 5mC. If 5hmC is a true intermediate in an 
active demethylation mechanism, it is possible that 5hmC turnover occurs too rapidly 
to be captured effectively by such genome-wide profiling methods.  
 mNSCs vs. mESCs Astrocytes vs. mNSCs 
5mC   
Hypo-DMRs 559 0 
Hyper-DMRs 5366 140 
5hmC   
Hypo-hDMRs 119 2 
Hyper-hDMRs 202 0 
Table 4-2: Summary of the total number of differentially methylated and hydroxymethylated 
regions called between sample types. The majority of DMRs and hDMRs are found between mESCs 
and mNSCs. Few changes in 5mC and 5hmC distribution are identified between mNSCs and 
astrocytes.  
4.3 Feature annotation of differentially methylated and hydroxymethylated 
regions 
Genomic feature annotation of identified DMRs and hDMRs was performed through 
the MeDUSA analysis pipeline, which assigned a DMR or hDMR to a particular 
feature if either 25% of the DMR fell within the defined feature or if at least 25% of 
the feature was covered by the DMR in question. For calculations of feature 
enrichment, a minimum 50% overlap was required in order for an association to be 
made between a DMR and genomic feature. 
During the mESC to mNSC transition, hypermethylated regions appear biased 
towards genic sites, with 68% of all hyper-DMRs falling within genes, compared to 
just 32% located in intergenic regions (Figure 4-1A). Significant percentages of 
genic hyper-DMRs are associated with CpG islands, shores and promoter regions 
(18%, 23% and 26% respectively), but significant enrichment is observed only 
within exons (Bonferroni-adjusted p-value = 1.83 x 10-186). In contrast, hypo-DMRs 
are distributed fairly evenly between genic and intergenic locations (57% and 43% 
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respectively) and less than 10% are located within promoters or CpG-dense regions. 
However, these hypo-DMRs are nevertheless significantly enriched in promoters 
(Bonferroni-adjusted p-value = 1.06 x 10-12), CpG shores (Bonferroni-adjusted p-
value = 1.04 x 10-7) and intragenic regions (both exons and introns, Bonferroni-
adjusted p-values equal 2.24 x 10-6 and 1.88 x 10-5, respectively). During the 
differentiation of mNSCs to astrocytes, only hyper-DMRs are observed. Of the 45% 
located within genes, 42% are associated with introns and less than 4% are 
associated with CpG islands, shores or promoter regions. It therefore appears that 
DMRs located within promoters and other CpG-dense regions undergo mostly 
hypermethylation during the mESC to mNSC transition and few additional gains 
occur during subsequent differentiation to astrocytes. 
The genomic attributes of DMRs were also assessed using EpiExplorer, an 
interactive web tool that allows annotation of custom user datasets with a wide range 
of genomic and epigenomic features (Halachev et al., 2012). Randomised control 
sets may automatically be generated for each custom dataset uploaded to 
EpiExplorer by reshuffling the genomic coordinates of the user-upload regions in the 
genome, allowing comparative analysis of both control and custom datasets to assess 
enrichment for particular genomic annotations (Figure 4-2). 
Both hypo- and hyper-DMR sets show significant enrichment compared to controls 
in regions associated with regulatory features including gene promoters, H3K4me1, 
H3K4me3, DNA polymerase II (Pol-II) binding and DNaseI hypersensitive sites and 
conversely a strong depletion in repetitive DNA sequence, indicating that 
methylation changes between mESCs and mNSCs are selectively associated with 
functionally relevant regions.  
With the exception of two hypo-hydroxymethylated regions, all 321 hDMRs are 
observed during the mESC to mNSC transition, rather than between mNSCs and 
astrocytes (Table 4-2). Comparison of the genomic distribution of hypo- and hyper-
hDMRs reveals little difference between the two categories (Figure 4-1B), with over 
50% of both hDMR categories found within intergenic regions. However, hypo-
hDMRs are significantly enriched within both CpG islands and shores (Bonferroni-
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adjusted p-values equal 1.38 x 10-5 and 3.25 x 10-4, respectively). No significant 
enrichment for particular genomic features is observed for hyper-hDMRs.  
 
Figure 4-1: Feature annotation of all DMRs and hDMRs identified between either the mESC to 
mNSCs or mNSC to astrocyte transition. A) Distribution of all DMRs according to genomic 
feature. B) Distribution of all hDMRs according to genomic feature. Categories found to be 
significantly enriched (Bonferroni-adjusted p-value < 0.05) for DMRs are labelled with an asterisk.  
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Figure 4-2: EpiExplorer analysis summaries for DMR datasets compared to randomised 
controls. The bar charts compare the percentage overlap of DMRs (orange bars) falling within 
genomic features (x-axis) to randomised control regions (grey bars). A) The percentage overlap 
between various genomic features and hyper-DMR regions identified between mNSCs and mESCs. 
B) The percentage overlap between various genomic features and hypo-DMR regions identified 
between mNSCs and mESCs. C) The percentage overlap between various genomic features and 
hyper-DMR regions identified between astrocytes and mNSCs. A DMR was associated with a 
particular genomic feature if they shared at least a 50% overlap in sequence coverage. Note that in 
some cases, the total numbers of hypo- and hyper-DMR regions examined here are slightly lower than 
those reported in Table 4-2 due to a few unsuccessful conversions of DMR coordinates from the 
mm10 to mm9 genome assembly prior to EpiExplorer analysis.  
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Analysis of the DNA sequence content of the identified 5hmC hotspots revealed a 
bias of hDMRs towards repeat regions of the genome, unlike DMRs which are 
predominately located in non-repetitive sequence. Only 13% and 27.4% of all hyper- 
and hypo-DMRs, respectively, fall within repetitive regions of the genome (Figure 
4-3A-B). In contrast, approximately 80% of both hyper- and hypo-hDMR sets are 
associated with repeat features (Figure 4-3C-D). High enrichment levels for 
repetitive DNA sequences has previously been noted for both MeDIP- and hMeDIP-
seq profiles (Matarese et al., 2011), whilst similar enrichment is lacking in 5mC 
profiles generated using alternative methods, such as MethylCap-seq and BS-seq. 
This may be explained at least in part by antibody bias towards regions of high 
cytosine density, preferentially immunoprecipitating unmethylated but cytosine-rich 
DNA over methylated regions with lower cytosine density.  
 
Figure 4-3: DMRs and hDMRs identified during the mESC to mNSC transition show distinct 
distributions within repetitive DNA sequences. Hypo-DMRs (A) and Hyper-DMRs (B) 
predominately fall within non-repetitive regions of the genome, shown in blue. However, the majority 
of hypo-hDMRs (C) and Hyper-hDMRs (D) are found within repeat regions: less than 25% of all 
differentially hydroxymethylated regions are associated with unique DNA sequence. 
Further interrogation of the genomic attributes of hDMRs using EpiExplorer 
revealed that both hypo- and hyper-hDMR datasets show enrichment for repeat DNA 
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regions compared to their randomised controls, but not for genic regions or histone-
associated sites, indicating that these hDMRs are unlikely to be functionally 
significant (Figure 4-4). In fact, hDMRs seem to be relatively depleted at H3K4me1 
peaks, a modification frequently associated with enhancers (Heintzman et al., 2007). 
Nevertheless, hypo-hDMRs do appear to be enriched at gene promoters (defined as 
between -5kb and 1kb of the transcriptional start site) and Pol-II binding sites, which 
may have biological implications. 
 
Figure 4-4: EpiExplorer analysis summaries for hDMR datasets compared to randomised 
control datasets. A) The percentage overlap between various genomic features (x-axis) and both 
hyper-hDMR regions (orange bars) and control set regions (grey bars). B) The percentage overlap 
between various genomic features (x-axis) and both hypo-hDMR regions (orange bars) and control set 
regions (grey bars). For both hDMR sets, the number of regions overlapping repeats is higher than 
expected by chance, suggesting enrichment for repetitive DNA. Note that the total numbers of hypo- 
and hyper-hDMR regions examined here are slightly lower than those reported in Table 4-2 because 
the original hDMR coordinates (mm10 assembly) needed to be converted to the mm9 assembly prior 
to EpiExplorer analysis, resulting in a few unsuccessful lift-overs. 
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4.4 Functional annotation of differentially methylated regions 
A combination of gene ontology analysis and individual examination of DMR 
regions was used in order to assess the potential functional relevance of the observed 
5mC and 5hmC changes and identify those likely to hold the most biological 
significance during the mESC to astrocyte transition. 
Differentially methylated and hydroxymethylated regions were assigned an 
associated gene ID if the regions fell within 100kb upstream or 50kb downstream of 
a known gene, according to Ensembl’s annotation of the GRCm38 genome assembly 
(Table 4-3). The top 10 most statistically significant hyper- and hypo-DMRs called 
between the mESC and mNSC transition and their associated genes are detailed in 
Supplementary Table 3 and Supplementary Table 4, respectively.  
During the mNSC to astrocyte transition, over 40-fold fewer regions of differential 
methylation were identified compared to the mESC to mNSC transition; all 140 
regions represented hypermethylation events in astrocytes, suggesting that previous 
gains in methylation between mESCs and mNSCs (5366 regions in total) were 
conserved upon subsequent astrocytic differentiation. Similarly, comparison of the 
coordinates of hyper-DMRs gained during mNSC to astrocyte differentiation to those 
of the hypo-DMRs called between mESCs and mNSCs reveal no overlap: all initial 
5mC changes were retained upon subsequent differentiation to astrocytes. Visual 
inspection of candidate DMRs using the UCSC genome browser (Figure 4-7 and 
Figure 4-8) confirmed that these methylation changes were unidirectional during the 
differentiation of mESCs to astrocytes.  
The Database for Annotation, Visualisation and Integrated Discovery (DAVID) 
online functional annotation tool (v6.7) was used for further analysis of these DMR-
associated gene lists. During the mESC to mNSC transition, gene-sets associated 
with both hypo- and hyper-DMRs showed the strongest enrichment for genes 
upregulated in brain tissue (Supplementary Figure 2). In addition, the second most 
enriched tissue expression category for the hypo-DMR gene-set was “neural stem 
cell”, suggesting that these loss-of-methylation regions may be involved in the 
upregulation of genes crucial for neural stem cell determination.  
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mNSCs vs. mESCs Astrocytes vs. mNSCs 
Total DMR 
number 
Associated 
genes  
Total DMR 
number 
Associated 
genes 
5mC     
Hypo-DMRs 559 430 0 0 
Hyper-DMRs 5366 2906 140 107 
5hmC     
Hypo-hDMRs 119 40 2 2 
Hyper-hDMRs 202 95 0 0 
Table 4-3: The number of annotated genes associated with all DMR and hDMR regions called 
between the mESC to mNSC transition (left) and the mNSC to astrocyte transition (right).  
Gene ontology (GO) analysis revealed high levels of enrichment for genes associated 
with organismal developmental processes, cellular differentiation, nervous system 
development and transcriptional regulation for both DMR-associated gene sets 
(Supplementary Figures 3 and 4), further indicating that these methylation changes 
may have an important functional role in the specification of neural stem cell 
identity.   
Functional annotation of the gene list associated with all 140 hyper-DMRs identified 
between the mNSC to astrocyte transition also showed significant enrichment for 
genes upregulated in brain, brain cortex and head tissue (Supplementary Figure 5), 
supporting a potential functional role for these DMRs in regulating neural 
specification. Genes upregulated in brain (39 total) include Cntnap2, Gata3, Atxn1, 
Nkx2-1, Tenm2 and Tenm4. However, GO analysis did not reveal any other terms 
suggestive of a specific association with neural developmental processes. Some of 
the most significantly enriched GO terms were those ubiquitously associated with 
normal eukaryotic cell function, including protein binding, cell part, metabolic 
processes and protein phosphatase type 2A regulator activity (Supplementary Figure 
6). 
Furthermore, GO analysis using the Genomic Regions Enrichment of Annotations 
Tool (GREAT, v3.0.0) returned similar annotation results for the identified DMR 
regions between mESCs and mNSCs as obtained by DAVID analysis of the DMR-
associated gene lists. Hyper-DMR regions were highly enriched for genes associated 
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with GO biological process terms such as embryonic morphogenesis, pattern 
specification process, cell fate commitment and rostrocaudal neural tube patterning 
(Figure 4-5A). The most significantly enriched GO biological process (embryonic 
morphogenesis) was associated with 777 hyper-DMR regions and 233 genes, 
including many involved in early embryonic development such Nanog, Nodal, Pax6, 
Otx1 and 2, Tbx2, Notch1, En1, Zfp281 and multiple Hox genes. Enrichment was 
also observed for genes upregulated during the early stages of embryonic and neural 
development and those associated with particular mouse phenotypes such as 
abnormal forebrain development and other disorders of the CNS (Figure 4-5B-C).  
Similarly, GREAT analysis of hypo-DMRs identified during the mESC to mNSC 
transitions found significant enrichment for genes associated with biological process 
terms including cell proliferation in the forebrain and stem cell differentiation, genes 
upregulated in various CNS tissues and genes associated with mouse phenotypes 
such as abnormal neuron differentiation and abnormal nerve morphology (Figure 
4-6). GREAT analysis of the 140 hyper-DMRs identified during the mNSC to 
astrocyte transition did not reveal any significant enrichment for particular GO terms 
covering biological processes, molecular function or mouse phenotype. However, 
gene enrichment was found for nine tissue expression terms in total, including 
branchial arch, hippocampus granule cell layer and the optic nerve (Supplementary 
Figure 11). Although branchial arch tissue showed the most statistically significant 
association with 34 of the DMR regions, the hippocampus granule cell layer showed 
the greatest fold enrichment out of the nine GO terms (15.6), over three times higher 
than all other tissue categories, suggesting that some of these hyper-DMR regions 
may be functionally involved in astrocytic differentiation. The relative lack of 
enrichment overall is probably due to the small number of input DMR regions. 
Taken together, the various GO analyses of DNA methylation changes between 
mESCs and mNSCs point to a strong association with several neural developmental 
processes and support a functional role for 5mC in the specification of neural cell 
fate. 
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Figure 4-5: Highest-ranked GO biological process (A), tissue expression (B) and mouse 
phenotype (C) terms according to binomial p-value for the test set of hyper-DMR genomic 
regions using GREAT (v3.0.0). The coordinates of Hyper-DMRs (mm10 genome assembly) 
identified between mESCs and mNSCs were submitted to GREAT (v3.0.0) for functional annotation.  
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Figure 4-6: Highest-ranked GO biological process (A), tissue expression (B) and mouse phenotype (C) terms according to binomial p-value 
for the test set of hypo-DMR genomic regions using GREAT (v3.0.0). The coordinates of Hypo-DMRs (mm10 genome assembly) identified 
between mESCs and mNSCs were submitted to GREAT (v3.0.0) for functional annotation. 
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 Figure 4-7: Example of a hypermethylated DMR called between mESCs and mNSCs. Wig tracks of all nine MeDIP-seq profiles were 
uploaded to the UCSC genome browser (mm10 build) to visualise DMRs. The black box (above) indicates the location of the most statistically 
significant hyper-DMR (Bonferroni-adjusted p-value = 7.01 x10-29), located within a CpG island in the final coding exon of the zinc finger protein 
865 (Zfp865) gene located on chromosome 7. The region remains hypermethylated upon subsequent differentiation to astrocytes.  Comparison to 
WGBS data available in Ensembl (Supplementary Figure 12) confirmed this region to be hypomethylated in mESCs and associated with both 
H3K4me3 and H3K27me3 modifications, indicating a poised chromatin state. In mNPCs, the region is fully methylated. 
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 Figure 4-8: Example of a hypomethylated DMR called between mESCs and mNSCs. Wig tracks of all nine MeDIP-seq profiles were 
uploaded to the UCSC genome browser (mm10 build) to visualise DMRs. The black box (above) indicates the location of one of the most 
statistically significant hypo-DMRs (5th most significant overall, Bonferroni-adjusted p-value = 2.00 x 10-13). This DMR sits within an intronic 
region of the neuron navigator 2 (Nav2) gene located on chromosome 7. Comparison to WGBS data available in Ensembl (Supplementary Figure 
13) confirmed that this region is fully methylated in mESCs and associated with the repressive histone modification H3K27me3. The same region 
is substantially demethylated in mNPCs, supporting the MeDIP-seq data presented above. 
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4.5 Functional annotation of differentially hydroxymethylated regions 
Functional annotation of the hypo- and hyper-hDMRs called between mESCs and 
mNSCs (Table 4-3) did not support a clear association between 5hmC changes and 
neural differentiation processes. Hyper-hDMRs submitted to GREAT revealed gene 
enrichment for four biological processes and five molecular function terms 
(Supplementary Figure 9), all related to cellular metabolism and respiratory function. 
Further analysis revealed that the majority hDMRs associated with these terms 
mapped to the mitochondrial genome (14 out of a total of 25 hyper-hDMRs) and are 
unlikely to be true regions of differential 5hmC content. Despite previous reports of 
mitochondrial DNA (mtDNA) methylation observed through MeDIP assays (Shock 
et al., 2011), base-resolution BS-seq analysis has ruled out the possibility of CpG 
methylation in mtDNA (Hong et al., 2013). The extremely high levels of both 5hmC 
and 5mC observed in mtDNA compared to autosomes through MeDIP- and 
hMeDIP-seq is perhaps due to an antibody immunoprecipitation bias towards 
mtDNA, which has a high copy number per cell relative to nuclear DNA 
chromosomes. 
The most strongly enriched tissue expression term, palatal shelf, highlighted 20 
hyper-hDMRs and 8 associated non-mitochondrial genes (including En1, Satb2 and 
Pax3) with potential functional relevance during neural specification. Satb2 encodes 
a protein involved in chromatin remodelling and transcription regulation through 
specific binding to nuclear matrix attachment regions and recruitment of histone-
modifying enzymes (HDACs and HATs) to regulatory DNA sites (Britanova et al., 
2005; Gyorgy et al., 2008). Satb2 thought to play a critical role in early embryonic 
development through the regulation of Nanog expression and ESC pluripotency 
(Savarese et al., 2009). There is also evidence for a regulatory role in the initiation of 
upper-layer 1 neurons and downregulation of genes specific to deep-layer neurons in 
the developing neocortex (Britanova et al., 2008; Leone et al., 2014). Interestingly, 
whole genome bisulphite sequencing (WGBS) data of mESC and mNPC genomes 
(available as regulatory tracks on the Ensembl genome browser) shows that the 
Satb2-associated hyper-hDMR is partially methylated in mESCs but fully methylated 
in mNPCs (Figure 4-9). As 5mC and 5hmC are indistinguishable after BS 
conversion, the hMeDIP-seq data suggests that this apparent increase in 5mC 
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between mESCs and mNPCs may in fact be due to gains in 5hmC rather than 5mC 
and may represent a region undergoing demethylation in differentiating mESCs. 
Further analysis of the hyper-hDMR associated gene set using the DAVID online 
tool found enrichment for 40 GO terms including cell projection, neurogenesis and 
multicellular organism development (Supplementary Figure 7). The most highly 
enriched tissue expression term corresponded to genes upregulated in brain (p-value 
= 4.5 x10-2; Supplementary Figure 8). One of these genes, Mid1, encodes a protein 
involved in microtubule dynamics and body axis patterning. The associated hyper-
hDMR was the most statistically significant region identified between mESC and 
mNSC samples which did not fall within repeat DNA sequence (Figure 4-10) and is 
located approximately 2kb downstream of Mid1. Further analysis using the 
regulatory feature tracks available for the mm10 genome assembly in Ensembl 
revealed that this hDMR sits over a DNase1 hypersensitive site and is marked by 
both active and repressive histone modifications (H3K4me3 and H3K27me3, 
respectively) in mESCs, but not mNPCs, suggesting that this may be an important 
regulatory region (Supplementary Figure 14). It appears that this region exists in a 
poised chromatin state in mESCs in the absence of either 5mC or 5hmC and appears 
to gain 5hmC during neural differentiation, concomitant with a loss of all histone 
modifications. However, WGBS data available on the Ensembl browser suggests that 
this region is partially methylated in both mESCs and mNPCs, contradicting the 
MeDIP-seq data presented here, which found the region to be unmethylated in both 
mESCs and mNSCs. It is possible that the either 5mC signal was underestimated in 
the MeDIP libraries due to limited sequencing depth or that the WGBS data 
overestimated the proportion of 5mC within this region due to the inability to 
distinguish 5mC from 5hmC after BS conversion.  
In contrast, GREAT analysis of hypo-hDMRs found no significant enrichment for 
particular GO annotations. However, analysis of this associated gene set (defined as 
genes within 100kb upstream or 50kb downstream of a particular hDMR) using the 
DAVID online tool found enrichment for a handful of GO terms, including for genes 
upregulated in head tissue and genes involved in cell communication and signal 
transduction (Supplementary Figure 10). Further investigation into the hDMR 
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regions associated with genes upregulated in head tissue (Vegfc, Dopey2, Aida, 
Abcb10 and Tmem196) using the UCSC genome browser revealed that all five 
regions mapped to repetitive DNA sequence and were unlikely to represent true 
5hmC signal. Moreover, just two of the 119 identified hypo-hDMRs did not overlap 
any repeat elements, highlighting the difficulty in assessing whether or not real 
differences in 5hmC distribution were detected through hMeDIP-seq profiling. The 
strong bias in sequence coverage towards repetitive DNA is likely due to a 
combination of partial cross-reactivity of the anti-5hmC antibody to cytosine-rich 
DNA sequence (e.g. CA/CT simple repeats) and the extremely low abundance of 
5hmC in genomic DNA, perhaps making immunoprecipitation of hydroxymethylated 
fragments much less efficient than seen for 5mC in MeDIP reactions.  
Nevertheless, the most statistically significant hypo-hDMR (Bonferroni-adjusted p-
value = 2.59 x 10-21) detected through the MEDIPS analysis pipeline corresponded to 
one of the two hypo-hDMRs falling within non-repetitive sequence (Figure 4-11), 
located 1kb upstream of Atpase6, a mitrochondrial protein-coding gene. This hDMR 
overlaps regulatory DNA sequence characterised by DNase1 hypersensitivity in 
mESCs and Pol-II enrichment in mNPCs (Supplementary Figure 15), indicating that 
5hmC dynamics at this region may have functional importance. 
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Figure 4-9: Ensembl genome browser of chr1:56953501-56954000, a 500bp window within an intronic region of the Satb2 gene. This 
region was identified as a hyper-hDMR between mESCs and mNSCs (unmethylated in mESCs and hydroxymethylated in mNSCs) through 
hMeDIP-seq. WGBS tracks of mESCs and mNPCs (labelled as “ES WGBS” and “NPC WGBS” above) show this region is partially 
methylated in mESCs (45-75% 5mC/5hmC) and fully methylated in mNPCs 
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 Figure 4-10: Example of a hyper-hDMR called between mESCs and mNSCs.  Wig tracks of all nine hMeDIP-seq profiles 
were uploaded to the UCSC genome browser (mm10 build) to visualise hDMRs. The black box (above) indicates the location of 
the most statistically significant hyper-hDMR that did not fall within either repeat elements or the mitochondrial chromosome 
(6th most significant overall, Bonferroni-adjusted p-value = 1.49 x 10-33), located 2kb downstream of Mid1. 
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Figure 4-11: Example of a hypo-hDMR identified during the mESC to mNSC transition. Wig tracks of all nine hMeDIP-seq 
profiles were uploaded to the UCSC genome browser (mm10 build) to visualise hDMRs. The black box (above) indicates the 
location of the most statistically significant hypo-hDMR that did not fall over repeat elements  (2nd most significant overall, 
Bonferroni-adjusted p-value = 2.59 x 10-21), located approximately 1kb upstream of Atpase6. 
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4.6 Validation of MeDIP- and hMeDIP-seq profiles using targeted oxBS-
pyrosequencing  
Due to concerns over the high proportion of repeat DNA sequence captured through 
the hMeDIP-seq analysis and inconsistencies with other publically available 
genome-wide 5hmC profiles, oxidative bisulphite conversion was adapted for use 
with pyrosequencing technology (oxBS-pyroseq) in order to validate the observed 
changes in 5mC and 5hmC during neural differentiation. This method allows single-
base resolution of both 5mC and 5hmC levels at individual CpG sites through the 
comparison of BS- and oxBS-converted DNA pyrosequencing results and was 
performed in a locus-specific manner to assess the absolute abundance of 5mC and 
5hmC at particular DMR and hDMRs of interest. 
First, in order to rule out the possibility that the hMeDIP reaction resulted in 
unspecific pull-down of genomic DNA fragments rather than specific enrichment of 
5hmC-containing DNA, four randomised hMeDIP datasets were generated and 
compared to all 18 MeDIP- and hMeDIP-seq profiles using unsupervised 
hierarchical clustering of their methylation score. Heatmap representation of the 
resulting clusters shows a distinct, inverse enrichment pattern for the hMeDIP 
datasets compared to MeDIP (Figure 4-12A). The four randomly-generated profiles 
clustered separately from all other samples and show uniform enrichment levels 
across all genomic features (CpG islands, CpG shores, exons, introns, intergenic 
regions, promoters and gene transcripts), although their profiles do show greater 
similarity to the enrichment patterns observed in hMeDIP profiles than those of 
MeDIP (Figure 4-12B). Taken together, this analysis suggests that all sequenced 
DNA libraries underwent a specific and non-random selection step during DNA 
immunoprecipitation, although the background signal in the hMeDIP profiles 
appears to be very high compared to the MeDIP data. 
Next, pyrosequencing assays were designed for eight individual hDMR regions (all 
identified between mESCs and mNSCs) and tested in triplicate on both oxBS- and 
BS-converted DNA from four biological samples: Sox1-GFP E14 mESCs, mNPCs 
(Sox1+), mNSCs (Sox1-) and differentiated astrocytes. The in vitro derivation of 
these samples is described fully in chapter 3, section 3.4.  
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Figure 4-12: Heatmap representation of unsupervised hierarchical clustering of all MeDIP and 
hMeDIP profiles according to their methylation enrichment scores (Z-scores) separate into two 
distinct groups. A) hMeDIP profiles cluster as a distinct group (left) and show low enrichment in 
intragenic genomic features such as introns, exons and promoters. In contrast, MeDIP profiles (right) 
show low enrichment in intergenic regions but are enriched for 5mC across all other features. B) 
Inclusion of 4 randomly-generated genome-wide methylation profiles into the analysis shows that 
both MeDIP and hMeDIP profiles remain clustered as two independent groups distinct from these 
controls (centre), which showed relatively uniform enrichment across all genomic features. This 
suggests that the DNA immunoprecipitation step during MeDIP and hMeDIP library preparation 
successfully resulted in the specific and non-random selection of fragmented DNA.  
The levels of 5hmC at each region were determined through subtraction of the oxBS-
pyroseq assay methylation scores from the BS-pyroseq assay methylation scores. 
However, no substantial differences in 5hmC were recorded between the mESC and 
mNSC samples using this assay at any of the eight regions. In addition, 5hmC levels 
were uniformly low across regions in all samples, ranging from 0 – 15.7% 5hmC. 
For example, validation of a hyper-hDMR called between mNSCs and mESCs 
revealed only a 4% increase in 5hmC levels through oxBS-pyrosequencing, from 2.7 
to 6.7% 5hmC (Figure 4-13A). In contrast, an oxBS-pyroseq assay designed around 
a hyper-DMR region identified between mNSCs and mESCs unambiguously 
confirmed the observed gain in 5mC (Figure 4-13B). The region, which appeared 
fully unmethylated in mESCs and substantially methylated in mNSCS according to 
MeDIP-seq profiling (Supplementary Figure 16), was found to contain just 5% 5mC 
in mESCs by oxBS-pyroseq, subsequently rising to 50% 5mC in mNSCs (Sox1-).  
  
115 
 
Figure 4-13: Pyrosequencing validation of 5mC and 5hmC levels at two genomic regions in 
Sox1-GFP mESCs, mNSCs and astrocytes. Sox1+ mNPCs represent an intermediary, rosette-
forming stage during the differentiation of mESCs into stable mNSC lines. A) Validation of a 
hyper-hDMR identified between mNSCs and mESCs located at chr17:27,422,001-	27,422,500, at the 
3’ end of Grm4, using an oxBS-pyroseq assay. The assay interrogated a 225bp region located at 
chr17:27,422,334-27,422,558. Despite substantial differences in 5hmC levels identified by hMeDIP-
seq across this region, only a small increase in 5hmC from 3.6 to 9.0% was observed between mESCs 
and mNSCs (Sox1-). 5mC levels in this region remained relatively constant during this transition, at 
approximately 18% 5mC, but increased to 64.5% 5mC upon differentiation into astrocytes. Error bars 
represent the standard deviation between triplicate oxBS-pyroseq assay results. B) Validation of a 
hyper-DMR identified between mNSCs and mESCs located at chr13:44,705,001-44,706,000 using an 
oxBS-pyroseq assay. This hyper-DMR falls in an intergenic region approximately 20kb upstream of 
Jarid2. The oxBS-pyroseq assay interrogated a 179bp sequence located at chr13:44,705,585-
44,705,763 and results confirmed that this region is hypermethylated in mNSCs compared to mESCs, 
with a methylation difference of 45% measured between the two sample types. This region remains 
substantially methylated upon subsequent differentiation into astrocytes, although a small decrease of 
7% 5mC is seen upon mNSC differentiation.  
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4.7 Comparison of global DNA 5mC and 5hmC levels between cultured and 
primary cells 
Genome-wide profiles based on immunoprecipitation techniques, such as MeDIP- 
and ChIP-seq, provide data only on the relative enrichment and distribution of a 
particular modification and cannot be used to calculate absolute levels within each 
sample. In order to assess whether 5hmC levels had increased significantly during 
neural differentiation, as had been previously predicted, global 5hmC levels were 
quantified using a sensitive liquid chromatography-mass spectrometry (LC-MS) 
method across the three defined cellular differentiation time points (mESCs, mNSCs 
and astrocytes) and compared to adult mouse brain tissue.  
Duplicate measurements of 5hmC and 5mC levels were made across 10 cultured cell 
samples, including three mESC samples, four mNSC samples, two in-vitro 
differentiated astrocytes samples and one in-vitro differentiated neuron-like sample 
(see Chapter 3 for details of in vitro cell samples). Surprisingly, very little change in 
global 5hmC levels was observed between mESCs, mNSCs and differentiated neural 
cells (Figure 4-14). Although a large increase in 5hmC content had been expected 
across these three stages of neural differentiation, both wild-type C57BL/6N and 
Sox1-GFP E14 mESCs had similar levels of 5hmC as differentiated astrocytes and 
neurons, in the range of 0.06 - 0.08% of total cytosine. A decrease in 5hmC levels of 
over 50% was noted in all mNSCs in comparison to mESCs, regardless of whether 
they were primary mNSCs (“WT C57 mNSCs”) or in-vitro differentiated mNSCs 
(“Sox1-GFP mNSCs”), falling within the range of 0.02 – 0.04%. 
In contrast, 5hmC measurements in DNA extracted from various adult mouse brain 
tissue samples revealed levels substantially higher (approximately 10-fold) than 
those in all in vitro cultured cell samples. 5hmC levels in four separate cerebellum 
samples fell within the range of 0.36 – 0.40% whilst 5hmC in the cortex, olfactory 
bulb and other unclassified brain tissue was found at even higher levels, in the range 
of 0.58 - 0.67%.  
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Figure 4-14: LC-MS quantification of the global 5hmC content of cultured cells and adult 
tissues. 5hmC levels are plotted as a percentage of the total cytosine content of each DNA sample; 
each bar represents the mean value of duplicate LC-MS measurements. Error bars represent the 
standard deviation. WT C57 cells refer to those samples used for MeDIP/hMeDIP-seq profiling. All 
E14 cells were derived in vitro from a Sox1-GFP E14 cell line (see Chapter 3, section 3.4). Mouse 
tissue samples were dissected from two 6-month old female mice (A and B, respectively).  
Despite striking differences in 5hmC content between cultured cell lines and primary 
tissue samples, the same pattern was not observed for 5mC (Figure 4-15). Global 
5mC levels showed some variation across samples, covering the range of 2.82 – 
4.23% of total cytosine, but did not show significant differences between cultured 
cells and primary tissues. There was also a fair amount of variation within biological 
replicates; two Sox1-GFP E14 astrocyte samples showed a difference of 0.73% in 
their total 5mC content, whilst two Sox1-GFP E14 mNPC samples (Sox1+ cells 
collected at day 10 of mESC differentiation; see Section 3.4 for derivation) showed a 
difference of 0.38%.  
There did not appear to be a direct inverse correlation between 5hmC and 5mC 
levels, as would be expected if 5hmC was a stable by-product of DNA 
demethylation; the small increase in 5hmC (~0.03%) between mNSCs and 
differentiated astrocytes, for example, was not accompanied by an equivalent 
reduction in 5mC levels. In fact, average 5mC levels decreased by 0.38% during this 
transition. If 5hmC is truly an intermediary product in a DNA demethylation 
pathway, it appears likely that the majority of 5hmC, as least within proliferating 
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cells in culture, rapidly undergoes further conversion to 5fC, 5caC or fully 
unmodified cytosine (not measured), making it difficult to capture the true modified 
cytosine content at a particular developmental stage. In addition, balanced gains and 
losses in either 5hmC or 5mC occurring throughout the genome would not be 
reflected in these global measurements, masking the existence of dynamic but 
equivalent changes in their distribution. 
 
Figure 4-15: LC-MS quantification of the combined 5mC and 5hmC content of various mouse 
DNA samples. Black bars indicate the total 5mC content and red bars indicate total 5hmC content of 
each sample type as a percentage of total cytosine. Each bar represents the mean value of duplicate 
LC-MS measurements. Error bars represent the standard deviation of the 5mC measurements only. 
WT C57 cells refer to those samples used for MeDIP/hMeDIP-seq profiling. All E14 cells were 
derived in vitro from a Sox1-GFP E14 cell line (see Chapter 3, section 3.4). Mouse tissue samples 
were dissected from two 6-month old female mice (A and B, respectively).  
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4.8 Discussion 
Genome-wide changes in 5mC and 5hmC were mapped between three defined 
cellular stages of a neural differentiation pathway in order to shed light on the 
dynamic relationship between these two cytosine modifications and the potential 
functional relevance of 5hmC. A general trend of increasing locus-specific gains in 
both 5mC and 5hmC was observed during the differentiation process, with most of 
these changes occurring early on in development, between the embryonic and neural 
stem cell stage. However, this pattern was not reflected by global changes in either 
5mC or 5hmC content. 5mC levels remained relatively constant across all samples, 
with both wild-type C57 mESCs and primary mNSCs containing 3.5% 5mC (of total 
cytosine), whilst differentiated astrocytes contained 3.4% 5mC. Conversely, 5hmC 
content decreased by approximately 50% between mESCs and mNSCs, despite over 
60% of the identified hDMRs during this transition corresponding to gains in 5hmC.  
These discrepancies highlight the fact that most immunoprecipitation-based genome 
profiling methods are not quantitative and cannot be used to infer absolute 
differences of their respective modifications. Interestingly, a recent study describes a 
novel comparative hMeDIP-seq method that employs barcode technology to perform 
antibody-based immunoprecipitation on multiple DNA samples in one reaction, 
thereby preserving quantitative differences in 5hmC between samples (Tan et al., 
2013). Using this method, they observed a 78% decrease in global 5hmC between 
mESCs and in vitro differentiated mNPCs, consistent with the LC-MS measurement 
data presented here, suggesting that embryonic and neural stem cells are 
characterised by distinct hydroxymethylation states that likely hold biological 
significance.  
Comparison between DMR and hDMR regions did not reveal any overlap in the 
location of observed 5mC and 5hmC changes. Although pre-existing 5mC is required 
for 5hmC generation via TET-mediated oxidation, sites of hyper-
hydroxymethylation did not coincide with any hypo-DMRs, as would be expected. 
However, this is probably due to underestimation of the total number of DMR and 
hDMR sites within the genome as a result of low sequence coverage. In addition, the 
kinetics of 5mC oxidation may simply occur too quickly to efficiently capture 
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intermediary products (5hmC, 5fC or 5caC) at sites of active demethylation, making 
it difficult to pinpoint regions undergoing dynamic hydroxymethylation changes. It 
appears that the hMeDIP assay was not sensitive enough on this occasion to detect 
more subtle differences in 5hmC over background signal. Further optimisation of the 
IP reaction in combination with much deeper sequencing is probably needed in order 
to draw definitive conclusions concerning 5hmC dynamics between samples.  
Analysis of the genomic distribution of hDMRs revealed that over 80% fell within 
repetitive DNA elements, more than would be expected by chance alone. This bias 
towards repeat sequence may reflect cross-reactivity of the anti-5hmC antibody to 
high-density regions of unmethylated cytosine. The extremely low abundance of 
5hmC in the genomic DNA samples being profiled combined with the tendency for 
5hmC to be located in regions of moderate-to-low CpG density (Yu et al., 2012) 
implies that immunoprecipitation efficiency is also likely to be much lower than that 
observed for 5mC in traditional MeDIP-seq reactions.  
Only a small percentage of the identified hDMRs between mESC, mSNCs and 
astrocytes seemed to represent true differences in 5hmC distribution, due to the 
apparent antibody bias towards cytosine-rich repeat regions of the genome. 
Attempted validation of hMeDIP-seq profiles using an alternative sequencing-based 
technology, oxBS-pyroseq, failed to confirm the presence of differential 5hmC levels 
at selected hDMR sites. However, this assay was constrained by the fact that 
pyrosequencing primer annealing sites could not fall within repeat DNA sequence or 
CpG loci, severely restricting the number of hDMRs that could be successfully 
interrogated. In addition, each oxBS-pryoseq assay only measured the methylation 
status of one or two CpG sites at a time due to the low CpG density of hDMRs. As a 
consequence, individual pyrosequencing assays are potentially unrepresentative of 
the 5hmC content of the corresponding hDMR as a whole.  
Despite fluctuations in global 5hmC levels between mESCs, mNSCs and astrocytes, 
5hmC content nevertheless remained very low (0.02-0.08% of total cytosine) across 
all cultured cell samples and did not increase substantially in differentiated 
astrocytes, as had initially been expected. 5hmC levels in cultured cell lines were at 
least 4-fold lower than 5hmC levels measured in adult mouse brain tissues, which 
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fell between 0.36 – 0.67% of total cytosine. It appears unlikely that low 5hmC levels 
are a constitutive element of astrocytes; several other studies have since described 
similarly low 5hmC levels across a wide range of cell lines. Decreased 5hmC 
appears to be a general feature of cell adaptation to culture conditions and is not 
restricted to particular cell types (Nestor et al., 2012).  
A 40% reduction in global 5hmC content in in vitro differentiated dopamine neurons 
compared to human ESCs was recently reported (Kim et al., 2014), contradicting 
earlier findings of exceptionally high 5hmC levels in primary neurons isolated from 
an adult mouse brain (Kriaucionis and Heintz, 2009). In addition, 
immunohistochemical analysis of foetal, paediatric and adult human brain sections 
demonstrated that all terminally differentiated neural cell types (neurons, astrocytes 
and oligodendroglial cells) show high levels of 5hmC staining (Orr et al., 2012), 
whilst progenitor cell populations show relatively low 5hmC staining. It therefore 
appears that in vitro differentiation protocols for the generation of neural subtypes do 
not recapitulate 5hmC states observed in vivo and suggests that further analysis of 
5mC/5hmC dynamics during neurodevelopment may be best addressed using 
primary cell and tissue samples.  
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Chapter 5 Novel methods for DNA methylation studies 
Work carried out in collaboration: 
The human frontal cortex DNA sample was kindly provided by Dr Harry Bulstrode 
(UCL Cancer Institute, University College London). Martin Bachman (Department 
of Chemistry, University of Cambridge) carried out all LC-MS analyses of genomic 
DNA samples. Mikiembo Kukwikila and Ha Phuong Nguyen (Department of 
Chemistry, University College London) carried out the synthesis, purification and 
HPLC analysis of the two caged nucleoside analogues, under the supervision of Dr 
Stefan Howorka.  
5.1 Introduction 
In this chapter, two new methods are presented for use in studies of DNA 
methylation. The first concerns a novel approach for the genome-wide profiling of 
5hmC alongside 5mC using a well-established DNA methylation microarray, the 
Infinium HumanMethylation450 BeadChip. The second concerns a proof of principle 
study for the use of light-sensitive nucleoside analogues to achieve targeted 
demethylation events in a living system, with the potential for use in functional 
methylation studies and ultimately for therapeutic purposes.  
5.2 An array-based method for genome-wide 5hmC analysis 
5.2.1 Introduction 
Current methods for profiling 5hmC at a genome-wide level rely largely on 
sequencing-based protocols that are both costly and time-consuming. The recent 
developments of both TET-assisted and oxidative bisulphite (oxBS) technologies 
have allowed single-base-resolution sequencing of 5hmC (Booth et al., 2012; Yu et 
al., 2012a), although the costs associated with whole-genome sequencing prevent 
widespread use of this technology, especially for projects depending on large sample 
cohorts. Immunoprecipitation-based methods for capturing hydroxymethylated DNA 
fragments represent an alternative approach to profiling DNA when coupled to 
sequencing, which substantially reduce the costs involved. However, these methods 
sacrifice single-base-resolution of 5hmC and are semi-quantitative at best. In 
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addition, antibody-based methods such as hMeDIP introduce bias in the 5hmC 
profile towards particular genomic regions due to preferential binding of the 
antibody to 5hmC in certain sequence contexts, including CpG-dense regions and 
repeat sequences (Matarese et al., 2011; Song et al., 2012).  
Sequencing-based methods all require a high degree of expertise both for successful 
implementation of the chosen assay and downstream data analysis. Hence, there is a 
need for novel, readily accessible methods to analyse 5hmC on a genome-wide scale 
as research interest into the role of 5hmC expands. The Infinium 
HumanMethylation450 BeadChip is a widely-used, robust and reliable tool for DNA 
methylation profiling (Bibikova et al., 2011; Sandoval et al., 2011), suitable for high-
throughput sample processing and is therefore the platform of choice for current 
epigenome-wide association studies (Michels et al., 2013; Rakyan et al., 2011). The 
450K array interrogates over 480,000 CpG sites across the human genome, making it 
an appropriate tool for 5hmC detection as this modification has been reported to 
occur exclusively in the CpG context in both mammalian embryonic stem cells and 
frontal cortex tissue (Booth et al., 2012; Lister et al., 2013; Yu et al., 2012b). 
However, current workflows for this microarray rely on sodium bisulphite 
conversion of DNA, which discriminates between methylated and unmethylated 
cytosine bases within the genome but cannot differentiate between 5mC and 5hmC 
(Huang et al., 2010; Figure 5-1).  
The availability of oxBS chemistry presents an opportunity to adapt BS-based 5mC 
profiling technology for 5hmC detection (Booth et al., 2012). Treatment of DNA 
with potassium perruthenate (KRuO4) selectively oxidises 5hmC to 5fC, whereas 
both 5mC and C show no reactivity with the oxidant and remain unchanged. 
Traditional BS conversion follows the oxidation step; 5fC behaves in a manner 
analogous to unmodified cytosine under BS conditions, allowing only true 5mC 
positions to be detected as cytosine after oxBS conversion and PCR amplification of 
the DNA sample. Subtraction of oxBS-generated methylation profiles from standard 
BS-only methylation profiles allows for the detection of hydroxymethylated cytosine 
positions within the genome. A more accurate 5mC profile can be obtained by 
removing the confounding factor of 5hmC, whilst traditional BS conversion leads to 
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potential overestimation of 5mC levels in a given sample due to the presence of 
5hmC.  
 
Figure 5-1: Overview of oxBS chemistry. Image courtesy of: Booth MJ, Branco MR, Ficz G, Oxley 
D, Kreuger F, Reik W, Balasubramanian S. Science 2012, 336(6083): 934-937.  
Global 5hmC levels are known to be lower than 5mC levels and more variable 
between different tissues (Globisch et al., 2010; Nestor et al., 2011).  Here, a novel 
method is presented for genome-wide profiling of 5hmC by coupling oxBS 
chemistry and the Infinium 450K BeadChip (oxBS-450K). Alternative approaches 
also using oxBS or TET-assisted bisulphite (TAB) chemistries have been developed 
by Field et al. (Field et al., 2015) and Chopra et al. (Chopra et al., 2014), 
respectively. In order to maximise the probability of successful 5hmC detection, two 
human brain samples were selected for profiling as it is thought to have the highest 
5hmC levels of any tissue: a commercial brain DNA sample from an unidentified 
region referred to as ‘brain1’ and a frontal cortex DNA sample, referred to as 
‘brain2’. In order to test the range of possible 5hmC detection, a whole blood sample 
was also profiled for comparison, as previous studies have shown blood to contain 
one of the lowest levels of 5hmC (Nestor et al., 2011). 5hmC was successfully 
measured in all three samples by comparison of BS- and oxBS-450K datasets and 
validation of the reported 5hmC signal is provided using two independent 
technologies: mass spectrometry quantification of 5hmC and oxBS-pyroseq 
assessment of selected CpG sites.  
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5.2.2 5hmC signal detection using the 450K BeadChip 
5hmC detection was achieved by identifying differentially methylated CpG sites 
between the BS- and oxBS-treated replicates within each sample set. The beta (β) 
value associated with each probe on an array reflects the methylation level at that 
particular location on a scale of 0 to 1, where 0 is unmethylated and 1 is fully 
methylated. β values resulting from BS-only treatment represent the total 
methylation score (5mC and 5hmC) as both cytosine modifications are resistant to 
deamination with comparable efficiency, resulting in both modifications contributing 
to the overall methylation signal. In contrast, β values resulting from oxBS treatment 
represent only the 5mC level at the corresponding probe locations; 5hmC is 
selectively converted to 5fC (whilst 5mC remains unchanged) during the initial 
oxidation step and therefore becomes susceptible to deamination during subsequent 
BS conversion. 
In order to assess the reproducibility of signal generated by the 450K array from 
oxBS-treated DNA, all samples were processed in duplicate in a trial of the oxBS-
450K workflow, using 500ng input DNA per sample per conversion (either BS or 
oxBS) as recommended for traditional BS conversion of DNA for 450K analysis. 
Unsupervised hierarchical clustering of the resulting dataset shows a clear separation 
between blood, brain1 and brain2 and also between treatment options, with both BS-
only and oxBS-treated replicates of each sample clustering in pairs (Figure 5-2).  
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Figure 5-2: Unsupervised hierarchical clustering dendrogram of oxBS-450K samples. BS-treated 
samples are indicated by "BS" label; oxBS-treated samples by "OX". Numbers in red and green 
indicate approximately unbiased (au) and bootstrap (bp) probability values (%), respectively. Number 
of bootstrap resamples = 1000.  
 
 
Figure 5-3: Kernel density plot of normalised  β values generated by the oxBS-450K arrays. Beta 
values show a proper bimodal distribution for BS-only conversion samples, whilst a left-skewed 
methylated peak is seen in the oxBS conversion samples, corresponding to lower global methylation 
levels. 
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A kernel density plot of all β scores for each sample shows a clear reduction in 
overall methylation after oxBS treatment as compared to BS-only treatment for both 
brain1 and brain2 (and to a lesser extent, blood) as would be expected if 5hmC were 
present in the sampled DNA (Figure 5-3).  
In order to identify potential 5hmC, normalised β values were used to calculate delta 
beta (∆β) values for each probe by subtraction of the oxBS β value from the BS-only 
beta value. The ∆β score is a reflection of the 5hmC level at each particular probe 
location. Using this method, both positive and negative ∆β scores were calculated. 
Positive ∆β values represent potential sites of 5hmC; negative ∆β values, or 
‘hypermethylation’ in the oxBS-treated sample, were not expected as the oxidation 
reaction is unidirectional and thus are likely to reflect background noise generated by 
this method. Visualisation of the ∆β distribution across all probes for the brain1 
sample reveals many more positive ∆β scores than negative, as expected (Figure 
5-4).   
 
Figure 5-4: All normalised Δβ  values for the brain1 sample. Calculated Δβvalues range from 0.6 
to -0.4, with the vast majority (>95%) falling above zero, indicating potential sites of 5hmC. 
Less than 3% of all negative ∆β scores correspond to a 5hmC level of more than 
10%, however over 30% of all positive ∆β scores correspond to a 5hmC level over 
10%. As two replicates per condition (i.e. BS-only & oxBS) were generated for each 
sample, significance analysis of the ∆β scores could be conducted by computing a t-
statistic for each probe in the array dataset using the ChAMP analysis package in R 
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(Morris et al., 2014). This analysis pipeline allows a p-value to be assigned for each 
∆β calculation, which may be either unadjusted or adjusted to control the false 
discovery rate using the Benjamini-Hochberg (BH) method (Benjamini and 
Hochberg, 1995). The largest ∆β scores are associated with the most significant p-
values and that significance falls away as the ∆β values approach zero (Figure 5-5). 
Frequency plots of all probes according to their associated p-values show that the 
majority of ∆β values above zero represent significant differences in methylation 
score (p ≤ 0.05). In contrast, the p-values associated with negative ∆β scores are 
distributed across the entire range (0 to 1), with increasing numbers of probes 
associated with higher p-values (Figure 5-6). This is consistent with the idea that the 
negative ∆β scores represent false differences in methylation score between the 
paired BS-only and oxBS datasets. 
 
Figure 5-5: Scatter plot of all Δβ  values against their associated p-value (unadjusted) for brain1. 
∆β distribution against their associated p-value. Data points highlighted in blue indicate those probes 
called as hydroxymethylated (∆β ≥ 0.3).  
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Figure 5-6: Frequency plots of all p-values associated with either positive Δβ  (panel A) or 
negative Δβvalues (panel B). A) Frequency distribution of all probes associated with a ∆β > 0, or 
potential sites of 5hmC. B) Frequency distribution of all probes associated with a ∆β < 0, i.e. false 
positives. 
There are various ways to define an appropriate ∆β threshold to identify a probe-set 
of significantly hydroxymethylated cytosines, including shrinkage estimation of 
variances but this approach requires each sample to be run in multiple (3-4) 
replicates resulting in extra costs [10]. As the amount of available genomic DNA is 
often limiting, the strategy employed here restricted the replicate number per sample 
to two, however this was not sufficient for any of the calculated ∆β scores to reach 
statistical significance (BH-adjusted p-value <0.05). A conservative threshold of ∆β 
≥ 0.3 (i.e. minimum 30% 5hmC) was therefore applied alongside an unadjusted p-
value cut-off of 0.05 for identifying hydroxymethylated probe locations, followed by 
validation. Using this approach, 6,578 and 7,692 probes were identified in the brain1 
and brain2 samples, respectively, in contrast to just 801 probes in whole blood DNA. 
Inclusion of a third technical replicate of the brain1 sample, however, increased the 
statistical power of the dataset by allowing the ∆β calculations to reach statistical 
significance. A BH-adjusted p-value threshold of 0.05 was now suitable to call 
5hmC, which dramatically increased the probe number because any significant ∆β 
values in the range of 0-30% 5hmC could now be identified alongside the more 
highly hydroxymethylated probes, resulting in the detection of 64,720 significant 
probes in total. Of these, only 117 sites were associated with negative (but 
nevertheless significant) ∆β scores, corresponding to a false discovery rate of less 
than 0.002 (Figure 5-7, panel A). 5hmC levels (i.e. all significant, positive ∆β scores) 
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fell within the range of 4-59%, with a mean level of 18% 5hmC; all negative ∆β 
scores (regardless of significance) corresponded to less than 20%.  
 
Figure 5-7: Frequency plots of Δβ  scores for all hydroxymethylated probe sites identified using 
either two (panel A) or three replicate datasets for brain1 DNA. A) Frequency distribution of 
5hmC levels, expressed as a ∆β score, across all 64,720 5hmC sites in the brain1 sample processed in 
triplicate with the initial protocol. B) Frequency distribution of 5hmC levels, expressed as a ∆β score, 
across all 165,495 5hmC sites in the brain1 sample, processed in duplicate with the optimised 
protocol. Both protocols detect similar ∆β ranges (5-60%). 
5.2.3 5hmC distribution in human blood and brain samples 
The distribution of 5hmC within different genomic features was investigated using 
probe sets of significant 5hmC sites compared to the overall distribution of probes 
present on the array. The following categories were used for classification of each 
probe: 3’UTR region, 5’UTR region, 1st exon, 200bp window upstream of the TSS 
(TSS200), 1500bp window upstream of the TSS (TSS1500), intergenic region or 
gene body. A permutation test was performed to calculate percentage enrichment for 
5hmC within each feature compared to 1,000 matched, random 450K probe sets. 
5hmC was found to be significantly enriched in the gene body in all three DNA 
samples (Figure 5-8). This is consistent with previous studies concerning the 
genomic distribution of 5hmC (Chopra et al., 2014; Szulwach et al., 2011). 
Conversely, 5hmC was found to be significantly depleted from promoter regions 
(defined as within 1500bp upstream of TSS) and from CpG islands (Figure 5-9), 
which agrees with several published studies that describe an inverse correlation 
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between 5hmC and CpG density at the promoter (Booth et al., 2012; Chopra et al., 
2014; Yu et al., 2012a).  
 
 
Figure 5-8: 5hmC enrichment within different genomic regions for brain1 sample. A) 
Distribution of all probes after filtering (432,056 total) on 450K BeadChip. B) Distribution of 
hydroxymethylated probes (6,578 total) in brain1 sample. C) Enrichment of 5hmC probes according 
to various genomic regions, compared to random 450K probe sets. Significant enrichment is seen in 
the gene body, and to a lesser extent 1500bp upstream of the TSS. Conversely, significant depletion is 
seen in the proximal promoter region (TSS200) and 1st exon. 
 
 
 
Figure 5-9: 5hmC enrichment within different CpG contexts for brain1 sample. A) Distribution 
of all probes after filtering (432,056 total) on 450K BeadChip according to CpG context. B) 
Distribution of hydroxymethylated probes (6,578 total) in brain1 sample according to CpG context. C) 
Relative enrichment of 5hmC probes in differing CpG contexts. Significant enrichment of 5hmC is 
seen in ‘open sea’ regions of low CpG density, although the most striking observation is the depletion 
of 5hmC at CpG islands.  
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5.2.4 Optimisation of sample processing for oxBS-450K analysis 
An assessment of the reproducibility between oxBS-450K replicates revealed far 
higher variation compared to traditional bisulphite 450K array processing. The 
correlations between oxBS-converted replicates were the lowest, with Pearson 
correlation coefficients (r) ranging between 0.95-0.97 across the three samples. BS-
converted replicates correlated slightly better, but their correlation coefficients were 
still lower than the 0.99 expected for 450K datasets (Table 5-1).   
In order to improve the quality and reproducibility of signal generated from oxBS-
450K arrays, several adjustments were made to the protocol in order to maximise the 
recovery of high-quality converted DNA at the end of the workflow. First, input 
DNA was increased from 500ng per conversion to 2µg to compensate for the 
additional centrifugation and purification steps present in the oxBS-450K protocol 
that reduce overall DNA yield as compared to standard BS conversion. An initial 
sonication step was included to shear high molecular weight gDNA to ≤10kb 
fragments in order to increase DNA recovery from the BioRad® P6 spin columns 
used in subsequent steps of the oxBS protocol and all DNA clean-up steps were 
performed with Agencourt Ampure XP beads instead of column-based purification 
methods, which minimised DNA loss. In addition, 7µl of eluted DNA was used for 
processing on the 450K BeadChip instead of 4µl DNA, as recommended by the 
manufacturer’s protocol. This ensures a maximum amount of DNA is hybridised to 
each array on the BeadChip and compensates for the lower DNA yield of the 
TrueMethyl protocol in comparison to the EZ DNA Methylation kit (Zymo 
Research) used for standard BS conversion of DNA.  
While the low-input oxBS-450K protocol only requires 1µg starting DNA, the high-
input protocol requires 4µg DNA but results in improved sensitivity and 
reproducibility. Using the same detection p-value threshold of 0.01 as for the low-
input protocol to filter probes, the technical replicates showed an improved 
correlation of r >0.99 compared to r >0.95 for the low-input protocol and comparable 
to current ‘gold-standard’ BS conversion protocols. Comparison of BS-only and 
oxBS datasets using just two replicates per sample was sufficient to call 165,495 
5hmC sites (BH-adjusted p-value <0.05) with just 627 false positive probes 
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associated with a negative ∆β score (Figure 5-7, panel B). 5hmC levels were detected 
in the range of 4-57%, with a mean 5hmC level of 15%. In contrast, negative ∆β 
values all fell below 20%. 
Analysis of the significant but negative ∆β probes between the low- and high-input 
protocols for the brain1 sample suggests that the locations of these negative sites are 
random: 117 sites were called by the low-input (three replicate) method compared to 
627 with the high-input method, yet only eight negative ∆β sites were found in 
common between the two (the increase in negative probe number is a reflection of an 
overall increase in the number of significant probes identified using the high-input 
method). Despite showing statistically significant β value differences, these pseudo 
false positives cannot reflect true differences in methylation level at these probe sites 
and should be filtered out before further downstream data analysis.  
Comparison of the 5hmC-containing probes identified by the different protocols 
showed that overlap is high, supporting the conclusion that these are sites of genuine 
5hmC. 83.6% of the 5hmC-containing sites initially called by the low-input, two-
replicate method remained significantly hydroxymethylated with the addition of a 
third replicate (5,498 of 6,578). This figure increased to 94.2% when comparison 
was made to the high-input, two-replicate dataset. Moreover, only 3.5% of the 5hmC 
probes called by the low-input, two-replicate method failed to reach significance 
when either replicate number or DNA input is increased, suggesting that the false 
positive rate of the low-input, two-replicate method is fairly low (Figure 5-10). 
In summary, the use of the high-input oxBS-450K protocol on just two replicates 
resulted in detection of 5hmC at over twice the number of probes compared to the 
low-input protocol using three replicates. However, both the mean and range of 
5hmC levels detected is very similar in both cases, suggesting that using lower 
amounts of input DNA does not necessarily affect the quality of the array data 
produced, but does severely limit the number of probes whose ∆β values reach 
statistical significance.  
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Sample type Correlation coefficient (r) 
Whole blood (BS) 0.982 
Whole blood (oxBS) 0.950 
Brain (BS) 0.985 
Brain (oxBS) 0.963 
Frontal cortex (BS) 0.984 
Frontal cortex (oxBS) 0.951 
  
Table 5-1: Pearson product-moment correlation coefficients (r) between replicates of each 
sample type processed using the low-input oxBS-450K protocol. Correlations are based on 
comparison of all normalised beta scores between each replicate pair.  
 
 
 
Figure 5-10: Hydroxymethylated probe overlap between the low- and high-input oxBS-450K 
protocols. Overlap is shown for the 6,578 probes called as hydroxymethylated using the low-input 
(two-replicate) protocol. Of these, 81.3% remained significantly hydroxymethylated both when the 
replicate number was increased and when the experiment was repeated using the high-input protocol. 
Only 3.5% of these probes were unable to reach significance when either replicate number was 
increased or when higher amounts of input DNA were used. 
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5.2.5 Validation of oxBS-450K methodology  
Two methods, liquid chromatography-mass spectrometry (LC-MS) and oxBS 
conversion coupled to pyrosequencing (oxBS-pyroseq), were used to validate the 
5hmC signal identified with oxBS-450K. On the global level, quantitative LC-MS 
was used to confirm that each of the profiled samples did indeed contain appreciable 
amounts of 5hmC, suitable for detection with oxBS-450K. Taking the average 
readings of two replicates, 5hmC levels of both brain samples were confirmed to be 
highly similar, at around 1% of total cytosine bases (0.92% in brain1 and 1.11% in 
brain2), whilst the whole blood sample contained only low levels of 5hmC, at 0.04% 
of total cytosine as expected. In contrast, 5mC levels in all three samples were 
broadly consistent at around 4% of total cytosine. The overall pattern of total 5hmC 
content per sample correlated well with the observed 5hmC signal from the 450K 
array data, where a ten-fold higher number of probes with significant 5hmC was 
observed in the brain as compared to whole blood (Figure 5-11).  
 
Figure 5-11: Quantification of global 5mC and 5hmC levels by mass spectrometry in three 
genomic DNA samples. The fraction of 5mC appears consistent across all samples, in contrast to the 
5hmC content, where nearly 30-fold higher levels are seen in the two brain samples as compared to 
whole blood. This pattern of increased levels of 5hmC in brain is reflected in the 450K dataset (low-
input protocol results are shown), where the numbers of CpG sites containing the highest levels of 
5hmC (≥30%) are around ten-fold higher in brain versus blood. 5hmC percentage was confirmed by 
quantitative LC-MS to be 0.039% for whole blood and 0.924% and 1.107% for the two brain samples, 
respectively. In comparison, the corresponding 5mC levels were ~4% in all three samples. 
On the single cytosine level, quantitative oxBS-pyroseq was used to validate selected 
5hmC sites identified with oxBS-450K in the brain1 sample. The 
hydroxymethylation status of six individual CpG sites across three genomic regions 
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was confirmed using this assay (Figure 5-12), with 5hmC levels differing by less 
than 10% between the two methods. In addition, these validation results suggest that 
there is little difference in the accuracy of 5hmC calling depending on the 450K 
protocol used, as both low-input and high-input methods generated 5hmC levels 
within 10% of the pyrosequencing readout.  
 
Figure 5-12: Pyrosequencing validation of 5hmC levels (%) at six individual CpG sites. 5hmC 
levels at six individual CpG sites distributed across three distinct genomic regions (indicated by 
orange, purple and yellow shading, respectively) were validated in the brain1 sample. Results are 
plotted as % 5hmC at each CpG locus as measured by pyrosequencing, low-input 450K and high-
input 450K assays. 
5.2.6 Discussion 
The data presented in this chapter shows that oxBS chemistry can be combined with 
the 450K DNA methylation microarray to reliably detect 5hmC and 5mC in the 
human genome. The oxBS-450K method results in highly reproducible technical 
replicates, comparable to current ‘gold-standard’ BS conversion kits. 5hmC can be 
detected at statistically significant levels at over 30% of all CpG sites interrogated on 
the array, with a mean 5hmC level of 15% in a human brain sample. Whilst the use 
of the optimised protocol offers an improvement in the correlation of technical 
replicates and allows a higher proportion of 5hmC sites to be called with statistical 
significance, the amount of input DNA required may prove limiting for many users. 
However, validation using oxBS-pyroseq suggests that accurate 5hmC levels, albeit 
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at fewer sites, can nevertheless be called using a lower input of 1µg DNA for oxBS-
450K analysis. Mass spectrometry measurements of global 5hmC and 5mC levels in 
human brain tissue agreed with previous findings showing 5hmC to be a significant 
contributor to the modified cytosine content of neural tissue types (Nestor et al., 
2011). 5hmC made up approximately 20% of modified cytosine in the two assessed 
brain samples, highlighting how significant the overestimation of 5mC levels could 
be if relying on traditional BS-based methods of methylation profiling for the 
analysis of particular tissue types.  
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5.3 Development of an in vitro culture method for targeted demethylation 
studies 
5.3.1 Introduction 
Aberrant methylation phenotypes are a major hallmark of disease, particularly cancer 
(Feinberg and Vogelstein, 1983). Both global and site-specific hypo- and 
hypermethylation events have been observed during cancer progression (Feinberg, 
2007); promoter hypermethylation has been frequently associated with tumour 
suppressor gene silencing events, such as p16 inactivation, in a wide array of human 
cancers, including colorectal and non-small-cell lung carcinoma (Herman et al., 
1995; Merlo et al., 1995).  
More recently, altered 5hmC patterns have also been associated with cancer 
phenotypes; reduced global 5hmC levels have been measured in various diseased 
tissues compared to controls, including liver, brain, lung, skin and pancreatic tissue 
(Jin et al., 2011; Lian et al., 2012; Liu et al., 2013; Yang et al., 2013). These findings 
support a hypothesis of 5hmC as an intermediary product of a DNA demethylation 
pathway that becomes deregulated during cancer progression, resulting in 
hypermethylation and associated hypo-hydroxymethylation in the affected tissue. 
DNMT1 is known to have a greatly reduced preference for 5hmC at a hemi-
hydroxymethylated CpG site as compared to 5mC: DNMT1 activity on a 5hmC 
substrate is approximately 60-fold lower than its methylated counterpart, suggesting 
that 5mC oxidation may be a mechanism of inhibiting DNMT1 activity during DNA 
replication (Hashimoto et al., 2012; Valinluck et al., 2004). Similarly, the UHRF1 
protein, a co-factor of DNMT1 essential for its methyltransferase activity, has a 
similarly reduced preference for hemi-hydroxymethylated CpG sites at a level 
comparable to its affinity for fully methylated or fully hydroxymethylated DNA 
sites. 5mC oxidation may be a method of ensuring passive DNA demethylation 
through blocking recognition of hydroxymethylated CpG loci by the DNA 
maintenance methylation machinery.  
Whilst there is still debate on whether DNA methylation alterations represent a 
causal mechanism behind human cancers, there has been much interest in developing 
therapeutic drugs that reverse these epigenetic changes to normal levels in diseased 
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tissue (Singh et al., 2013; Yang et al., 2010). DNA methyltransferase (DNMT) 
inhibitors are a major class of epigenome-modifying drugs currently being developed 
for clinical use, of which two have already been granted approval by the US Food 
and Drug Administration (FDA) for the treatment of myelodysplastic (MDS) 
syndrome subtypes (Kaminskas et al., 2005; Kantarjian et al., 2006). 5-azacytidine 
(5-aza) and 5-aza-2’-deoxycytidine (DAC), also known by their trade names Vidaza 
and Dacogen respectively, are nucleoside analogues first synthesised in 1964 
(Pískala and Šorm, 1964). 5-aza and DAC exert their demethylating activity through 
incorporation into DNA during replication and subsequent sequestration of DNMT1, 
the maintenance DNA methyltransferase, due to irreversible covalent binding of the 
enzyme to the analogues at hemi-methylated CpG sites. The DNMT enzymes are 
eventually degraded, leading to hypomethylation after successive rounds of DNA 
replication and thus restoring a passive DNA demethylation process. 
Unlike DAC, 5-aza is also incorporated into RNA and disrupts protein synthesis 
through a variety of mechanisms, including inhibition of tRNA methyltransferases, 
histone methylase activity, rRNA processing and reduction in mRNA stability 
(Cihak et al., 1974; Li et al., 1970; Lu and Randerath, 1980; Momparler et al., 1976; 
Wada et al., 2005). Several studies have shown statistically significant changes in 
gene expression profiles following in vitro 5-aza or DAC treatment of various cell 
lines (Gius et al., 2004; Suzuki et al., 2002). In 2002, publication of one of the largest 
clinical trials investigating the treatment potential of 5-aza in 191 MDS patients 
showed a response rate of 60%, an increase in median survival rate and a significant 
improvement in quality of life for those patients receiving a low dose 5-aza treatment 
compared to those receiving only supportive care.  These results made a considerable 
contribution to the FDA approval granted in 2005 for the use 5-aza to treat MDS.  
However, the nonspecific mode of action of this class of DNMT inhibitors has 
caused concern over its potential use in the treatment of cancer. An in vitro study 
using pancreatic cancer cell lines showed an increase in the metastatic potential of 
four of the five cell lines tested after DAC treatments which was associated with the 
transcriptional activation of several matrix metalloproteinases critical for tumour cell 
invasion (Sato et al., 2003). Consequently, there is a real need to develop targeted 
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demethylating therapies to allow for tailored treatments to specific cancer subtypes 
and avoid the inadvertent activation of oncogenes in the process, which is a major 
concern with current globally acting, nonspecific demethylating agents (Feinberg, 
2007; Gius et al., 2004). 
One approach to achieve such targeted demethylation is through the use of an 
inactive, or caged, DNMT inhibitor whose subsequent activity can be induced by an 
external signal, in this instance UV light. Photocaged 5-azacytidine (caged-aza) 
comprises of two covalently linked photosensitive moieties at the N4 position of the 
pyrimidine ring of 5-azacytidine, which may be removed via photolysis upon 
exposure to light to produce the biologically active molecule. Photocaged 5-aza-2’-
deoxycytidine (caged-DAC) was efficiently synthesised with just one photosensitive 
moiety attached at the same N4 position, affording the molecule fasting uncaging 
kinetics than the double-tagged 5-aza compound (Figure 5-13).  
 
Figure 5-13: Molecular structure of the photocaged DNMT inhibitors. A) Unmodified 5-
azacytidine. B) Photocaged 5-azacytidine (“caged-aza”). Two photosensitive moieties (2-
nitrophenethyl carboxyl) are attached at the N4 position of the pyrimidine ring of 5-azacytidine. C) 
Photocaged 5-aza-2’-deoxycytidine (“caged-DAC”). One photosensitive moiety (7-
diethylaminocoumarin-4-ylmethyl carboxyl) is attached at the N4 position of the pyrimidine ring of 5-
aza-2’-deoxycytidine. 
In this section, I outline a preliminary in vitro study into the use of the photocaged 5-
aza and DAC molecules for targeted demethylation. A well-characterised 
osteosarcoma cell line (Saos-2), whose methylation profile had previously been 
established by the Beck lab, was chosen as the in vitro cell culture model for caged-
aza treatment for its high proliferation rate and known hypermethylation phenotype, 
typical of many cancer cell lines. The stability of the photocaged molecules, their 
potential for temporally controlled activation through exposure to UV light and their 
C A B 
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effects on the genome-wide DNA methylation profile of the Saos-2 cell line are 
discussed below.  
5.3.2 Optimisation of 5-azacytidine in vitro treatment conditions 
5.3.2.1 Concentration range 
An initial titration experiment was performed using commercially available 5-aza to 
assess a suitable concentration range for use in subsequent experiments involving 
caged-aza that would result in a measurable decrease in methylation whilst 
minimising any potential cytotoxicity. Based on previous literature concerning 5-aza 
dosage (Hagemann et al., 2011), a concentration series in the range of 1-10µM was 
tested over a period of five days, with a total of three doses of 5-aza administered 
once every 24 hours to each treatment well. Five concentrations of 5-aza were tested 
in duplicate wells of 24-well culture plate: 1, 3, 5, 7 and 10 µM. The cells were 
harvested on day 5, 24 hours after the third and final dose of 5-aza.  
On day 3, 24 hours after administering the first dose of 5-aza, a significant negative 
effect on cell growth could already be observed across all 5-aza treatment conditions. 
By day 5, the control wells had reached full confluence, whilst those undergoing 5-
aza treatment had reached a maximum confluence of 50%, with increased inhibition 
of cell growth visible in the 5, 7 µM and 10µM treatment wells as compared to the 
lower doses of 1 and 3µM (Figure 5-13). This concentration-dependent increase in 
cell death was confirmed on day 5 after collecting all remaining cells for DNA 
extraction. The total amount of DNA recovered from the control wells was 24.4µg, 
compared to 13.2 µg for the 1µM treatment wells, 9.6µg for the 3µM treatment, 
7.8µg for the 5µM treatment, 6.8µg for the 7µM treatment and 5.2µg for 10µM 
treatment, suggesting that the higher levels of cell death occurred in wells exposed to 
increasing concentrations of 5-aza.  
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 Figure 5-14: Concentration-dependent effect of 5-azacytidine treatments on cell growth. A) Control wells. B) 1µM 5-aza. C) 3µM 5-aza. D) 
5µM 5-aza. E) 7µM 5-aza. F) 10µM 5-aza. First dose was administered on day 2; by day 3, a negative effect on cell growth is evident in all treatment 
wells (columns B-E) compared to control (column A). The control wells (column A) reached full confluence on day 5. In contrast, considerable cell 
death was observed in all wells receiving 5-aza, with higher concentrations (columns D and E) resulting in a more pronounced toxic effect. 
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Two factors were important when it came to determining an optimal concentration 
point for subsequent experiments testing the photocaged 5-aza and DAC molecules. 
First, it was critical to obtain sufficient DNA from each treatment condition to enable 
further downstream analysis of methylation levels either by an ELISA assay or 
Infinium 450K array; however, since typically only 500ng-1µg is needed per sample 
for either method, all 5-aza concentrations tested seemed reasonable. Second, it was 
important that the cells continued to undergo as many cell divisions as possible 
during the treatment time course, as 5-aza only exerts its demethylating effect 
through incorporation into the genome during DNA synthesis. Due to the replication-
dependent nature of 5-aza bioactivity, the lowest concentration of 1µM 5-aza seemed 
the most appropriate as the toxicity of the drug is greatly reduced and only a 
moderate inhibition of cell division is observed under this treatment condition.  
To confirm that a 1µM 5-aza treatment would be sufficient to generate a significant 
decrease in DNA methylation levels and thus successfully distinguish cells treated 
with ‘inactive’ photocaged 5-aza versus ‘active’ photolysed 5-aza compounds, global 
DNA methylation levels in the 5-aza treated samples were measured using a 
colorimetric ELISA assay. 
A total of six samples were run in duplicate on an ELISA plate, along with a 5mC 
DNA standard curve. Whilst the 5mC standard curve did not show a linear 
correlation between absorbance and 5mC content as expected, a strong positive 
correlation was observed nevertheless (Figure 5-15). The highest absorbance 
reading, and hence DNA methylation level, observed amongst the six samples 
belonged to the control sample, i.e. untreated ‘normal’ Saos-2 cells, as expected. All 
samples subjected to 5-aza treatment showed a minimum 70% reduction in 
methylation levels compared to control, with an increasing 5-aza concentration from 
1µM to 5µM correlating with a decreasing absorbance reading (0.0328 to 0.0114) 
and therefore global DNA methylation level. Interestingly, treatment with the two 
highest concentrations of 5-aza (7µM and 10µM) resulted in a reversal of this trend, 
with methylation levels higher than that observed for the 5µM-treated sample, albeit 
still at a fraction of the control sample’s 5mC level (Table 5-2). This is likely due to 
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higher levels of cytotoxicity resulting from these treatments and consequently a 
greater restriction on cell growth and, crucially, DNA synthesis.  
Based on these preliminary results, a 1µM concentration of 5-aza was deemed 
sufficient to cause a significant decrease in global DNA methylation levels whilst 
causing the least disruption to the proliferative capacity of the cells.  
 
Figure 5-15: 5mC DNA standard curve generated using a colorimetric ELISA assay. Data points 
shown are the average of duplicate run for each sample. 5mC DNA standards were generated by serial 
dilution of a commercially available 100% methylated human DNA standard, creating samples 
containing 75%, 50%, 25%, 10% and 5% 5mC DNA. 
Sample type Raw absorbance reading at 405nm 
Adjusted absorbance 
reading at 405nm 
Control cells (no 5-aza treatment) 0.1666 0.1110 
1µM 5-aza  0.0884 0.0328 
3µM 5-aza 0.0751 0.0195 
5µM 5-aza 0.0670 0.0114 
7µM 5-aza 0.0701 0.0145 
10µM 5-aza 0.0770 0.0214 
Blank (DNA binding buffer only) 0.0556 0.0000 
   
Table 5-2: 5mC DNA ELISA assay results for the 5-aza-treated Saos-2 cell samples. Absorbance 
readings shown are an average of duplicate samples for each treatment point. Adjusted absorbance 
reading = raw absorbance reading – blank measurement. 
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5.3.2.2 Solvent selection 
Unlike 5-aza, the caged-aza compound is hydrophobic and needs to be dissolved in 
an alternative buffer in order to be administered in cell culture. Both dimethyl 
sulphoxide (DMSO) and acetonitrile (ACN) are two commonly used polar aprotic 
solvents for organic compounds, but are known to produce toxic side effects in living 
cells. Although exposure to these solvents could be minimised by using highly 
concentrated stocks of the caged-aza compound for the cell culture treatments, 
exposure cannot be entirely eliminated. A preliminary test was therefore performed 
to assess and compare the effect of pure DMSO and ACN on cell viability at the 
highest concentrations likely to be used in subsequent caged-aza experiments in 
order to select the most suitable dilution buffer. 
In parallel to testing the effects of 5-aza at four different concentrations (0.5, 1.0, 1.5 
and 2µM, dissolved in sterile water), both ACN and DMSO were also administered 
to cells in triplicate at a final concentration of 1.5µM, where one dose of the solvent 
was equivalent in volume to one 1.5µM dose of 5-aza. Both solvents had a 
surprisingly strong negative effect on cell growth compared to control, analogous to 
treatment with 0.5 to 1µM 5-aza (Figure 5-16A). However, the effect of ACN on cell 
growth was less severe, resulting in approximately 10% higher final cell confluence 
readings compared to DMSO-treated wells. This observed difference was amplified 
in a replicate culture plate, run in parallel to the treatment described above, which 
was left at room temperature under the cell culture hood for 1 hour after addition of 
each treatment before being returned to an incubator (set at 37°C, 5% CO2). Under 
this condition, the 1.5µM ACN treatment resulted in an additional 25% confluence 
compared to DMSO (Figure 5-16B). However, the effect of the 1-hour exposure 
across all treatment types was minimal, suggesting that removal of the cells from the 
controlled environment of an incubator for 1 hour per day had little observable effect 
on cell viability. This was an important point to establish before proceeding with 
planned experiments to irradiate cell culture dishes containing the caged-aza 
compound. Irradiation would need to take place over the course of 1 hour outside of 
an incubator in order to produce sufficient quantities of the active compound via 
photolysis. As a result of this treatment course, ACN was chosen for use as the 
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solvent and caged-aza was stored at a stock concentration of 1mM at -20˚C and 
diluted further in ACN to 100µM just prior to use.  
 
Figure 5-16: Growth curves demonstrating the effect of varying concentrations of 5-aza 
treatment against two alternative solvents, acetonitrile (ACN) and dimethyl sulphoxide 
(DMSO). (A) and (B) show the results from two replicate 24-well cell culture plates, both of which 
received identical treatments in parallel over the same time period. In addition, plate (B) was left at 
room temperature under the cell culture hood for 1 hour after addition of each treatment, in contrast to 
plate (A), which was immediately returned to an incubator (37°C, 5% CO2). A concentration-
dependent decrease in cell growth was observed in both plates for all 5-aza conditions tested. Control 
cells grew at near-identical rates in both plates, reaching a maximum confluence of 100% at the point 
of collection, suggesting that the additional time plate B spent outside of a controlled CO2 incubator 
compared to plate A was well tolerated by the cells and did not have any negative effect on 
proliferation. NB: in both graphs above, time zero represents initial seeding of the culture plates. 
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5.3.3 Concentration-dependent effect of caged-aza on cell viability 
The aim of these experiments was to establish whether the caged-aza molecule could 
be deprotected (i.e. activated) in a temporally controlled manner through irradiation 
of a cell culture dish after receiving a dose of the compound. 
Prior to testing the demethylating potential of the photocaged 5-aza compound 
(“caged-aza”) in cell culture, the following factors needed to be examined: first, the 
stability of the caged-aza molecule in culture media; second, the relative activity of 
the fully photolysed caged-aza compound compared to commercially available 5-
aza; third, the feasibility of ensuring full deprotection of the caged-aza molecule 
through in vitro irradiation of a cell culture plate; and fourth, the possibility of toxic 
side effects resulting from the presence of the lysed phototag in the culture medium 
after deprotection and/or the hydrolytic breakdown of the caged-aza compound into 
harmful by-products. 
5.3.3.1 Comparison of photolysed caged-aza versus 5-aza treatment in vitro 
Solutions of both caged-aza and pre-irradiated (i.e. activated) caged-aza were freshly 
prepared and tested at three concentrations on the Saos-2 cell line over a period of 
four days, with one dose administered every 24 hours for a total of three doses before 
ending the time course on day 4, 24 hours after the third and final dose. The 
compounds were administered directly into the culture media to produce final 
concentrations of either 0.5, 1.0 or 1.5µM. Cell confluence was monitored 
throughout the course of treatment to assess the effect of the compounds on cell 
proliferation.   
Both non-irradiated and pre-irradiated caged-aza were observed as having a 
deleterious effect on cell growth as compared to control cells receiving no treatment 
(Figure 5-17), although all three concentrations of the pre-irradiated treatments had a 
larger inhibitory effect on cell proliferation than any of the three non-irradiated 
caged-aza treatments, as would be expected of a biologically active 5-aza molecule. 
Furthermore, the lag in cell growth observed for the three non-irradiated, inactive 
compounds was comparable to that of the control cells receiving 1.5 µM doses of 
pure acetonitrile only, thereby mimicking the effect of the caged-aza solvent. It 
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seems reasonable to conclude that the inhibitory effect of the non-irradiated 
compound is likely to be due to the toxicity of acetonitrile, rather than the presence 
of active 5-aza in the culture media. Whilst the possibility of spontaneous photolysis 
in the culture media cannot be dismissed, the high rates of proliferation seen in all 
three non-irradiated treatments, resulting in >90% confluence across all three 
concentrations after the 4-day treatment, makes it unlikely that a significant 
proportion of the compound underwent any aberrant activation over the course of the 
treatment.  
As expected, the pre-irradiated compound resulted in greater inhibition of cell 
proliferation at each concentration tested compared to both its non-irradiated 
equivalent and controls (Figure 5-17). The effect appeared more pronounced at 
higher concentrations, although considerable variation in confluence measurements 
across replicates means a definitive conclusion on the concentration-dependent 
nature of growth inhibition cannot be drawn. Interestingly, the pre-irradiated caged-
aza did not replicate the growth inhibition to the same extent as previously observed 
in our treatments with 5-aza (Figure 5-16), with significantly slower growth observed 
over the treatment course of 5-aza from the time of the first dose (hour 24) to cell 
collection (hour 120), compared to the same time period for the pre-irradiated 
compound (hour 0 to hour 96 in Figure 5-17). This is likely due to incomplete 
photolysis of the caged-aza compound during irradiation, causing the concentration 
of active compound present in the irradiated solution to be lower than that of an 
equivalent concentration of 5-aza. This was confirmed by photolysis time course 
analysis of the irradiated caged-aza compound at 365nm, performed by collaborators, 
which found that 26% of the caged-aza compound was still present intact after 1 hour 
of irradiation, with the remaining 74% successfully uncaged to the active form.  
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Figure 5-17: Growth curves of Saos-2 cells treated with varying concentrations of pre-irradiated 
or non-irradiated caged-aza. One dose was administered every 24 hours for a total of three doses, 
each indicated by dashed lines above. The cells were collected 24 hours after the final dose (at 96-
hour time point, above). The non-irradiated caged-aza treatments had a less noticeable negative effect 
on cell viability than the pre-irradiated molecules, as would be expected for an inactive compound. 
All three concentrations of the inactive compound (0.5, 1.0 and 1.5µM) resulted in higher cell 
confluence readings at the end of the 4-day time course than the lowest concentration of active 
compound tested (0.5µM). Error bars represent the standard deviation in confluence measurements 
between three replicates for each treatment condition.  
5.3.3.2 In situ irradiation of the caged-aza compound 
The ability to successfully cleave the caged analogue after addition to cell culture 
was investigated as a first step towards achieving temporal control over the activity 
of this demethylating drug. Treatments were extended 1 day in comparison to 
previous experiments, in order to administer a total of four doses of caged-aza. Doses 
were added every 24 hours over a 5-day period at three different concentrations 
alongside appropriate controls, starting 24 hours after initial seeding of the culture 
plates. Treatments were run in parallel in two cell culture plates, one of which (plate 
B) was exposed to 1 hour of ultraviolet (UV) irradiation at 365nm immediately 
following the addition of each of the final three caged-aza doses. The control plate 
(A) remained protected from UV light throughout.  
Previous work in the Howorka group established the absorption spectrum of the 
caged-aza molecule and identified that the maximum deprotection rate would occur 
through UV irradiation at 260nm. However, due to the known mutagenic effects of 
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UV exposure (Ichihashi et al., 2003; Ravanat et al., 2001), a longer wavelength 
(365nm) falling within the UVA spectrum of 320-400nm was chosen for the in vitro 
irradiation experiments in order to minimise DNA damage and overall cell toxicity. 
Although the measured absorption at 365nm was quite low (2%), after 60min of 
irradiation 74% of the caged-aza molecules had undergone photolysis. Assuming that 
the observed breakdown of caged-aza resulted in full deprotection of the compound 
(i.e. cleavage of both phototags), 1 hour of irradiation was therefore deemed 
sufficient to activate the caged-aza compound whilst minimising cell exposure to 
potentially damaging irradiation. 
Growth curve profiles for cells grown in the control condition on both plates were 
almost identical, resulting in ~90% confluence by the end of the treatment course 
(hour 120), suggesting that UV irradiation on its own had no effect on the 
proliferative capacity of these cells.  
As would be expected of a biologically inactive compound, caged-aza treatment in 
the absence of light exposure had little discernable effect on cell growth (Figure 
5-18A). Growth curves for cells subjected to varying concentrations of caged-aza or 
pure acetonitrile had similar profiles to control cells exposed to full growth media 
only, suggesting the caged compound has little or no toxicity in its inactive form and 
is well tolerated by cells in culture. Treatment with the highest concentration of 
caged-aza, 1.5µM, did cause a small decrease in cell growth relative to other 
treatment conditions, as observed in previous treatments with the inactive caged-aza 
compound (Figure 5-17), likely due to either a small percentage of the compound 
spontaneously breaking down to produce uncaged 5-aza or to the increased volume 
of ACN present in each dose.  
In contrast, caged-aza treatment in combination with UV irradiation produced a clear 
concentration-dependent reduction in cell proliferation (Figure 5-18B), with 1.5µM 
caged-aza resulting in almost complete cell death in the corresponding wells. Caged-
aza treatment in the absence of UV irradiation had no discernable effect on cell 
growth, as shown by the tight clustering of growth profiles for all treatment 
conditions during the first 48 hours after initial seeding (time zero), during which 
both plates A and B were subjected to identical conditions, including the first 
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treatment dose at hour 24 and no UV exposure. However, the introduction of UV 
irradiation for plate B after the second dose at hour 48 resulted in immediate, visible 
reduction in cell growth rates for all three caged-aza concentrations.  
 
Figure 5-18: Growth curves demonstrating the effect of UV irradiation on the proliferation 
capacity of Saos-2 cells treated with caged-aza. Graphs A and B show the growth curve profiles of 
duplicate culture plates subjected to identical treatment conditions but differing light exposure. Both 
plates were administered four doses of caged-aza/ACN as appropriate at 24, 48, 72 and 96 hours post-
seeding, indicated by the dashed vertical lines above. Plate A was protected from all UV exposure, 
whilst plate B was irradiated for 1 hour at 365nm a total of three times, directly following the addition 
of caged-aza/ACN doses at 48, 72 and 96 hours post-seeding. Irradiation of plate B was withheld after 
the first dose to mimic the conditions of control plate A. 
5.3.3.3 Effect of photolysis by-products on cell viability 
Saos-2 cells were treated with two concentrations of the isolated phototag (not 
conjugated to 5-aza) in parallel to the caged-aza treatments described previously in 
order to assess whether it produced any cytotoxicity of its own. Whilst the phototag 
was predicted to be pharmacologically inactive, it was important to confirm that the 
phototag would not produce any negative side effects once the caged-aza compound 
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underwent photolysis. Addition of the phototag over a 5-day treatment period at 
either 1 µM or 1.5µM concentrations had no appreciable effect on cell proliferation, 
even in combination with UV irradiation (Figure 5-19). All four photolysis by-
product treatment conditions resulted in similar sigmoid growth curves, with all 
culture dishes reaching full confluence by the end of the time course. The rate of 
growth observed was comparable to treatment with caged-aza in the absence of UV 
(Figure 5-19; orange label), as expected. These results suggest that exposure to the 
lysed phototag does not result in cytotoxicity, or at least not at levels sufficient to 
induce senescence. The differential growth rate observed with caged-aza treatment 
(Figure 5-18) is therefore likely due to the activity of the uncaged cytidine analogue 
rather than the accumulation of phototags in the cell culture media.  
 
Figure 5-19: The effect of treatment with the photolysis by-product. Cells were treated with either 
1 µM or 1.5µM solutions of the isolated photolysis by-product in both the presence and absence of 
UV irradiation at 365nm. Dashed lines (above) indicate dosage time points. A total of 4 doses of the 
phototag were administered every 24 hours in fresh media in two cell culture plates run in parallel. 
One plate was exposed to 1 hour of UV immediately after each dose; the second plate was protected 
from light throughout.  
5.3.4 Genome-wide DNA methylation analysis of caged-aza treatment 
Although the in vitro experiments described above showed promising results for the 
efficacy of the caged-aza compound, its demethylating activity needed to be 
confirmed before it could be considered as a viable alternative to traditional 5-aza. 12 
DNA samples were subjected to genome-wide DNA methylation analysis using the 
Infinium 450K array. DNA was extracted from Saos-2 cells that had undergone the 
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following treatments: 5-aza, caged-aza and pre-irradiated caged-aza treatments at 
0.5, 1.0 and 1.5µM. In addition, 3 control conditions were included: no treatments, 
UV irradiation only, and 1.5µM acetonitrile treatment combined with UV irradiation. 
Data was processed using the ChAMP analysis pipeline in R (see Chapter 2, section 
2.9.6). Normalised beta values for each probe on the array, representing the 
methylation level at each CpG site on a scale of 0 to 1, were obtained for each of the 
12 samples. Comparison of the frequency distributions of beta values between 
samples highlights a clear reduction in DNA methylation following 5-aza treatment 
(aza; Figure 5-20). However, no such reduction in DNA methylation was seen for the 
caged-aza treatments combined with UV irradiation (cagedAzaUV; Figure 5-20). 
The density plots for the ‘cagedAzaUV’ samples were identical to the control and 
caged-aza samples, suggesting that this compound did not induce widespread DNA 
demethylation in the treated cells.  
 
Figure 5-20: Kernel density plot of all normalised beta values. The frequency distribution of 
normalised beta values generated from the 450K array are plotted for all 12 samples and grouped 
according to treatment type. Samples subjected to 0.5, 1.0 and 1.5µM 5-aza are labelled as ‘aza’ 
(green). ‘CagedAza’ refers to samples subjected to caged-aza in the absence of UV (orange). 
‘CagedAzaUV’ refers to samples subjected to caged-aza combined with UV irradiation (purple). 
‘Control’ refers to the three control samples (pink). 
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Analysis of the degree of correlation between samples confirmed that the caged-aza 
treatments did not cause any alteration in the DNA methylation profile of the Saos-2 
cells (Supplementary Figure 17). All three ‘cagedAzaUV’ samples had a correlation 
coefficient of 0.99 when compared to any of the three control samples. Similarly, 
comparison of ‘cagedAza’ samples to controls all resulted in correlation coefficients 
of 0.99 or above. In contrast, all three ‘aza’ samples showed much lower correlations 
when compared either to caged-aza samples or controls (r=0.78-0.79), suggesting 
that the 5-aza treatments did have a substantial effect on the DNA methylation 
profile of their respective cells, as had been expected. Treatment with 0.5µM 5-aza 
decreased median DNA methylation levels by approximately 10%, from 69% 5mC 
in the control cells to 62% in the treated cells. Increasing concentrations of 5-aza 
decreased 5mC levels still further, with 1µM and 1.5µM 5-aza treatments resulting in 
averages of 58% and 57% 5mC, respectively.  
The lack of demethylating activity observed for the caged-aza treatments may be due 
to either insufficient uncaging or instability of the compound when dissolved in the 
cell culture media. High performance liquid chromatography (HPLC) analysis of the 
compound found that caged-aza was extremely prone to hydrolytic breakdown when 
in aqueous solution (mimicking cell culture conditions). Further HPLC analysis of 
the compound subjected to UV irradiation found that 52% remained unchanged after 
1 hour of irradiation at 365nm and only 16% of the compound was fully uncaged. 
The remaining 32% had undergone cleavage of a single phototag to produce a mono-
tagged 5-aza molecule.  
5.3.5 Concentration-dependent effect of caged-DAC on cell viability 
An alternative caged cytidine analogue containing a single phototag was synthesised 
in an attempt to overcome the slow uncaging kinetics and hydrolytic instability 
observed with the caged-aza compound. The phototag was exchanged for one with 
higher absorption at the desired wavelength of 365nm. In addition, DAC was chosen 
over 5-aza as the preferred demethylating agent to undergo modification due to its 
greater hydrolytic stability at 37ºC and lower cytotoxicity (Lin et al., 1981; Notari 
and DeYoung, 1975; Stresemann and Lyko, 2008). The resulting molecule, mono-
DEACM-deoxyazacytidine (caged-DAC; Figure 5-13C), was then subjected to 
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HPLC analysis whilst undergoing irradiation at 365nm. 92% of the compound was 
converted to the biologically DAC after 1 hour, with only 0.5% of the original 
compound remaining intact.   
Treatment of the Saos-2 cell line with varying concentrations of caged-DAC 
combined with UV irradiation at 365nm resulted in a strong concentration-dependent 
reduction in cell growth (Figure 5-21A), as previously observed with the caged-aza 
compound. All concentrations of caged-DAC resulted in a decline in the rate of cell 
growth, although the effect was much more pronounced at the higher concentrations 
of 4.5 and 13.5µM, with the latter resulting in almost complete cell death. These 
observations are consistent with the idea that the compound has undergone 
successful uncaging to its biologically active form, which can then incorporate into 
newly synthesised DNA. Secondary cytotoxic effects are often observed during 5-
aza or DAC treatment, which are attributed to the decrease in DNMT1 levels rather 
than DNA demethylation activity (Jackson-Grusby et al., 1997; Jüttermann et al., 
1994). The presence of increasing numbers of DNMT1-aza adducts facilitates 
mutagenesis at these CpG sites, leading an inhibition of DNA synthesis and 
cytotoxicity.  
In contrast, treatment with caged-DAC in the absence of UV exposure caused only 
minor attenuation in growth over the 5-day treatment period, as would be expected 
from an inactive compound (Figure 5-21B). The minor reduction in cell growth 
observed for the highest caged-DAC concentrations is perhaps indicative of a low 
level of spontaneous uncaging of the compound. Further analysis of the stability of 
the compound in aqueous solution or an assessment of DNA methylation levels in 
these samples would be needed to definitively conclude whether spontaneous 
uncaging is occurring over the course of treatment.  
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Figure 5-21: Negative concentration-dependent effect of caged-DAC treatment on cell growth. 
Saos-2 cells were subjected to 4 doses of either 0.5, 1.5, 4.5 or 13.5µM caged-DAC at 24-hour 
intervals in two parallel culture plates, one of which was exposed to 1 hour of UV irradiation 
following each dose. A) Cell confluence over time for all treatment conditions without UV exposure. 
B) Cell confluence over time all treatment conditions subjected to UV irradiation.  
If full uncaging of the caged-DAC compound was successful during the given 
periods of UV irradiation, it would be expected to have a similar effect on cell 
growth as treatment with unmodified DAC. However, DAC treatment at all three 
concentrations tested (0.5, 1.5 and 4.5 µM) resulted in a larger inhibition of cell 
growth in comparison to the equivalent caged-DAC treatment (Figure 5-22B), 
suggesting that the caged-DAC compound does not undergo full uncaging under the 
irradiation conditions used here, perhaps due to partial UV absorption by the culture 
media or cells themselves, which would decrease the total amount of UV reaching 
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the compound. Alternatively, it is possible that the caged-DAC compound underwent 
partial hydrolysis to further inactive products.  
Although UV exposure alone had no visible effect on cell proliferation (“growth 
media only” conditions, Figure 5-22A), UV in combination with DAC treatment 
appeared to have a much stronger inhibitory effect on cell growth compared to DAC 
treatment in the absence of irradiation. This was unexpected and may reflect the 
cells’ inability to effectively counteract the increasing levels of DNA damage and 
cellular stress caused by the combined treatment.  
 
Figure 5-22: Effect of DAC treatment on cell growth. Three concentrations of both DAC and 
caged-DAC were administered to Sao2-cells in a total of four doses over five days. Treatments were 
given to duplicate cell culture plates, one of which was irradiated at 365nm for 1 hour following the 
addition of each treatment dose. A) Comparison of varying concentrations of DAC treatment with and 
without UV irradiation. B) Comparison of DAC versus caged-DAC treatment under UV irradiation. 
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5.3.6 Genome-wide DNA methylation analysis of caged-DAC treatment 
The final aim of this chapter was to establish whether the caged-DAC molecule 
could produce a demethylating effect comparable to that of DAC after deprotection. 
DNA was extracted from Saos-2 cells treated with 1.5µM caged-DAC (both with and 
without UV irradiation at 365nm) and subjected to Infinium 450K BeadChip 
analysis. The raw data was processed using the ChAMP analysis pipeline in R 
alongside the previously generated 450K data for the caged-aza experiments (see 
section 5.3.4). The frequency distribution of normalised beta values across all probes 
shows a clear shift in the methylation profile of both caged-DAC samples towards a 
hypomethylated state (Figure 5-23). The ‘CagedDAC_UV’ sample shows the largest 
decrease in global methylation levels, indicating that successful uncaging of the 
caged-DAC molecule occurred in vitro to release the biologically active DAC. 
However, a similar but less pronounced effect was observed for the 
‘CagedDAC_control’ sample that did not receive UV irradiation and was 
consequently expected to remain unaffected by the caged-DAC treatment. The 
median methylation score across all probes decreased from 68% in the control 
sample (Saos-2 cells under normal growth conditions) to 51% in the caged-
DAC_control sample (compared to 36% in the caged-DAC_UV sample) suggesting 
that a significant proportion of the caged-DAC compound underwent spontaneous 
hydrolysis and was not stable in culture media.  
 
Figure 5-23: Kernel density plot of normalised beta values from the Infinium 450K array. 
Frequency distribution for all normalised beta values. ‘CagedDAC_c’ refers to treatment with caged-
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DAC in the absence of UV; ‘CagedDAC_UV’ refers to treatment with caged-DAC combined with 
UV irradiation. 
Visualisation of the average methylation level across all probes on the 450K array in 
both control and caged-DAC-treated samples (Figure 5-24B) shows that the 
demethylating activity of caged-DAC is not constricted to particular genomic regions 
but instead acts indiscriminately across the genome, producing an unbiased genome-
wide hypomethylation phenotype.  
 
Figure 5-24: Effect of caged-DAC treatment on genome-wide DNA methylation profile of Saos-2 
cells. A) Bar chart shows the decrease in median methylation level from 68% to 36% across all 450K 
probes between control cells and those treated with caged-DAC and UV irradiation. Heatmap shows 
all normalised beta values plotted in order of chromosome location for the two samples. B) Scatterplot 
of all normalised beta values for caged-DAC (+UV) against control, showing a distinct pattern of 
hypomethylation in the caged-DAC (+UV) sample.  
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5.3.7 Discussion 
The potential for achieving targeted demethylation using an in vitro culture system 
was evaluated using two alternative caged nucleoside analogues containing a 
photoprotective group that may be cleaved through UV irradiation at a particular 
wavelength, thereby releasing the active molecule. The cytotoxicity of the 
compounds was assessed alongside their effect on DNA methylation.  
The caged-aza molecule was found to be much more toxic to cells in culture than the 
caged-DAC molecule at equivalent concentrations after irradiation, resulting in 
almost complete cell death at a final concentration of 1.5µM. Caged-DAC was well 
tolerated by the cells and produced no noticeable reduction in cell growth rate at 
1.5µM when compared to either the control condition or the equivalent non-
irradiated treatment. The same observation is made when comparing unmodified 5-
aza versus DAC treatment: cells tolerated concentrations of up to 4.5µM DAC 
(Figure 5-22A), which caused an approximately 40% reduction in final cell 
confluence, whilst just 1.5µM 5-aza was sufficient to cause a 60% reduction in final 
cell confluence (Figure 5-16A). As this observation was true of both unmodified and 
caged versions of these two nucleoside analogues, it is unlikely to be a result of 
slower uncaging kinetics of the caged-DAC molecule or weaker absorption at 
365nm. Furthermore, both possibilities were ruled out after further analysis of the 
absorption spectra and photolysis dynamics of the two compounds when irradiated 
(carried out by a collaborator). The differing toxicity may be explained by 5-aza’s 
ability to incorporate into newly synthesised RNA as well as DNA. It has been 
previously reported that up to 80-90% of 5-aza is preferentially incorporated into 
RNA as it is a ribonucleoside and cytidine analogue (Li et al., 1970), blocking 
protein synthesis and triggering apoptosis. This may also explain why significant cell 
death was seen with the caged-aza treatments in combination with UV irradiation but 
was not associated with a corresponding decrease in DNA demethylation when the 
isolated DNA was profiled using the 450K microarray.  
The caged-DAC molecule showed significant advantages over the caged-aza 
molecule, including faster uncaging kinetics, stronger absorption at 365nm and 
reduced cytotoxicity. Critically, caged-DAC treatment in combination with UV 
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resulted in a significant reduction in global DNA methylation levels with only a 
minor reduction in cell growth rate. After a 5-day course of treatment, median DNA 
methylation levels decreased by 47% compared to the control condition (Figure 
5-24), whilst the treated cells still achieved confluence levels of approximately 90% 
(Figure 5-21B). Unfortunately, the caged-DAC molecule appears to be fairly 
unstable in aqueous solution and prone to spontaneous hydrolysis, releasing active 
DAC in the absence of irradiation and reducing median methylation levels by 25%. 
In order for true temporal control to be achieved over the action of such 
demethylating drugs, alternative phototags or DAC binding sites need to be explored 
in order to ensure long-term stability of the drug in its inactive form.  
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Chapter 6 Discussion 
6.1 5hmC: a novel epigenetic modification in mammalian DNA 
Since the rediscovery of 5hmC as a novel epigenetic modification in mammalian 
DNA in 2009, there has been intense interest in the potential role of 5hmC in both 
transcriptional regulation and DNA demethylation dynamics. The TET proteins were 
identified as mediators of the oxidative conversion of 5mC to 5hmC and were shown 
to catalyse the formation of two further oxidative derivatives of 5hmC (5fC and 
5caC), leading to the hypothesis that 5hmC was an intermediate in an active DNA 
demethylation pathway (Ito et al., 2011). However, the accumulation of high levels 
of 5hmC in particular tissues and identification of 5hmC-specific binding proteins 
suggests that this modification can be relatively stable and may exhibit its own 
unique gene regulatory functions, much like 5mC (Spruijt et al., 2013; Yildirim et 
al., 2011).  
Initial publications focused on quantifying global 5hmC levels in a variety of 
mammalian tissues before attempting to map the distribution of this novel 
modification throughout the genome in order to gain insight into its possible 
physiological roles. Tissues of the CNS were consistently found to contain the 
highest global 5hmC content, around five to ten times higher than all other somatic 
tissues or stem cell lines, where it can represent up to 40% of the modified cytosine 
content of DNA (Globisch et al., 2010; Kriaucionis and Heintz, 2009; Song et al., 
2011). In addition, 5hmC appeared depleted in highly proliferative tissues and cell 
lines, including blood and human cancers, suggesting an inverse relationship 
between 5hmC and proliferative capacity. Many of the first genome-wide profiles 
used affinity-based methods, such as hMeDIP, GLIB and CMS enrichment 
strategies, to map 5hmC in ESCs at moderation resolution and in a semi-quantitative 
manner (Ficz et al., 2011; Pastor et al., 2011; Robertson et al., 2011; Stroud et al., 
2011; Szulwach et al., 2011a; Williams et al., 2011; Wu et al., 2011; Xu et al., 2011).  
As a result of the observation of uniquely high 5hmC levels in the mammalian CNS, 
focus shifted to 5hmC profiling in tissues of the brain, including mouse cerebellum, 
hippocampus and human frontal cortex samples (Jin et al., 2011a; Song et al., 2011; 
Szulwach et al., 2011b). Dot blot analyses of DNA extracted from mouse cerebellum 
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at several developmental time points revealed a substantial increase of global 5hmC 
with age, from 0.10% of total nucleotides in the postnatal day 7 (P7) brain to 0.41% 
in the adult (10-month-old) brain. The P7 mouse brain is composed mainly of 
proliferative cells undergoing developmental maturation, further strengthening the 
hypothesis that 5hmC is acquired during neural development and cellular 
differentiation. 5hmC levels in cultured mESCs and mNSCs were measured at 
0.047% and 0.036% of total nucleotides, respectively, just over 50% lower than 
observed in P7 cerebellum, consistent with the notion that these cells are at a less 
developmentally mature, pluripotent state (Song et al., 2011). Genome-wide 
profiling of 5hmC in adult mouse cerebellum using ß-GT labelling, enrichment and 
sequencing revealed that 5hmC was highly enriched in gene bodies and depleted at 
the TSS and more distal genomic regions, in contrast to 5mC (as profiled using 
MeDIP-seq), where around 80% of all reads mapped to repeat sequences and satellite 
DNA regions. Localised enrichment of 5hmC at proximal upstream and downstream 
regions surrounding the TSS was also observed (up to approximately 875bp 
upstream and 200bp downstream). 5hmC levels at intragenic and proximal promoter 
regions were also positively correlated to gene expression levels in adult cerebellum, 
suggesting a role for 5hmC in transcriptional regulation.  
The first hMeDIP-based genome-wide 5hmC profile in neural tissue investigated the 
distribution of 5hmC in human frontal cortex a using NimbleGen 720K CpG island 
(CGI) plus promoter microarray (Jin et al., 2011a). Significant 5hmC enrichment was 
found in the gene body, whilst a slight depletion was observed at intergenic CGIs 
and promoters, as previously observed by Song et al. (2011) using an alternative 
5hmC enrichment strategy. Comparison of 5hmC to 5mC distribution (mapped using 
a MIRA assay coupled to microarray hybridisation) showed that 5hmC is much more 
frequently targeted to promoter regions than 5mC, whilst the latter is enriched in 
both intergenic and intragenic CGIs. 5hmC was enriched the promoter of genes 
associated with neural development and patterning processes and showed a positive 
correlation with gene expression levels when present at low CpG-density (but not 
intermediate- or high-CpG density) promoters, indicating that 5hmC generation at 
these regions may promote transcription by relieving the repressive effect of 5mC 
through a DNA demethylation mechanism. 
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Further investigation of the genome-wide distribution of 5hmC during neural 
development was performed through ß-GT labelling, enrichment and sequencing of 
mouse cerebellum and hippocampus samples at three distinct developmental time 
points: P7, 6 weeks and 1 year of age (Szulwach et al., 2011b). Overall, 5hmC was 
enriched within the gene body and gene proximal regions (875bp upstream to 200bp 
downstream of TSS), but strongly depleted at the TSS and more distal regions. 
Although hierarchical clustering of the genome-wide profiles showed both 
cerebellum-specific and hippocampus-specific 5hmC enrichment, all profiles across 
the three time points in both tissues were highly correlated to each other (0.81≤ r ≥ 
0.96), suggesting 5hmC is a stable modification whose genome-wide patterns are 
mostly conserved through development.  
Recent evidence for the existence of 5hmC as a stable modification comes from 
single-base-resolution profiling of 5hmC, 5fC and 5caC within mESCs. A method 
for single-base-resolution, simultaneous 5fC and 5caC profiling, termed M.SssI-
assisted bisulphite sequencing (MAB-seq), has recently been demonstrated in 
mESCs (Wu et al., 2014). Integration of this dataset with a comparable 5hmC profile 
generated by TAB-seq (Yu et al., 2012) revealed that 5hmC and 5fC/5caC are 
predominantly found at different CpG sites. Only 7.5% of all CpGs associated with 
5hmC (n=1,571,715) were also associated with 5fC/5caC (n=117,327), suggesting 
stable 5hmC accumulation occurs at these sites, whilst 81.2% of all 5fC/5caC loci 
were not associated with the 5hmC modification (n=508,261). It appears that not all 
5hmC generation represents an intermediary stage in active DNA demethylation, 
supporting an additional functional role for 5hmC within the genome.  
Due to the intrinsic link between 5mC and 5hmC abundance throughout the genome, 
profiling both modifications in parallel is key to understanding DNA methylation 
dynamics during a particular developmental transition. The central aim of this project 
was to investigate the changes in 5mC and 5hmC distribution across multiple time 
points during neural differentiation, which had not been previously investigated at 
the time. It was thought that the substantial gains in 5hmC observed in neural tissue 
(compared to ESCs and other pluripotent cell types) must have an important 
functional role during normal development and that precise mapping of these 
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changes in relation to 5mC would shed light on the possible significance of 5hmC 
accumulation in the CNS. Previous 5hmC profiles of neural cell types had been made 
using DNA obtained from heterogeneous tissue samples containing a diverse array of 
cell types. As epigenetic states vary enormously depending upon cell type, 
developmental stage, proliferative capacity, disease status and environmental 
influences, heterogeneous samples can confound downstream analysis and result in 
misinterpretation of the observed signals. An in vitro culture model of neural 
differentiation was therefore established for the collection of homogeneous cell 
populations for dual 5mC/5hmC profiling. 
6.2 Global 5hmC levels in cultured cells 
ESCs have traditionally been cultured in serum- and LIF-containing expansion 
media, but these cells exhibit both molecular and transcriptional heterogeneity. 
Heterogeneous expression of the pluripotency transcription factors Nanog, Rex1 and 
Stella are observed under serum- and LIF-containing conditions, leading to variable 
differentiation potential (Chambers et al., 2007; Hayashi et al., 2008; Toyooka et al., 
2008). The existence of interconvertible subpopulations within ESC cultures with 
fluctuating transcriptional states, once thought to be an inherent characteristic of 
pluripotent stem cells, is now seen as a destabilisation of the core pluripotency 
network and consequence of the cell culture environment (Graf and Stadtfeld, 2008; 
Wray et al., 2010). 
More recently, alternative ESC culture conditions have been defined that use three 
small molecule inhibitors (known as “3i”) to block GSK-3-mediated, FGF receptor 
and ERK signalling, dispensing of the need for exogenous stimuli (growth factors, 
cytokines or serum constituents) to maintain the pluripotent state through induction 
of inhibitor-of-differentiation protein expression (Ying et al., 2008). The use of 3i-
containing media maintains ESCs in a basal, ground state of self-renewal and 
pluripotency without the need for serum or feeder cells and exhibit homogeneously 
high expression levels of both Nanog and Rex1 (Wray et al., 2010). Recent 
characterisation of the global transcriptome of ESCs grown in either serum-
containing media or “2i” conditions showed that the two populations have distinct 
gene expression profiles (Marks et al., 2012). 2i represents an alternative media 
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condition using two inhibitors in combination with LIF, resulting in comparable ESC 
cultures to those grown in 3i (Ying et al., 2008). Over 3,000 genes showed differing 
transcription levels (>2-fold difference) between the two culture conditions, 
including 461 genes expressed only in serum and 160 expressed only in 2i.  Genes 
upregulated in serum are enriched for those involved in developmental processes and 
lineage specification, such as Pax6, Brachyury and Runx1. In addition, analysis of 
several histone modifications by ChIP-seq under both media conditions showed 
differing distributions of the repressive histone modification H3K27me3 at the 
promoters of silent genes and Hox clusters, whilst H3K4me3, H3K9me3 and 
H3K36me3 profiles were very similar across the genome. In particular, substantial 
reduction of H3K27me3 at the promoters of silent genes in the 2i condition meant 
that only around 1,000 genes were classified as bivalent in this condition compared 
to around 3,000 bivalent genes in serum, where bivalency is defined as colocalisation 
of H3K27me3 and H3K4me3 at the promoter. Taken together, these results suggest 
that ESCs grown under 2i/3i or serum conditions represent cells at developmentally 
distinct time points; the use of serum-free culture conditions allows the generation of 
homogeneous cultures which are more suitable for epigenetic or expression analysis. 
Cells grown in 3i media were found to show a more homogeneous morphology, 
uniformly high expression of the pluripotency marker Oct4 and reduced spontaneous 
differentiation compared to those grown in LIF- and serum- containing media. 
NSCs have traditionally been expanded in culture within clonal structures termed 
neurospheres. However, neurospheres exhibit significant cellular heterogeneity and 
include various differentiated neural cell types in addition to progenitor cells, making 
them unsuitable for epigenetic or expression analysis (Bez et al., 2003; Suslov et al., 
2002). For the purposes of this project, NSCs were instead cultured as adherent 
monolayers in serum-free media in the presence of EGF and FGF-2, which has been 
shown to result in homogeneous NSC cultures, as defined by various morphological 
and molecular markers, all with tripotent differentiation capacity (Conti et al., 2005; 
Glaser et al., 2007). Both primary and embryonic mNSCs showed uniformly high 
nestin expression, a bipolar morphology and grew in a characteristic lattice-like 
formation within the culture dish.  
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Finally, in vitro-derived astrocytes were chosen for analysis of a terminally 
differentiated neural cell type due to the ease of producing large numbers of 
homogenous, GFAP-positive astrocyte cultures from NSCs via serum exposure; a 
differentiation for 48 hours is sufficient to produce functionally mature astrocytes 
(Brunet et al., 2004). Two studies comparing the transcriptomes of in vitro-derived 
astrocytes (using either 10% serum, BMP2, CNTF or PACAP exposure over seven 
days) to both in vivo-derived astrocytes and a variety of other primary neural cells 
revealed that all astrocytes shared a common expression profile distinct to all other 
samples (Bachoo et al., 2004; Cahoy et al., 2008), supporting the conclusion that 
such in vitro protocols can produce truly differentiated functional astrocytes 
comparable to their in vivo counterparts. However, hierarchical clustering of the 
various gene expression profiles showed that that in vitro-derived astrocytes 
consistently formed a distinct subgroup within the astrocytic population. Although 
some differences between the transcriptomes of in vivo and in vitro astrocytes were 
observed, they all showed clearly distinct expression profiles from neurons, 
oligodendrocytes, neural stem cells and CNS tissues. It has been suggested that in 
vitro-derived astrocytes may not represent fully mature astrocytes and instead may 
be more similar to immature in vivo astrocytes, although the precise reasons behind 
these differences have not been fully elucidated.  
The discovery that in vitro differentiated astrocytes (after a 14-day exposure to 
serum) had similar levels of global 5hmC to mESCs, at around 0.06-0.08% of total 
nucleotides, rather than the five- to ten-fold higher levels found in primary CNS 
tissues, suggests that in vitro differentiation protocols may not accurately recapitulate 
in vivo developmental processes (see Chapter 4, Figure 4-14). It is possible that even 
if the cells present the morphological characteristics of terminally differentiated 
cells, they may still possess the epigenetic profile of immature astrocytes or glial 
progenitors; two weeks of differentiation may not sufficient for the phenotypic 
changes to be reflected in the methylome and/or hydroxymethylome. It is also 
possible that in vivo primary astrocytes have constitutively low levels of 5hmC, as 
observed in the in vitro culture model. The high levels of global 5hmC found in CNS 
tissue may not be a shared characteristic of all neural cell types, but instead may be a 
feature unique to neurons. The global 5hmC content of isolated primary neurons is 
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consistently found to be high, in the range normally associated with the mammalian 
brain (Hahn et al., 2013; Kriaucionis and Heintz, 2009), but global 5hmC 
measurements have not yet been made in purified astrocyte or oligodendrocyte 
populations for comparison. Interestingly, in vitro terminally differentiated dopamine 
neurons have been found to contain a similarly low 5hmC level to that of neural 
progenitors (and lower than mESCs), suggesting that reduced 5hmC is primarily a 
consequence of cell culture conditions, rather than an inherent characteristic of the 
cell type in question (Kim et al., 2014). If this is the case, 5hmC accumulation within 
primary astrocytes cannot be ruled out.  
Both embryonic mNSCs and primary mNSCs (cultured in vitro) showed a reduction 
in global 5hmC levels of approximately 50% in comparison to both mESCs and 
astrocytes, with 5hmC comprising 0.02% to 0.04% of total nucleotides. This 
observation is in line with several other publications that have also found a 
significant decrease in 5hmC levels upon ESC differentiation to neural progenitors 
(Kim et al., 2014; Song et al., 2011; Tan et al., 2013). However, liquid 
chromatography tandem mass spectrometry (LC-MS/MS) analysis of nestin-positive, 
primary mNSCs isolated directly from the mouse brain (without in vitro culture) 
revealed that 5hmC represented approximately 0.15% of all cytosines, over ten-fold 
higher than the levels of cultured mNSCs (Hahn et al., 2013).  
Reduced 5hmC upon adaptation to cell culture has previously been noted for non-
neural tissues, suggesting that in vitro culture systems do not accurately reflect the 
true hydroxymethylome of primary cell types (Nestor et al., 2012). 5hmC reduction 
appeared to be a result of Tet1-3 downregulation after adaption to cell culture and 
5hmC continued to decrease with each subsequent passage, without any concomitant 
change to 5mC levels. Reduced 5hmC levels are also observed in cancer cell lines 
compared to the corresponding normal tissue, whilst immunohistochemical analysis 
of various tissues show reduced 5hmC staining in stem cell compartments compared 
to surrounding differentiated tissue (Haffner et al., 2011; Jin et al., 2011b; Kraus et 
al., 2012; Lian et al., 2012; Orr et al., 2012). Low 5hmC may be a general feature of 
highly proliferative cells, perhaps due to the existence replication-dependent, passive 
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DNA demethylation process that allows complete 5hmC turnover to unmodified 
cytosine. 
6.3 Genome-wide 5hmC profiling during neural development 
The genome-wide distribution of 5mC and 5hmC was profiled in mESCs, mNSCs 
and in vitro differentiated astrocytes using MeDIP-seq and hMeDIP-seq. The vast 
majority of DMRs and hDMRs (97.7% and 99.3% of all DMRs and hDMRs, 
respectively) were identified between mESCs and mNSCs, suggesting that the most 
significant changes in DNA methylation occur early on in development, during the 
initial lineage commitment of mESCs to neural precursors. This is consistent with 
findings concerning hESC differentiation, where the majority of observed DNA 
methylation changes (both 5mC and 5hmC) were found during the early 
developmental transition to hNPCs rather than during the terminal differentiation 
step to neurons (Kim et al., 2014).  
However, nearly 20-fold fewer hDMRs were identified overall than DMRs (323 
compared to 6,065), which may reflect the reduced abundance of 5hmC in the 
genome. It is possible that 5hmC undergoes rapid turnover to further oxidative 
derivatives, such as 5fC or 5caC, or unmodified cytosine, making it difficult to 
capture sites of active DNA demethylation through 5hmC profiling. The low 
absolute levels of 5hmC at any given CpG, combined with the fact that 5hmC is 
preferentially found in regions of low CpG density (Yu et al., 2012), suggests that 
antibody-based immunoprecipitation is not ideally suited to 5hmC profiling due to 
bias towards highly-modified and/or CpG-dense genomic regions. The latter was 
supported by the observation that around 80% of all identified hDMRs fell within 
repetitive regions of the genome (see Chapter 4, Figure 4.3). Several published 
hMeDIP-generated 5hmC profiles of mESCs have also identified significant 
enrichment within repetitive DNA and a strong bias towards CA/CT repeats (Ficz et 
al., 2011; Matarese et al., 2011; Williams et al., 2011), despite the fact that more 
recently developed methods of single-base-resolution profiling have found that 
5hmC is largely absent from repeat and satellite DNA and is found almost 
exclusively in the CpG context in both ESCs and brain tissue (Lister et al., 2013; 
Wen et al., 2014; Yu et al., 2012). It appears that the high enrichment within simple 
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repeats seen in hMeDIP-based profiles is an artefact of the enrichment method, likely 
resulting from cross-reactivity of the anti-5hmC antibody against unmodified 
cytosine in cytosine-rich regions. Interestingly, a hMeDIP-seq profile of primary 
mNPCs did not observe a bias towards CA repeats in their analysis, but significantly 
higher global 5hmC (approximately 0.15% of total nucleotides) was reported in this 
sample in comparison to the cultured cells studied here, suggesting that the hMeDIP-
seq protocol may not be sufficiently optimised to efficiently enrich for low-
abundance 5hmC but is effective in samples with high global 5hmC levels (Hahn et 
al., 2013). Genome-wide TAB-seq profiling of both ESCs and prefrontal cortex 
tissue has highlighted the discrepancy in 5hmC abundance between these samples: 
just over 2 million 5hmC bases were identified in E14 mESCs, whilst 28.4 million 
5hmC bases were identified in human adult prefrontal cortex (Wen et al., 2014; Yu et 
al., 2012). Analysis of human foetal prefrontal cortex (aged 22 weeks) found similar 
5hmC levels to mESCs (approximately 2.6 million 5hmC bases), perhaps reflecting 
of the highly proliferative state of the foetal brain.  
Approximately equal numbers of hypo- and hyper-hDMRs were identified during the 
mESC to mNSC transition. No particular patterns of enrichment were seen for the 
hyper-hDMR set, but hypo-hDMRs were significantly enriched at CGIs and CpG 
shores (see Chapter 4, Figure 4.1). A similar enrichment was observed by Szulwach 
et al., who profiled 5hmC during mouse brain development (between postnatal day 7, 
6-week and 1-year-old mice) using ß-GT labelling, enrichment and high-throughput 
sequencing (Szulwach et al., 2011b). They found that hDMRs were enriched at non-
TSS CGIs, as well as being enriched more generally for both CpG frequency and GC 
content.  
Comparison of the full 5hmC peak set against a randomised control set for each 
biological cohort showed 5hmC enrichment only within repeat regions of the 
genome, whilst 5hmC distribution within enhancers, intragenic regions and 
transcription factor binding sites mirrored the distribution expected by chance alone 
(Supplementary Figure 18). No 5hmC enrichment was found within the gene body or 
enhancer elements, unlike many other reported 5hmC profiles (Ficz et al., 2011; Kim 
et al., 2014; Pastor et al., 2011; Szulwach et al., 2011b; Tan et al., 2013; Xu et al., 
 171 
2011; Yu et al., 2012). Furthermore, EpiExplorer analysis of the hDMR coordinates 
showed depletion at enhancer regions (marked by H3K4me1 occupancy), in 
disagreement with another study that reported significant fold changes in 5hmC 
distribution at enhancers and other distal regulatory elements between ESCs and 
neural progenitors (Kim et al., 2014). Kim et al. found that during the hESC to hNPC 
transition, the largest fold changes in 5hmC enrichment were found at exons and 
enhancers (approximately 8-fold), whilst smaller but significant changes were also 
observed in promoters. Similarly, single-base-resolution analysis using BS- and 
TAB-seq in both hESCs and mESCs has found that nearly half (46.4%) of all 
identified 5hmC bases are located within promoter-distal regulatory elements, and 
the highest absolute 5hmC levels are also found at these sites, most notably at poised 
enhancers (marked by H3K4me1 only) (Yu et al., 2012). 5hmC enrichment within 
enhancer regions has also been observed in human adult prefrontal cortex, with 
poised enhancers displaying the highest genomic 5hmC level, at 32.6% (Wen et al., 
2014). These results support a regulatory role for 5hmC in gene transcription, 
possibly by mediating DNA demethylation events at these functionally important 
genomic regions or altering the DNA-binding affinity of regulatory proteins.  
In contrast to 5hmC, the majority of DMRs called between mESCs and mNSCs fell 
within intragenic regions and were significantly enriched within exons and depleted 
in repeat regions (see Chapter 4, Figure 4-1A). EpiExplorer analysis revealed that 
DMRs identified between mESCs and mNSCs were extensively enriched at gene 
regulatory sites, including those marked by H3K4me1, H3K4me3, DNaseI 
hypersensitivity and CTCF binding, in addition to evolutionarily conserved regions 
(see Chapter 4, Figure 4-2). Hyper-DMRs also showed enrichment at Pol-II binding 
sites, promoters (-5kb to 1kb) and CGIs, although the latter category was not found 
to contain statistically significant DMR enrichment during MeDUSA analysis of the 
MeDIP-seq datasets. Overall, these results suggest that the identified DNA 
methylation changes have functional relevance during this initial transition towards 
neural lineage commitment. Likewise, GO analysis of DMR-associated gene sets 
revealed enrichment for genes associated with developmental processes, such as 
embryonic morphogenesis and neural tube patterning, as well as genes upregulated in 
neural stem cells and brain tissue. 
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Approximately 40-fold fewer DMRs were called during the mNSC to astrocyte 
transition in comparison to the mESC to mNSC transition, all representing gains in 
5mC. These hyper-DMRs did not show significant enrichment for any particular 
gene feature and further analysis using EpiExplorer supported this conclusion, 
finding no enrichment in alternative genomic features; the distribution of hyper-
DMRs within various genomic features followed the same pattern as expected by 
chance. However, GO analysis of the hyper-DMR-associated genes did find 
significant enrichment for genes upregulated in various CNS tissues, such as 
Cntnap2, pointing to a biologically significant role for these DMRs in astrocytic 
differentiation.  
No overlap was found between hypo-DMR coordinates and hyper-hDMRs during the 
astrocytic differentiation of mESCs, made difficult by the low numbers of hDMRs 
observed overall in comparison to DMRs (323 versus 6,065), preventing any direct 
observation of a dynamic relationship between these two modifications. Many other 
regions of differential 5hmC content are likely to have been overlooked due to an 
inability to immunoprecipitate DNA fragments with low CpG content. The 
identification of hDMRs was also constrained by the overrepresentation of repetitive 
DNA sequences in the hMeDIP DNA libraries, resulting in a high ‘background’ 
5hmC signal that masked small but significant changes in 5hmC distribution. 
Moreover, regions with low absolute levels of 5hmC, even if present at high density 
in CGIs, may have been missed due to insufficient sequencing depth. It is now 
apparent that hMeDIP-seq profiling is not ideally suited to profiling 5hmC, unless 
extensive optimisations are made to compensate for the low abundance of this 
modification in comparison to 5mC. Base-resolution 5hmC analysis of mESCs 
within CGIs, using reduced representation oxBS-seq, found that just 800 CGIs 
(~6%) contained detectable 5hmC (out of 12,660 covered by sequencing) (Booth et 
al., 2012). The average 5hmC level across these CGIs was just 3.3% (at a maximum 
of 18.5%) and was inversely correlated to CpG density. Similarly, genome-wide 
TAB-seq profiling of mESCs also found an inverse correlation between 5hmC and 
CpG content, highlighting the difficulty in profiling 5hmC using an enrichment 
method biased towards CpG-dense regions such as CGIs (Yu et al., 2012).  
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6.4 Developments in 5hmC profiling  
At the start of this project, methods for analysing genome-wide 5hmC were not well 
established. Popular methods of 5mC detection, including 450K BeadChip analysis 
and single-base-resolution sequencing assays, were not easily adapted for 5hmC 
analysis because they rely on BS conversion of DNA, which cannot discriminate 
between 5hmC and 5mC within DNA molecules (Huang et al., 2010; Nestor et al., 
2010). Genome-wide 5hmC profiling was restricted to affinity enrichment-based 
assays coupled to either sequencing or microarray analysis, but these methods offer 
only moderate resolution, may show bias or cross-reactivity to cytosine-dense region, 
as in the case of antibody-based methods, or may require custom-made reagents, as 
in the case of the ß-GT selective chemical labelling method implemented by Song et 
al. (2011).  
The development of two single-base-resolution 5hmC profiling methods, TAB-seq 
and oxBS-seq, have dramatically increased our understanding of 5hmC distribution 
within the genome, although the considerable cost of high-throughput sequencing 
has limited the wider application of these methods (Booth et al., 2012; Yu et al., 
2012). The development of oxBS conversion as a method of distinguishing 5hmC 
from 5mC opened up the possibility of adapting exiting BS-dependent protocols for 
5hmC analysis (Booth et al., 2012). One aim of this project was to adapt the oxBS 
conversion protocol for use with the Infinium HumanMethylation450 BeadChip, 
allowing the detection of 5hmC and 5mC in parallel at significantly lower cost than 
high-throughput sequencing. An optimised “high input” protocol was successfully 
developed (Stewart et al., 2015) that allowed sensitive and reproducible 5hmC 
detection in human DNA samples in a comparable manner to 5mC detection using 
the gold standard BS conversion protocol (EZ DNA Methylation Kit from Zymo 
Research). Technical replicates of oxBS-450K datasets were highly correlated to 
each other (r > 0.99), whilst statistically significant 5hmC levels were detected at 
individual CpG sites at levels as low as 4%. There was initial concern that the 450K 
probes may not adequately cover genomic regions associated with 5hmC because 
5mC and 5hmC have been observed as having very distinct distributions within the 
genome. However, application of the oxBS-450K method to a human brain DNA 
sample highlighted the suitability of the 450K array 5hmC profiling: over 30% of all 
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CpG loci represented on the array were called as 5hmC, with an mean level of 15% 
that reached a maximum of 57% at some sites.  
In order to measure 5hmC at single-base-resolution in any genomic region of 
interest, oxBS conversion was subsequently adapted to BS pyrosequencing (oxBS-
pyroseq) (Stewart et al., 2015). Pyrosequencing is frequently used for targeted 5mC 
analysis and is generally considered the gold standard technique for validation of 
5mC profiling methods, including MeDIP-seq and 450K arrays (Dejeux et al., 2009; 
Harris et al., 2010; Roessler et al., 2012). Comparison of the pyrosequencing readout 
of oxBS-converted and BS-converted DNA amplicons allowed the 5hmC content of 
individual CpG sites to be determined and was used to successfully validate oxBS-
450K datasets, with 5hmC levels measured in the range of 30-50% at these targeted 
CpG sites. Measurements differed by less than 10% between oxBS-450K and oxBS-
pyroseq (corresponding to a difference of less than 5% in absolute 5hmC 
abundance), suggesting that both represent reliable methods of detecting base-
resolution 5hmC within DNA.  
More recently, an alternative method of 5hmC detection using the Infinium 450K has 
been developed that relies on Tet-assisted bisulphite conversion to discriminate 
5hmC from 5mC, referred to as TAB-array (Chopra et al., 2014; Nazor et al., 2014). 
TAB conversion protects 5hmC whilst resulting in the conversion of both 5mC and 
unmodified C to uracil, allowing 5hmC detection within a DNA sample using just 
one 450K array. For both 5mC and 5hmC detection, a BS-converted DNA sample 
must be assayed in parallel, in a similar manner to the oxBS-450K method. However, 
this TAB-array relies on the production of highly active recombinant TET1 for DNA 
oxidation, which is both laborious and technically challenging, whilst the oxidation 
reagent used for oxBS-450K analysis (potassium perruthenate) is commercially 
available. Nevertheless, both methods offer genome-wide, single-base resolution 
profiling of 5hmC within human DNA at substantially lower cost than DNA 
sequencing. In addition, the bioinformatics analysis required to process 450K data is 
much less complex than that of sequencing datasets, greatly increasing the 
accessibility of these 5hmC detection methods to researchers.  
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6.5 Developments in targeted DNA demethylation 
Epigenetic deregulation is frequently linked to disease progression and both aberrant 
5mC and 5hmC distributions have been associated with cancer (Feinberg and 
Vogelstein, 1983; Jin et al., 2011b; Jones and Baylin, 2007). Consequently, there is 
great need to both understand the cause of this deregulation and develop new 
therapies targeting the DNA methylation and/or demethylation machinery. Acute 
myeloid leukaemia (AML), which is characterised by the presence of a TET1-MLL 
oncofusion protein, is frequently associated with either TET2 or isocitrate 
dehydrogenase (IDH1/2) mutations and a global hypo-hydroxymethylation 
phenotype, most likely due to disruption of TET-mediated 5mC oxidation (Figueroa 
et al., 2010; Ko et al., 2010), although 5hmC reduction may be a secondary event to 
the loss of its substrate, 5mC. Indeed, both global hyper- and hypomethylation are 
observed in AML samples harbouring TET2 mutations, suggesting that many other 
components of the DNA methylation machinery are disrupted during the 
development of this malignancy, resulting in complex and varying alterations to the 
methylome.  
Two DNMT inhibitors (5-aza and DAC) have been granted FDA approval for the 
treatment of various myelodysplastic syndromes (MDS), including AML and 
primary myelofibrosis (see Chapter 5, section 5.3.1). Both drugs have shown 
effectiveness at reducing aberrant hypermethylation and restoring normal gene 
expression in cancer cell lines (Bogani et al., 2008; Hagemann et al., 2011; 
Hollenbach et al., 2010) and improving the overall survival and quality of life of 
MDS patients (Kuykendall, 2005; Silverman, 2002; Szmigielska-Kaplon and Robak, 
2011). In addition to their DNA demethylating activity, these drugs exhibit extensive 
cytotoxity due to their incorporation into DNA during replication, which results in 
DNA damage and inhibition of DNA synthesis at high concentrations (Li et al., 
1970; Qin et al., 2009; Stresemann and Lyko, 2008). Both cytosine analogues are 
also non-specific in action and unstable in aqueous solution, with a half-life of only 
around 20 minutes in blood plasma, making their use in a clinical setting very 
challenging (Krečmerová and Otmar, 2012). Patients must be given drug infusions 
over many hours and serious side effects are common due to the drug’s effects on 
healthy tissue. 5-aza, but not DAC, is also readily incorporated into RNA molecules, 
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substantially increasing its potential cytotoxity due to its ability to alter mRNA 
processing (and thus gene expression levels) in both proliferative and non-
proliferative cells. The development of novel drugs with increased specificity is will 
be crucial for improving the efficacy of these epigenetic therapies for cancer 
treatment. 
The final aim of this project was to explore the potential of targeted DNA 
demethylation therapy using photocaged DNMT inhibitors to selectively target 
cancerous cells in a spatially and temporally controlled manner. This part was 
conducted in collaboration with Ha Phuong Nguyen and Stefan Howorka from UCL 
Chemistry, who synthesised two photocaged DNMT inhibitors through the addition 
of a photosensitive moiety at the N4 position of the pyrimidine ring of both 5-aza 
and DAC, forming caged-aza and caged-DAC respectively. The phototag renders 
these molecules biologically inactive but may be cleaved from the pyrimidine ring by 
UV irradiation, releasing the active cytidine analogue. It was thought that these 
DNMT inhibitors could be administered to patients in an inactive form and then 
activated only at the site of diseased tissue through targeted irradiation. The viability 
of this treatment option was first explored in vitro on an osteosarcoma cancer cell 
line (Saos-2). Varying concentrations of caged-aza and caged-DAC were 
administered to Saos-2 cells in order to assess cytotoxicity, stability, uncaging rate 
and DNA demethylating activity in comparison to traditional 5-aza and DAC 
treatments.  
Both caged-aza and caged-DAC treatments resulted in reduced cell viability in a 
concentration-dependent manner, suggesting they were prone to hydrolysis in cell 
culture even in the absence of UV irradiation, resulting in the release of active 5-aza 
and DAC molecules. However, cell viability was reduced further upon irradiation of 
the treated cells, despite the fact that irradiation on its own had no visible effect on 
cell growth rate or survival. This observation implied that UV irradiation (at 365nm) 
resulted in further uncaging of the compounds in cell culture and only partial 
hydrolysis had occurred under normal growth conditions. Furthermore, comparisons 
with 5-aza and DAC treatments at equivalent concentrations over a five-day period 
revealed that the photocaged molecules were far less toxic to the cells than the 
 177 
traditional DNMT inhibitors, suggesting that only partial uncaging of the active 
molecule occurred in the culture medium after UV irradiation.  
At equivalent concentrations, caged-aza exhibited much greater cytotoxicity than 
caged-DAC under irradiation conditions. Treatment with 1.5µM caged-aza followed 
by UV irradiation over the course of five days resulted in almost complete cell death, 
whereas 1.5µM caged-DAC in combination with UV was well-tolerated by the cells, 
resulting in only a minor decrease (approximately 10%) in cell confluence compared 
to controls. This difference could not be explained by the differential uncaging 
kinetics of the two molecules during irradiation, as HPLC analysis confirmed that 
caged-DAC actually underwent much faster uncaging to its active form, with over 
92% of the compound uncaged after one hour, in compared to just 16% of caged-aza. 
The higher cytotoxicity of caged-aza must have arisen from the generation of other 
hydrolytic breakdown products during treatment or the effects of RNA incorporation, 
rather than simply the release of larger quantities of active 5-aza. 
Overall, the highest caged-DAC dose tolerated by the cells was at a 1.5µM final 
concentration within the culture medium, resulting in a minimal reduction in the 
overall growth rate. As the DNA demethylation activity of DNMT inhibitors is 
dependent on DNA replication, the proliferative capacity of the cells needs to be 
maintained in order to assess the effects of the treatment on DNA methylation. The 
Infinium 450K array was used for genome-wide 5mC profiling of the Soas-2 cell line 
before and after 1.5µM caged-DAC treatments, either with or without UV 
irradiation. A substantial reduction in global 5mC levels was observed after 1.5µM 
caged-DAC in combination with UV, from a median abundance of 68% 5mC in 
control cells to 36% 5mC after treatment. The demethylation effects of caged-DAC 
treatment were not constricted to particular genomic sites but acted genome-wide on 
the methylome of the Saos-2 cells, resulting in a global hypomethylation phenotype. 
However, a smaller but nevertheless significant reduction in global 5mC levels (from 
68% to 51%) was observed in the non-irradiated, caged-DAC-treated sample, 
confirming that spontaneous hydrolysis of caged-DAC to its active form occurs 
within the culture media. Nevertheless, caged-DAC remains a promising new 
treatment option for epigenetic therapy that has the potential to offer increase 
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specificity and minimal toxicity compared to the currently available DNMT 
inhibitors.   
Further work is needed in order to achieve true temporal control over the activity of 
caged-DAC. Firstly, the stability of the caged azanucleoside will need to be 
increased to ensure the molecules remains inactive in aqueous solution. Secondly, it 
is currently unknown whether uncaging occurs predominantly inside or outside of 
the treated cells. Whether or not the cells are capable to taking up the photocaged 
molecules prior to irradiation will be crucial in determining if the targeted in vivo 
irradiation of solid tumours is a viable treatment option. If strict spatial and temporal 
control over the site of caged-DAC activation can be demonstrated, the cytotoxic 
effects of caged-DAC at high doses could also be exploited for use as a 
chemotherapy agent, selectively targeting malignant tumours through the precise 
application of UV irradiation.  
Intriguingly, a recent publication has reported that 5hmC levels are also affected by 
DAC treatment in an AML cell line (Chowdhury et al., 2015). Despite a reduction in 
global 5mC, Chowdhury et al. observe an increase in 5hmC levels (along with 5fC 
and 5caC) after DAC treatment alongside an increase in the TET1-bound fraction of 
DNA. As a global reduction in 5hmC levels is frequently observed in cancer, this 
finding offers a new mechanism by which DAC may be mediating its therapeutic 
effect and highlights the importance of understanding the dynamic interrelationships 
between 5mC, 5hmC and their further oxidative derivatives when considering the 
role of DNA methylation in both health and disease. In conclusion, the work 
presented in this thesis contributes towards a better understanding of the complex 
methylome dynamics during neural differentiation, suggests limitations to the use of 
in vitro cell models for studying 5hmC and provides a novel method for the genome-
wide detection of this modification at single-base resolution.  
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Appendix 1: Supplementary Tables 
Primer pair name Forward Primer Sequence  
(5’ à  3’) 
Reverse Primer Sequence  
(5’ à  3’) 
20CpG (MeDIP QC1) GGTGAACTTCCGATAGTG CAGTCATAGATGGTCGGT 
15CpG (MeDIP QC1) TATCACTGTTGATTCTCGC TATCACTGTTGATTCTCGC 
Unmethylated Region 
(MeDIP QC2) 
GGCTAGAACTGACCAGACAG
AC 
ATCTGTAGCCAATCCTAGAGCA 
Methylated Region  
(MeDIP QC2) 
CATGGCCCACAAAGTAATAA
AA 
AACGACTTACAACGAGCTCAA
A 
Actin Positive (BS 
conversion efficiency) 
TGGTGATGGAGGAGGTTTAGT
AAGT 
AACCAATAAAACCTACTCCTCC
CTTAA 
Actin Negative (BS 
conversion efficiency) 
TGGTGATGGAGGAGGCTCAG
CAAGT 
AGCCAATGGGACCTGCTCCTCC
CTTGA 
Grm4 hyper-hDMR 
(oxBS-pyroseq) 
GTTGTTTTGGTAAGTTTAGAA
AGTAGTT 
*CACTTCCCCTCAACATCTCTA
A 
Atpase6 hyper-hDMR 
(oxBS-pyroseq) 
AGGTAGATGGTATATTGGTAA
TTATGA 
*ACCTTTATTCTAATCACAATT
CTATCTC 
Colgalt2 hyper-hDMR 
(oxBS-pyroseq) 
ATGAAAAGTGATGAGGATTG
AATAAG 
*AATTACCTCACTATAATATTC
ATCTACATC 
Jarid2 hyper-DMR 
(oxBS-pyroseq) 
GTTAAAAGGGATTTTAGAGGA
GGATT 
*CCCTAAACTTTACCTTCCTTA
ACC 
 oxBS-pyroseq: sequencing primers (5’ à  3’) 
Grm4 hyper-hDMR AAGATGTAGGGGTTTT 
Colgalt2 hyper-hDMR TTATAGATAAAAAAGTATTAATGTT 
 
Atpase6 hyper-hDMR ATGAATATTATTATAATTTAATGAG 
Jarid2 hyper-DMR GGATTTTAGAGGAGGATTT 
 
Supplementary Table 1: Primer pair sequences. Biotinylated primers are indicated by (*). 
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MeDIP-seq ESC1.bed ESC2.bed ESC3.bed NSC1.bed NSC2.bed NSC3.bed AST7.bed AST8.bed AST9.bed 
ESC1.bed 1.000 0.991 0.987       
ESC2.bed 0.991 1.000 0.996       
ESC3.bed 0.987 0.996 1.000       
NSC1.bed    1.000 0.997 0.995    
NSC2.bed    0.997 1.000 0.995    
NSC3.bed    0.995 0.995 1.000    
AST7.bed       1.000 0.909 0.968 
AST8.bed       0.909 1.000 0.868 
AST9.bed       0.968 0.868 1.000 
 
hMeDIP-seq hESC1.bed hESC2.bed hESC3.bed hNSC1.bed hNSC2.bed hNSC3.bed hAST7.bed hAST8.bed hAST9.bed 
hESC1.bed 1.000 0.994 0.995       
hESC2.bed 0.994 1.000 0.995       
hESC3.bed 0.995 0.995 1.000       
hNSC1.bed    1.000 0.995 0.986    
hNSC2.bed    0.995 1.000 0.989    
hNSC3.bed    0.986 0.989 1.000    
hAST7.bed       1.000 0.959 0.955 
hAST8.bed       0.959 1.000 0.980 
hAST9.bed       0.955 0.980 1.000 
Supplementary Table 2: Correlation matrices of MeDIP-seq profiles (above) and hMeDIP-seq profiles (below). 
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DMR Location Adjusted P-value 
CpG 
Count 
Associated 
Gene 
Symbol 
Gene Description 
chr7: 5030501-5031000 7.01 x 10
-29
 48 Zfp865 
Zinc finger protein 865: 
DNA binding protein 
involved in regulation of 
transcription. 
chr7:16811001-16811500 1.46 x 10
-28
 63 Fkrp  
Fukutin related protein: 
protein processing within 
Golgi apparatus. 
chr1:56969501-56970000 6.83 x 10
-27
 36 Satb2 
Special AT-rich sequence 
binding protein 2: 
involved in chromatin 
remodelling, regulation of 
transcription and neuron 
migration. 
chr11:69399501-69400000 9.40 x 10
-27
 38 
Kdm6b 
(also known 
as Jmjd3) 
 
KDM1 lysine (K)-specific 
demethylase 6B: 
epigenetic regulator 
required for normal 
development and neuronal 
survival. 
chr3:84190501-84191000 3.04 x 10
-26
 37 
Trim2 (also 
known as 
Narf) 
Tripartite motif-
containing 2: an E3 
ubiquitin ligase; 
regulates neuronal 
polarization. 
 
chr1:166309001-
166309500 5.67 x 10
-26
 67 
Ildr2 (also 
known as 
Dbsm1) 
 
Immunoglobulin-like 
domain containing 
receptor 2: involved in 
cell differentiation and 
pancreas development. 
chr4:136290501-
136291000 1.08 x 10
-25
 49 
Zfp46 (also 
known as 
Znf436) 
Zinc finger protein 46: 
DNA binding protein and 
transcriptional regulator. 
chr2:18031501-18032000 1.84 x 10
-25
 34 Gm17762 Predicted gene 17762: non-coding RNA gene. 
chr14:54417501-54418000 3.53 x 10
-25
 24 
Slc7a7 (also 
known as 
my+lat1) 
Solute carrier family 7, 
member7: an amino acid 
transporter; mutations in 
human ortholog are 
associated with glioma 
risk. 
chr8:70594501-70595000 4.33 x 10
-25
 51 Isyna1 
Myo-inositol 1-phosphate 
synthase A1: enzyme 
involved in and myo-
inositol (MI) biosynthesis; 
altered MI levels are 
associated with multiple 
brain disorders. 
 
Supplementary Table 3: Top 10 most statistically significant hyper-DMRs identified between 
mNSCs and mESCs. Associated genes refer to the nearest gene falling within 100kb upstream and 
50kb downstream of the DMR. DMRs falling within repeat regions, with a CpG count of zero, were 
excluded from the list. Gene annotations are taken from the NCBI Gene database and the MGI 
database, unless otherwise specified. 
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DMR Location Adjusted P-value 
CpG 
Count 
Associated 
Gene Symbol Gene Description 
chr8:124765501 - 
124766000 1.07 x 10
-14 15 Fam89a 
Family with sequence 
similarity 89, member A: 
protein coding gene; function 
unknown. 
chr7:49120001 - 
49120500 2.00 x 10
-13 18 
Nav2 (also known 
as POMFIL2, 
HELAD1) 
Neuron navigator 2: encodes 
a protein involved in cellular 
growth and migration; 
associated with nervous 
system development. 
chr8:55346501 - 
55347000 1.20 x 10
-12 14 N/A N/A 
chr8:10978501 - 
10979000 2.98 x 10
-11 22 9530052E02Rik Long non-coding RNA 
chr17:36031501 - 
36032000 6.45 x 10
-10 24 H2-T23 (also known as Qa1) 
Histocompatibility 2, T 
region locus 23: gene within 
the Qa region of the H2 
complex; homologous to 
MHC class I genes. 
chr7:48897501 - 
48898000 2.12 x 10
-09 4 E2f8  
E2F transcription factor 8: 
Transcriptional repressor of 
the E2F family; regulates cell 
cycle progression; critical for 
embryonic development. 
chr3:119498501 - 
119499000 3.02 x 10
-09 16 N/A N/A 
chr5:139051501 - 
139052000 3.47 x 10
-09 18 Prkar1b 
Protein kinase, cAMP 
dependent regulatory, type I 
beta: Involved in cAMP 
signalling; required for normal 
metabolism, ion transport and 
gene transcription. 
chr13:120025001 - 
120025500 4.08 x 10
-09 25 Gm21370 Predicted gene 21370 
chr15:78833001 - 
78833500 4.08 x 10
-09 12 Cdc42ep1 (also known as Borg5) 
CDC42 effector protein 
(Rho GTPase binding) 1: 
regulates actin polymerisation 
and cytoskeleton 
reorganisation. 
Supplementary Table 4: Top 10 most statistically significant hypo-DMRs identified between 
mNSCs and mESCs. Associated genes refer to the nearest gene falling within 100kb upstream and 
50kb downstream of the DMR. DMRs falling within repeat regions, with a CpG count of zero, were 
excluded from the list. Gene annotations are taken from the NCBI Gene database and the MGI 
database. 
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Appendix 2: Supplementary Figures 
 
Supplementary Figure 1: A) Primer pair designed around the Grm4-associated hyper-hDMR 
(chr17:27,422,334-27,422,558). B) Primer pair designed around the Jarid2-associated hyper-DMR 
(chr13:44,705,585-44,705,763). 
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Supplementary Figure 2: DAVID functional annotation of both hyper-DMR (A) and hypo-DMR 
(B) gene-sets identified during the mESC to mNSC transition. Gene enrichment scores for tissue 
expression terms are above. Both gene-sets show the most significant enrichment for genes 
upregulated in brain tissue.  
A 
B 
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Supplementary Figure 3: DAVID gene ontology (GO) of the hyper-DMR gene-set 
corresponding to the mESC to mNSC transition. Gene enrichment scores for GO terms are shown 
above. The most significantly enriched term was multicellular organismal development, although 
other related terms such as organ development, transcriptional regulation, cell differentiation and 
nervous system development were highly enriched for genes associated with hyper-DMRs and 
occurred within the top 20 most significant GO terms. 
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Supplementary Figure 4: DAVID gene ontology (GO) of the hypo-DMR gene-set corresponding 
to the mESC to mNSC transition. Gene enrichment scores for GO terms are shown above. The most 
significantly enriched term was system development, closely followed by nervous system 
development and anatomical structure development. Other highly enriched GO terms occurring within 
the top 20 include cell differentiation, neurogenesis, central nervous system development and 
generation of neurons. 
 
Supplementary Figure 5: DAVID functional annotation of the hyper-DMR gene-set identified 
during the mNSC to astrocyte transition. Gene enrichment scores for the annotation category 
“tissue expression” are shown. Only 3 terms (brain, brain cortex and head) showed significant 
enrichment. 
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Supplementary Figure 6: DAVID GO analysis of the hyper-DMR gene-set identified during the 
mNSC to astrocyte transition. Gene enrichment scores for GO terms are shown above. 
  217 
 
Supplementary Figure 7: DAVID analysis of the hyper-hDMR gene set identified between 
mESCs and mNSCs. All 40 gene ontology terms enriched for hDMR-associated genes are detailed 
above. 
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Supplementary Figure 8: DAVID analysis of the hyper-hDMR associated gene set identified 
between mESCs and mNSCs. All terms enriched for hDMR-associated genes falling within either 
(A) tissue expression or (B) Swiss-Prot Protein Information Resource (SP-PIR) keyword categories 
are detailed above. 
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Supplementary Figure 9: GREAT functional annotation of hyper-hDMR regions identified 
between mESCs and mNSCs. hDMR-associated genes were enriched for GO terms classified under  
mouse tissue expression, biological processes and molecular function categories, as detailed above. 
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Supplementary Figure 10: DAVID analysis of the hypo-hDMR gene set identified between 
mESCs and mNSCs. Gene enrichments for (A) gene ontology, (B) PIR keywords or (C) tissue 
expression terms are detailed above. 
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Supplementary Figure 11: Highest-ranked tissue expression terms according to binomial p-value for hyper-DMRs identified between mNSCs and astrocytes using 
GREAT (v3.0.0). Enrichment for the term “hippocampus granule cell layer” was due to five hyper-DMR regions associated with the genes Tenm2, Tenm4 and Usp29. The 
two teneurin transmembrane (TENM) proteins are known to be involved in neural development, anterior-posterior axis formation and are most highly expressed in the brain 
tissue of adult mice (Feng et al., 2002). 
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 Supplementary Figure 12: Ensembl genome browser view of chr7: 5,020,376-5,033,223. The DNA region identified as the most statistically significant 
hyper-DMR between mNSCs and mESCs by MeDIP-seq is highlighted by a black box, corresponding to the same DMR highlighted in Figure 4-7. Ensembl 
regulatory tracks of whole genome bisulphite sequencing (WGBS) data from mESC and mNPC lines confirm this region to be hypermethylated (indicated by 
dark blue vertical lines) in mNPCs and hypomethylated (indicated by pale green-yellow vertical lines) in mESCs. This DMR region is also associated with both 
repressive (H3K27me3) and activating (H3K4me3) histone modifications in mESCs only. 
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 Supplementary Figure 13: Ensembl genome browser view of chr7:49,118,733-49,122,164. The DNA region identified as a hypo-DMR between mNSCs and 
mESCs by MeDIP-seq is highlighted by a black box, corresponding to the same DMR highlighted in Figure 4-8. Ensembl regulatory tracks of whole genome 
bisulphite sequencing (WGBS) data from ESC and NPC lines confirm this region to be hypomethylated (indicated by pale green-yellow vertical lines, above) in 
NPCs compared to ESCs, in which the region is highly methylated (indicated by dark blue vertical lines). In addition, the DMR sits within a region associated with 
the repressive histone modification H3K27me3 in ESCs only (red bar, above).   
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Supplementary Figure 14: Ensembl genome browser view of chrX:169,986,956-169,996,224. The DNA region identified as a hyper-hDMR 
between mNSCs and mESCs by hMeDIP-seq is highlighted by a black box, corresponding to the same hDMR highlighted in Figure 4-9. Ensembl 
regulatory tracks show that the hDMR sits within a region associated with the repressive histone modifications H3K27me3 (red) and H3K9me3 (pink) 
as well as the active medication H3K4me3 (blue) in ESCs. The region also sits on a DNaseI hypersensitive site (yellow). WGBS data suggests the 
region is moderately methylated in both ESCs and NPCs. 
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 Supplementary Figure 15: Ensembl genome browser view of chr1:24,611,953-24,615,816. The DNA region identified as a hypo-hDMR between mNSCs 
and mESCs by hMeDIP-seq is highlighted by a black box, corresponding to the same hDMR highlighted in Figure 4-10. Ensembl regulatory tracks show that 
the hDMR sits within a DNaseI hypersensitive site in mESCs (yellow), whereas in mNPCs the region overlaps a Pol II-enriched site (green) and partially 
overlaps with H3K9me3 (red). 
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Supplementary Figure 16: UCSC genome browser view of a hyper-DMR identified between mNSCs and mESCs, approximately 2kb upstream of Jarid2, 
at chr13:44,705,001-44,706,000. The region appears fully unmethylated in mESCs and partially methylated in both mNSCs and astrocytes. 
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 Supplementary Figure 17: Correlation matrix of beta values for 12 samples interrogated on the Infinium 450K array. The correlation coefficients (r) of all 
sample pairings are listed above. A correlation coefficient of 1 indicates identical beta value measurements across all 450K probes for the two samples. Only the three 
5-aza treatments (0.5, 1.0 and 1.5µM 5-aza) appeared to have any measurable effect on DNA methylation level, indicated by a lower correlation coefficient (0.78-0.79) 
between 5-aza samples and controls. 
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Supplementary Figure 18: EpiExplorer analysis of 5hmC peak distribution compared to a 
randomised control set. A) 5hmC peak distribution in mESCs. B) 5hmC peak distribution in 
mNSCs. C) 5hmC peak distribution in astrocytes. One representative profile is shown per biological 
cohort. All hMeDIP profiles were characterised by a greater number of 5hmC peaks within repeat 
regions than expected by chance, and a very slight depletion of 5hmC peaks within genic region, 
DNaseI hypersensitivity sites, conserved regions, CTCF and Pol-II binding sites. 
 
